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“Let your food be your medicine and your medicine be your food. Each one of the 
substances in a man’s diet, acts upon his body and changes it in some way, and 
upon these changes his whole life depends, whether he be in health, in sickness or 
convalescent. To be sure, there can be little knowledge more necessary” 
 
       Hippocrates (460-377 BC) 
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SUMMARY 
 
The HIV pandemic in South-Africa has created a new form of vulnerability for 
households with regards to food security and nutritional status which are vital 
components in the general care of HIV-infected individuals. The risk of nutritional 
deficiencies and malnutrition are predictors of disease progression and treatment 
in resource limited settings. Furthermore, HIV affects nutritional status by 
increasing the energy requirements, reducing food intake, affecting nutrient 
absorption and metabolism inadequacies due to cytokine activity and diarrhea. 
 
Several vitamins and minerals are important in fighting HIV infection because 
they are required by the immune system and major organs to attack infectious 
pathogens. Many of these micronutrients have been found to be deficient in HIV-
infected persons and several studies were launched worldwide to investigate the 
feasibility of food assistance and nutrient supplementation. Nutritional 
supplementation has been advocated in HIV-infected persons especially in low-
income countries such as South Africa. Therefore, a study to evaluate the role of 
nutritional supplementation in HIV-positive patients becomes necessary, 
especially in a developing country such as South Africa. It is against this 
background that the present research was initiated to examine the influence of a 
nutritional supplement on the immune status and health status of HIV-
positive/AIDS adult individuals. 
 
The aim of the investigation was to determine if supplementation with a mixture 
comprised from specific minerals, vitamins and herbs over a period of one year, 
affected the haematological status, immune status, viral load and pulmonary 
function in forty (40) HIV-infected individuals living in the Mangaung Metropolitan, 
RSA. 
 
viii 
 
A quantitative, open-labeled, before-after clinical trial was conducted at the 
Central University of Technology, in Bloemfontein, Free State Province in the 
RSA. 
 
Socio-demographic and dietary intake questionnaires were completed. All data 
pertaining to anthropometric measurements, haematological status, immune 
status, viral load and pulmonary function were obtained my means of using 
standard procedures and technological equipment. The data were subjected to 
parametric and non-parametric statistical analysis. 
 
The results of the present investigation show that the eating pattern of this 
urbanized group of individuals reflects high energy (KJ) and macronutrient 
intakes coinciding with sub-optimal intake of Vitamin D and iodine. 
 
Of all the haematological variables the only statistical significant changes 
observed were increases in the median erythrocyte sedimentation rate (ESR) 
(p=0.0219) and mean cell haemoglobin concentration (MCHC) (p=0.0245) after 
six months of nutritional supplementation. At 12 months a statistical significant 
decrease in the median CD/CD8 ratio (p<0.0048), median Hematocrit 
concentration (p<0.0312), median mean cell volume (MCV) (p<0.0359), and 
median RDW (p<0.0273) accompanied a statistically significant increase in the 
MCHC (p<0.0003) at 12 months after supplementation. 
 
At 6 months 89% (CI95%: 73%; 96%) of the individuals showed a decline in viral 
load counts with a median percentage decline of 34% (CI95%: 73%; 96%). At 12 
months 85% [CI95%: 68%; 94%] of the individuals show a decrease in viral load 
counts with a median percentage decline of 62.9% (CI95%: 50%; 78.6%) following 
the intake of the supplement. 
 
The main findings of the present investigation reveal that 68% (50%-81%) of the 
individuals show a statistical median increase (p=0.0302) of 16.9% (11.5%; 
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36.1%) in the Peak Expiratory Flow (PEF) at six months. A significant decrease 
(p=0.0484) in the median FEF75 of 28.1% (14%; 35.3%) is observed in 70% 
(53%-83%) of the individuals after 12 months of exposure to the supplement. No 
statistical significant changes are observed for FVC, FEV1, FEV1/FVC and FEF50 
over the entire trial period. 
 
The present results suggest that a significant measurable decrease in viral load in 
HIV-infected individuals can be obtained by means of subjecting individuals to a 
nutritional fortification supplement strategy for 6 months or more. 
 
 
KEY WORDS 
HIV/AIDS; Nutritional supplementation; Dietary intake questionnaire; 
Anthropometry; Pulmonary function; Immune status; Haematological status; Liver 
function; Viral load. 
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1.1. INTRODUCTION 
All African countries, south of the Sahara desert are known as Sub-Saharan Africa. 
This area represents 10% of the global population housing 67% (22 million) of the 
individuals infected with Human Immunodeficiency virus (HIV) (Sztam, Fawzi & 
Duggan, 2010; HIV and AIDS Statistics –Worldwide, 2010). 
 
The HIV and AIDS (Acquired Immune Deficiency Syndrome) epidemic in South 
Africa rate amongst the highest in the world. In 2011, 10.6% (5.38 million) of the 
total population of South Africa was HIV-positive. The number of women living with 
HIV was 19.4% with 16.6% of the  population between the age of 15 and 49 years 
during the same year and the total population of South Africa was estimated at 50 
586 757 (Statistics South Africa, 2011). 
 
The enormity of the HIV and AIDS epidemic in South Africa is further emphasized 
with almost one-in-three women aged 25 to 29  and 25% of men aged 30 to 34 
being HIV-infected. Premature deaths attributed to HIV and AIDS have increased in 
the past 10 years from 39% to 75% in 2010. Children who were infected with the 
virus during birth were born into families where HIV and AIDS have disrupted 
income, health, productivity as well as the ability to care for each other. HIV and 
AIDS is a major contributor to poverty in South Africa as there is a 80% chance that 
households may lose about half their income due to the demise of the highest 
financial supporter (UNAIDS, 2010). 
 
To achieve and maintain proper health, a healthy adult needs at least 500 
kilocalories (2100 KJ) per day, of which 10 – 20% should comprise of protein. 
Unfortunately protein intake makes out a very small portion of the daily diet of many 
communities in Southern Africa (Spencer, Harman, Botha, Rollins, Labadarios & 
Visser, 2009). A study in the Ga-Rankuwa area in Gauteng, South Africa found that 
neither HIV-infected males nor females met the minimum prescribed daily energy 
requirement through their diet and indicates a serious shortcoming in micronutrient 
intake and dietary diversity (Venter, Gericke & Bekker, 2009). Impaired nutritional 
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status may be caused by a reduced intake and availability of food due to the effect 
of HIV and AIDS on household income (Lemke, 2005). Vitamins and minerals are 
organic substances that are not used to provide energy, but assist the body to 
utilize macronutrients to build the body. In most instances vitamins act as 
coenzymes. With the exception of vitamin D, small amounts of vitamin B and 
vitamin K, produced by intestinal bacteria, all vitamins are obtained from food or 
vitamin supplementation. Minerals are needed in moderate amounts and make up 
approximately 4% of the body weight (Marieb & Hoehan, 2010). The reduction and 
deficiency of vitamins A, C, E, B6 and B12, as well as zinc and selenium have been 
shown to compromise the immune response (Campa & Baum, 2010). 
 
Furthermore, physiological symptoms like oral thrush; vomiting; appetite loss; 
reduced nutrient absorption due to diarrhea and intestinal damage may effect food 
consumption (Oketch, Paterson, Maunder & Rollins, 2011). The negative effect of a 
nutrient imbalance on the human body, especially on the immune system, is shown 
in malnutrition (Savino & Dardanna, 2010). Malnutrition was also recognized as a 
major problem since the early history of HIV infection. Even before the emergence 
of the HIV malnutrition has been a major cause of death due to infection 
(Cunningham-Rundles & Lin, 1998). Malnutrition in HIV-infected individuals is a 
series of conditions that occurs when the body is deprived of optimal amounts of 
minerals, vitamins and nutrients to maintain immune function and general health 
(Evans, Maskew, & Sanne, 2012). Infection and AIDS reflect on nutritional status as 
a “wasting syndrome” (Leah & Mascioli, 1995). Loss of body cell mass and muscle 
mass may be prevalent early in the course of the HIV infection suggesting that the 
loss is due to the HIV infection and not opportunistic co-infections (Faintuch, 
Soeters & Osmo, 2006). 
 
To address the problem of poor nutrition and HIV, Gramlich and Mascioli (1995) 
identified several issues to be addressed: These include diagnoses of malnutrition; 
causes of malnutrition; specific micro- or macro elements involved; more 
susceptible subpopulations and the value of supplementation. 
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To reverse or prevent the negative effect of nutritional undernourishment in people 
living with HIV and AIDS, several studies were launched worldwide to investigate 
the feasibility of food assistance and nutrient supplementation (Oguntibeju, Van 
Schalkwyk, Van den Heever & Veldman, 2003; Baum, Lai, Sales, Page & Campa, 
2010; Sztam et al., 2010; Doa, Patel, Overton, Rhame, Pals, Johnson, Bush & 
Brooks, 2011; Tirivayi & Groot, 2011). A study by Venter and co-workers (2009) 
shows that several nutrients (macro and micronutrients) plays an important role in 
the prevention of malnutrition in people living with HIV and AIDS and they 
recommend that more studies regarding larger sample size and follow-up 
investigation be done. 
 
HIV-infected individuals commonly have symptoms of airway disease associated 
with air trapping and significantly lower forced expiratory air flow in one second 
(FEV1) and forced mid expiratory flow (FEF50). Small airways disease is frequently 
present in HIV-positive individuals (Gelman, King, Neal, Pacht, Clanton & Diaz, 
1999). With fewer opportunistic infections due to better treatment and prevention, 
noninfectious lung pathology like emphysema, lung cancer and pulmonary arterial 
hypertension have been diagnosed more frequently in people living with HIV and 
AIDS (PLWHA). Chronic obstructive pulmonary disease (COPD) has been 
associated with HIV-infection (Gelman et al., 1999). Experimental evidence showed 
that zinc supplementation may improve lung health in HIV and AIDS in developing 
countries (Morris & Guidhof, 2010). 
 
 
1.2 PROBLEM STATEMENT 
As the HIV and AIDS pandemic enters its third decade and case numbers continue 
to increase, no definitive cures have been found nor has an effective vaccine been 
developed. It is time to examine other approaches to reduce the HIV infection 
burden.  Nutritional intervention may be one of these approaches particularly in the 
Free State Province of the Republic of South Africa, where the effect of a nutritional 
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supplement on the immune status of HIV-positive/AIDS patients has not been 
examined over a period of 1 year. 
Malnutrition has been an endemic problem in Africa for decades, complicated by a 
combination of factors, and more recently the impact of HIV/AIDS.  HIV infection 
exacerbates malnutrition through its attack on the immune system and its impact on 
nutrient intake, absorption and nutrient utilization. It has been demonstrated that 
nutritional deficiencies affect immune functions in ways that may influence viral 
expression and replication, further affecting HIV progression and mortality. Several 
vitamins and minerals are important in fighting HIV infection. They are required by 
the immune system and major organs to attack infectious pathogens. Several of 
these micronutrients have been found to be deficient in HIV-infected persons, thus 
nutritional supplementation has been advocated in HIV-infected persons especially 
in low-income countries such as South Africa.  
Although the effects of HIV infection on the nutritional status are likely to be more 
pronounced among under-privileged populations with low dietary intake, 
unfortunately, relatively few data have been reported in developing countries (Ivers, 
Cullen, Freedberg, Block, Coates & Webb, 2009). 
 
Data on the prevalence of malnutrition, dietary intake and/or supplementation in 
HIV-infected persons in industrialized countries, is widely available.  However, this 
information is often scarce in Africa where endemic malnutrition and lack of nutrition 
management are common.  Therefore, a study to evaluate the role of nutritional 
supplementation in HIV positive patients becomes necessary, especially in a 
developing country such as South Africa. 
 
It is against this background that the present research was initiated to examine the 
influence of a nutritional supplement on the immune status and health status of HIV-
positive/AIDS adult patients. 
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1.3 RATIONALE FOR THE RESEARCH PROJECT 
The interaction between nutritional status and increased disease susceptibility is 
well known. Many of the immunological abnormalities seen in HIV infection are very 
similar to those seen in malnutrition and single nutrient deficiencies and interaction 
between nutrient deficiencies and HIV-induced immune deficiency has been 
identified (Leah & Mascioly, 1995; Ockenga, Grimble, Jonkers-Schuitema, 
Macallan, Melchior, J-C., Sauerwein & Schwenk, 2006). 
 
Providing sufficient food and nutrition to meet people‟s needs for health, growth and 
development has been a long-standing challenge for African people. This challenge 
is further exacerbated by the emergence of HIV and AIDS. HIV contributes to 
malnutrition for physiological reasons related to the infection itself and also because 
most people living with HIV/AIDS often have diets that are deficient in energy, 
proteins, vitamins and other nutrients (Sztam et al., 2010). 
 
Data on the prevalence of malnutrition, dietary intake and/or supplementation in 
HIV-infected persons in industrialized countries, is widely available (Oguntibeju et 
al., 2003). However, this information is often scarce in Africa where endemic 
malnutrition and lack of nutrition management are common.  Therefore, a study to 
evaluate the role of nutritional supplementation in HIV positive patients becomes 
necessary, especially in a developing country such as South Africa. 
 
Literature also reveals that information regarding the effect of nutritional 
supplementation on noninfectious lung diseases such as asthma and COPD in Sub-
Saharan Africa, also seems to be lacking. 
 
In accordance, a sound investigation should be of value if baseline dietary intake, 
lung function screening tests and haematological and immunological parameters be 
implemented to evaluate the effect of HIV infection in a specified population where 
malnutrition may play a role. 
 
7 
 
1.4 RESEACH AIM AND OBJECTIVES 
The aim of this study was to evaluate the impact of the intake of the supplement on 
various and numerous variables indicative of the health status of HIV-infected 
individuals i.e. baseline dietary intake, immune and haematological variables.  
The following immunological parameters were measured: CD4, CD8 and viral load 
counts. 
 
The objectives of the study were to: 
 Determine the baseline dietary intake of the study population. 
 Evaluate the impact of the supplement on the immune-and health  
status of the patients over a period of one year. 
 Determine the relationship between nutritional supplementation and 
pulmonary function of the study population. 
 Determine the relationship between haematological parameters, 
immune status and lung function status. 
 
 
1.5 SIGNIFICANCE OF THE RESEARCH 
People living with HIV and AIDS experience nutritional deficiencies resulting in the 
aggravation of weight loss, decline in immunity, infectious disease and the presence 
of lung disease like COPD. The value of the present investigation lies within the 
notion that nutrient supplementation could possibly affect the HIV-status of 
malnourished individuals and improve quality of life as well as well being/wellness. 
Not only will the results from this investigation provide constructive information to 
individuals infected with the HIV-virus, but also a possibility that could affect quality 
of life and clinical well being and/or wellness accordingly. 
The present investigation could also provide information to other researchers 
wanting to explore this field of study. 
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1.6 STRUCTURE AND LAYOUT OF THE THESIS 
 
CHAPTER 1: INTRODUCTION 
A synopsis of the rationale for the research project as 
such and the rationale for the research design provides 
a benchmark for the importance and the validity of the 
investigation. 
 
CHAPTER 2:  LITERATURE REVIEW 
Prelude on HIV/AIDS in general and a holistic objective 
comparable literature survey on nutritional intake, 
immunity and pulmonary function revealed in terms of 
the present investigation.  
 
CHAPTER 3: METHODOLOGY 
Contains a description of the methods and techniques 
used, as well as study procedures, sampling criteria and 
all other related matters on how the results are obtained. 
 
CHAPTER 4: BASELINE DIETARY INTAKE OF HIV-INFECTED 
INDIVIDUALS LIVING IN THE MANGAUNG 
METROPOLITAN 
Introduction, literature survey, methodology, results and 
discussion of the results revealed in this chapter. 
 
CHAPTER  5: INFLUENCE OF NUTRITIONAL SUPPLEMENT   
                              INTAKE ON THE HAEMATOLOGICAL STATUS,    
                              IMMUNE STATUS AND VIRAL LOAD, IN HIV- 
                              INFECTED INDIVIDUALS LIVING IN THE MANGAUNG  
                              METROPOLITAN 
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Introduction, literature survey, methodology, results and 
discussion of the results revealed in this chapter. 
 
CHAPTER 6: INFLUENCE OF NUTRITIONAL SUPPLEMENT 
INTAKE ON PULMONARY FUNCTION IN HIV-
INFECTED INDIVIDUALS LIVING IN THE MANGAUNG 
METROPOLITAN. 
Introduction, literature survey, methodology, results and 
discussion of the results revealed in this chapter. 
 
CHAPTER 7: SUMMARY AND CONCLUSION ON THE 
INTEGRATED RELATIONSHIP BETWEEN THE MAIN 
FINDINGS 
    Discussion of: 
 The main findings of the present investigation; 
 The main findings of the present investigation 
relative to the findings of other researchers stated 
in the literature; and  
 An integrated and aligned approach between the 
various chapters (variables) of the present 
investigation. 
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2.1 HISTORICAL OVERVIEW 
In early 1981, a rare form of cancer, Kaposi‟s sarcoma was detected among gay 
men in New York (Hymes, Green & Marcus, 1981). At the same time a rare form of 
pneumonia caused by Pneumocystis carini was also noticed in Atlanta. In June 
1981 the United States Centre for Disease Control and Prevention (CDC) formed a 
team to investigate the occurrence of Kaposi‟s sarcoma and opportunistic 
infections. This immune compromising disease, still without a name, was officially 
defined as: ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) by the CDC in 
September 1982. This may be described as the beginning of AIDS awareness in the 
world. During this time the cause of the “gay disease” was not known. It was 
suspected that the cause of this disease may have had an infectious origin (Noble, 
2009). 
 
The first break through in isolating the unknown virus was made in 1983, by 
Montagnier and co-workers at the Institute Pasteur in France. Montagnier et al., 
investigated the so-called retrovirus and its role in the disease. They were able to 
culture the virus from the lymph nodes of infected individuals. After identifying the 
virus these researchers were able to develop an antibody test to screen for the 
infection. This saved the lives of many haemophiliacs as more than 100 000 had 
received infected blood. Retroviruses were first described in 1970 by Haward Temin 
and Davis Baltimore, who discovered that the virus has Ribose nucleic acid (RNA) 
genes unlike most viruses which have Deoxyribonucleic acid (DNA) genes. They 
also found an enzyme, reverse transcriptase, in the virus (Bagasra & Pace, 2008). 
The virus was named lymphadenopathy-associated virus (LAV), and is a virus with 
the CD4 cells as primary target (Conner & Kingman, 1988). In October 1983 
Montagnier et al., concluded that the LAV was responsible for the immune 
deficiency syndrome and the virus came to be known as HIV. 
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2.2 THE EPIDEMIOLOGY OF HIV AND AIDS 
The epidemiology of HIV and AIDS is unique for every world region due to socio-
demographical variables and should be discussed accordingly as subgroups are 
often not adequately represented (Mavedzenge, Olson, Doyle, Changalucha & 
Ross, 2011). 
 
2.2.1. Global epidemiology of HIV and AIDS 
It is estimated that in 2010 about 34 million adults were living with HIV and AIDS 
and 2.7 million people became newly infected with HIV (HIV and AIDS Statistics – 
Worldwide, 2010). This is 15% less than figures reported for 2001 and 21% less 
than in 1997 at the peak of the epidemic. The incidence of HIV has fallen in 33 
countries of the world with 22 of these countries in sub-Saharan Africa (UNAIDS, 
2011). 
 
The Caribbean has the highest occurrence of HIV per capita where the mode of HIV 
transmission is unprotected sex. Due to increased access to treatment the mortality 
associated with AIDS dropped significant in this region (UNAIDS, 2011). 
 
In South and South East Asia, with approximately 270 000 new infections during 
2010 was 40% less infections that was recorded in 1996. The prevalence of HIV is 
lower in the South and South East Asian region than in most world areas but the 
size of the population causes it to present with a high HIV-infected population (4 
million adults and children) (UNAIDS, 2011). 
 
Eastern Europe and Central Asia presented with a 250% increase in the number of 
HIV-infected individuals from 2001 to 2010. Injection drug use and the infection of 
drug use partners are the main modes of HIV infection in this region.  South and 
South East Asia are main regions where AIDS related deaths are continuing to 
increase (UNAIDS, 2011). 
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The occurrence of HIV in North America and Central Europe remains stable with an 
estimated 2.2 million individuals infected. AIDS related deaths remained stable 
since 2000, despite a 34% increase in the total number of infected individuals 
(UNAIDS, 2011). 
 
The mode of transmission of new infections was: Mother to baby (11%), injecting of 
drugs (10%), sex between men (5-10%) and sex between men and women 
(approximately 66%). Of the mentioned figures, more than half were infected before 
the age of 25 years and died before the age of 35 years. The majority of HIV-
infected people (95%) live in poor and developing countries (UNAIDS, 2008). 
 
2.2.2. Prevalence of HIV and AIDS in sub-Saharan Africa 
The sub-Saharan African area presents 10% of the global population with 67% (22 
million) of HIV-infected individuals (Sztam, Fawzi & Duggan, 2010; HIV and AIDS 
Statistics–Worldwide, 2010). Approximately 1.9 million people were infected with 
HIV and 1.5 million died of AIDS in 2007 in this region.  The occurrence of HIV and 
AIDS varies from country to country.  In sub-Saharan Africa the HIV infection rate 
varies, with less than 0.1% in the Comoros and 26.1% in Swaziland (UNAIDS, 
2008). In 2010 half the AIDS related deaths in sub-Saharan Africa occurred in 
Southern Africa. Furthermore 70% of all newly reported HIV infections in 2010 
occurred in sub-Saharan Africa. Globally, new HIV infections peaked in 1997 with a 
decline in new infections as well as HIV related deaths (UNAIDS, 2011). 
 
West and Central Africa have the lowest infection percentage amongst the younger 
population, with Senegal at 0.4% of the population and the Central African Republic 
at 5.7%. The prevalence of HIV-infected individuals in Eastern Africa varies from 
1.1% of the population in Ethiopia to 4.5% in Kenya. The highest percentage of 
infected population occurs in Southern Africa (Mavedzenge et al., 2011). The 
current prevalence of HIV and AIDS in the most southern region of Africa amounts 
to 11.3 million people (USAID, 2011). The figures in some countries neighbouring 
South Africa expressed as a percentage of the population are as follows: Botswana 
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24.8%, Swaziland 25.9% and Lesotho 23.6% (USAID, 2011). The number of people 
living with HIV and AIDS in South Africa where 17.8% of the population between 15 
and 49 years, is amongst the highest of the 44 sub-Saharan African countries 
(UNAIDS, 2010). 
 
The most vulnerable subgroup to HIV acquisition in sub-Saharan Africa is young 
women between 15 and 24 years. These women are eight times more likely to be 
infected than males of the same age due to biological susceptibility such as 
immature cervix. Africa is known for its gender power struggle and women do not 
always have choice of a sex partner or protected sex (Mavedzenge et al., 2011). 
 
2.2.3. Prevalence of HIV and AIDS in South Africa 
Females represent the majority of HIV-infected persons in South Africa with about 
one-in-three women infected with the virus (UNAIDS, 2010). In 2006 the life 
expectancy of South Africans with HIV and AIDS dropped from 64 years (without 
AIDS) to 54 years (Dorrington, Johnson, Bradshaw & Daniel, 2006). Young adults 
who died from HIV and AIDS related diseases died with their offspring very young 
placing an increased economic burden on the family structure. This percentage of 
premature deaths due to HIV and AIDS increased during the last decade from 39% 
to 75% in 2010 (Harrison, 2009). 
 
South Africa is divided into nine provincial regions each experiencing a different 
stage of the HIV and AIDS epidemic. Except for Limpopo, Eastern Cape, Western 
Cape and Northern Cape, the HIV and AIDS epidemic in the rest of South Africa 
has stabilized with the rate of new infections equaling the number of HIV and AIDS 
related deaths. 
 
The prevalence and distribution of HIV-infected people in South Africa varies from 
province to province. The largest HIV-infected population is in KwaZulu-Natal (1.5 
million, 28% of the local population) (Oketch, Paterson, Maunder & Rollins, 2011) 
with the Western Cape at the lower end with 3.8% of the local population being HIV-
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infected (UNAIDS, 2010). In 2010 the HIV prevalence among antenatal clinic visits 
in KwaZulu-Natal was 39.5 % and in the Western Cape 18.5%. The percentage of 
HIV-infected females who visited antenatal clinics in the Free State was 30.6% 
(South Africa HIV & AIDS Statistics, 2011). 
 
Dorrington and co-workers postulated that by  2015 the total population of the Free 
State will be 2 793 265. The growth rate will be 0.0%, total number of HIV-infected 
people 390 469, cumulative AIDS deaths 395 621 and about 54 381 people sick 
with AIDS (Dorrington et al., 2006). 
 
 
2.3. STRUCTURAL BIOLOGY OF HIV 
The HIV virion of 120 nm in diameter (see Figure 2.1) belongs to the lentivirus 
genus and it includes the retroviruses with cone shape capsid core particles (Turner 
& Summers, 1999; Teixeira, Gomes, Gomes & Maurel, 2011). The icosahedral 
structure of the HIV contains 72 spikes formed by two viral-envelope proteins 
(gp120env and gp41env). The lipid bilayer of the virion contains several host proteins 
(Class I and II histocompatibility antigens) necessary for virion budding.  The 
nucleocapsid proteins (p17gag, p9gag, p7gag and p24gag) making up the core of the 
HIV were cleaved proteolytically from a 53-kD Gag precursor. The inner part of the 
nucleocapsid is formed by a phosphorylated p24 polypeptide. The inner nucleotide 
core is formed by the p7 protein bound to the genomic RNA and a p9 protein. The 
two copies of the genomic RNA are involved with the enzymes protease, integrase 
and reverse transcriptase (Greene, 1991; Iweala, 2004; Teixeira et al., 2011). 
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       Figure 2.1. Schematic presentation of the HIV-1 Virion with cone shape capsid   
                                    and core particles (Adapted from Briggs, 2008) 
 
2.3.1. Subtypes of HIV 
HIV is a virus that changes it structure easily, implying that several different strains 
of HIV have been identified on grounds of genetic similarities and are divided into 
types, groups and subtypes. There are two distinct types of HIV: HIV-1 and HIV-2 
(Hahn, Shaw, De Cock & Sharp, 2000). HIV-2 is less common and is mainly, but not 
completely, restricted to West Africa. 
 
HIV-1 can be classified into three groups (see Figure 2.2): Group M (major), group 
N (new, mainly in Cameroon) and group O (outlier, mainly in West to Central 
Africa). HIV-1, group M is divided into 11 different subtypes ranging from A to K.  A 
combination of subtypes is named circulating recombinant forms (CRFs), for 
21 
 
example CRF A/C is a combination of subtype A and C (Noble, 2009). The 
predominant type of HIV in South Africa is HIV-1, Group M, subtype C (Redd, 
Avalos & Essex, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Schematic presentation of HIV-1 and HIV-2 indicating different 
groups and sub groups. (Adapted from Reeves & Doms, 2002) 
 
 
2.3.2. Entry of HIV into receptor cells 
HIV uses its gp120 and gp41 envelope protein to bind with its cellular receptor 
protein of the CD4 cells (see Figure 2.3) to enter the host cell. The gp120/gp41 
connection to the CD4 cells is responsible for mediating the process of viral and 
cellular membrane fusion causing entrance of HIV into the host cell. The binding of 
gp120/gp41 to the CD4 cells and chemokine receptor CCR5 or CXCR4 (a co-factor) 
results in the loosening  of gp120 from gp41 creating a thin structure in gp41 to 
penetrate into the host cell membrane, allowing  membrane merging and fusion, 
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with entrance of HIV into the host cell (Briggs, 2008; Checkley, Luttige & Freed, 
2011). 
 
 
 
 
 
 
 
 
 
 
     Figure 2.3. HIV cell entry demonstrating the role of gp 41 and gp 120 (Adapted   
                            from Briggs, 2008) 
 
 
2.3.3 Cell entry into the host cell and replication of the HIV 
Figure 2.4 is a schematic presentation of the steps taken for entry of the HIV into 
the host cell and the replication of the virus (NIAID, 2010): 
1. Binding of the HIV to the host cell (Fusion): By means of gp120, an HIV 
glycoprotein with a molecular weight of 120 and co-receptors CCR5 or 
CXCR4 on the service of the lymphocytes or monocytes (Teixeira et al., 
2011). The gp120 protrudes from the virus surface and binds with the CD4 
receptor of the T-cells, monocytes, macrophages and dendrite cells to 
facilitate the viral nucleic acid and protein to enter the host cell (Friedrich, 
Dziuba, Li, Endlsey, Murray & Ferguson, 2011). 
2. Ribonucleic acid (RNA), reverse transcriptase and viral proteins enter the 
host cell (Lu, Heng & Summers, 2011). 
3. Viral DNA is formed by reverse transcriptase: Reverse transcriptase is an 
enzyme produced by the HIV to form double stranded DNA as a copy of the 
viral RNA. Two RNA molecules are used for recombination during reverse 
transcriptase but only one DNA allele is formed (Lu et al., 2011). 
Several cellular factors are necessary for reverse transcription: 
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 A cellular peptidal-prolyl isomerase (Pin1). Pin1 is involved with the 
phosphorylation of HIV-1 capsid. 
 Cyclophilin A (Cyp A). Cyp A binds to the HIV-1 C89 and P90 residues 
tossist with virus disassembly. 
4. Newly formed viral DNA forms a pre-integrated complex with the host 
proteins to be transported across the nucleus and integrated into the DNA of 
the host cell. The integration of the newly formed DNA into the host DNA is 
facilitated by the enzyme integrase found in HIV. 
5. Translation of new viral DNA into viral proteins. 
6. New viral RNA and proteins assemble on the cell surface as immature HIV 
forms. The immature HIV forms are converted into mature viruses by 
protease that cleaves the polyprotein precursors to trigger the conversion. 
7. After the viruses mature, budding takes place releasing the HIV in the blood 
stream to initiate a new cycle of infection (Checkley et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.  Summary of HIV entry into the host cell and the replication of 
the virus (Adapted from NIAID, 2010) 
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2.4. HIV INFECTION 
This section reveals information on a classification system for HIV infection, 
relationship between HIV infection and TB, diagnosis of HIV and treatment of HIV. 
 
2.4.1. Classification system for HIV infection 
The revision of the classification system for HIV infection by the CDC in 1993 was to 
emphasize the importance of the CD4 cell count regarding the related clinical 
conditions found in infected individuals (CDC, 1993). 
 
The CDC and World Health Organisation (WHO) disease classification system of 
HIV is primarily to compare the CD4 cell count with the presence of specific HIV 
related features. By using the lowest available CD4 cell count (see Table 2.1) and 
previously diagnosed HIV related conditions (Table 2.2 and Table 2.3) the CDC is 
able to categorize HIV and AIDS (CDC and WHO, 2006; CDC and WHO, 2011). 
 
   Table 2.1. CDC Classification System for HIV-infected adults and adolescents 
 
 
 
 
 
 
    (Adapted from CDC and WHO, 2011) 
   Table 2.2. CDC Classification System: Category B Symptomatic Conditions 
 
 
 
 
 
 
(Adapted from CDC and WHO, 2011) 
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   Table 2.3. CDC Classification System: Category C AIDS-Indicator Conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    (Adapted from CDC and WHO, 2011) 
 
In 2005 the WHO revised the clinical staging of HIV and AIDS of the case definition 
of HIV that was compiled in 1990.  The new staging derives from clinical findings to 
guide the diagnoses, evaluation and management rather than a CD4 cell count. 
Clinical stages start with stage 1 and progress to stage 4 (advanced HIV and AIDS) 
(Table 2.4 (CDC and WHO, 2006; CDC and WHO, 2011). 
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Table 2.4. The WHO Clinical Staging of HIV and AIDS for Adults and 
Adolescents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Adapted from CDC and WHO, 2011) 
 
27 
 
2.4.2. HIV infection and Mycobacterium tuberculosis (TB) 
South Africa is the country with a great burden of HIV-infected individuals and the 
second highest incidence of Mycobacterium tuberculosis (TB) infection per capita in 
the world (Houlihan, Mutevedzi, Lessells, Cooke, Tanser & Newell, 2010). The 
infection of HIV-infected individuals with TB is a serious public problem, with a much 
lower CD4 count in TB and HIV co-infection compared with TB infection alone  
(Ligidi, Gebre-Selassie & Tsegaye, 2011; Naido, Naido, Padayatchi & Karim, 2011). 
 
The increase in TB notification also coincided with the increase in HIV and AIDS 
(Kapata, Chanda-Kapata, O‟Grady, Schwank, Bates, Mukonka, Zumla & Mwaba, 
2011). This connection between HIV and AIDS and the prevalence of TB must 
prompt the screening of HIV in all TB patients (Pennap, Makpa & Ogbu, 2010). The 
association between HIV and TB co-infection is further strengthened by the 
increased risk of TB infection with an increased HIV-1 RNA (Sterling, Lau, Zhang, 
Freeman, Bosch, Brooks, Deeks, French, Gange, Gebo, Gill, Horberg, Jacobson, 
Kirk, Kitahata, Klein, Martin, Rodrigues, Silverberg, Willig, Eron, Goedert, Hogg, 
Justice, McKaig, Napravnik, Thorne & Moore, 2011). 
 
2.4.3. Diagnosis of HIV 
The necessity for on-site diagnosis of infected HIV individuals prompted the industry 
to develop rapid diagnostic testing methods. On-site diagnosis improves treatment 
planning and it is not necessary for a trained phlebotomist to perform a 
venipuncture to obtain blood for a rapid test because blood is collected by means of 
a fingertip or heel prick with a lancet (Nabatiyan, Parpia, Elghanian & Kelso, 2011). 
 
Standardisation of HIV-1 testing was necessary and is administrated by WHO using 
reference materials from the National Institute for Biological standard. The cell 
cultured unit standard consists of HIV-1 group M subtype B in concentration of 5.56 
log10IU/vial. With this common standard HIV testing is a uniform test across the 
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world (Glaubitz, Sizmann, Simon, Hoffmann, Hesse, Lang, Kroeh, Simmler, Dewald, 
Haberhausen, Lindauer, Beyser, Reber, Baumeister, Wolf, Haeger & Babiel. 2011). 
Enzyme-linked immunosorbent assay (ELISA), Western Blot (antibody test) and 
Polymerase Chain Reaction (PCR) viral load testing are usually used to test and 
confirm HIV infection. In combination the CD4 cell count, ELISA, Western Blot and 
viral load are used to diagnose as well as determine the progress of AIDS and the 
monitoring of the anti-retroviral effectiveness.  The ELISA test is a rapid screening 
test while the Western Blot and PCR (Viral load) are used as confirmation testing. 
The diagnostic tests for HIV are based on the presence of one or more of the 
molecules in the structure of the virus (HIV p24 antigen or HIV RNA) or the 
antibodies produced by the infected host (Iweala, 2004; Talha, Salminen, Sheikh, 
Swaminathan, Soukka, Pettersson & Khanna, 2011). 
 
The diagnosis of HIV infection in sub-Saharan Africa is mainly done by serological 
rapid testing. This immuno-chromatographic test changes in less than 20 minutes 
colour to indicate an infected result (Santos, Clemente, Bartolo, Palladino, Cavaco, 
Franco, Epalanga, Pinto & Taveira, 2011). 
 
The acute HIV infection phase follows the initial HIV infection before antibody 
seroconversion. During this acute phase serological rapid testing may yield false 
negative results and HIV RNA assay testing is recommended. Confirmation of any 
infected HIV results is necessary with a second specimen for HIV testing (Bassett, 
Chetty, Giddy, Bishop, Lu, Losina, Freedberg & Walensky, 2011). The acute phase 
(diagnostic window, serological latency) HIV p24 antigen and viral nucleic acid may 
be detected in the plasma of the infected individual. A second diagnostic window 
may occur if p24 antigen concentration decreases as detectable antibodies increase 
(Niederhauser, Strohle, Stolz, Muller & Tinguely, 2009). 
 
2.4.4. Treatment of HIV 
The treatment of HIV and AIDS includes a full range of interventions by the 
government of South Africa, including: Information, education, prevention 
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programmes, increased access to counseling and testing, the prevention of mother 
to child transmission, robust nutritional intervention and choice of treatment. 
Treatment regimes of HIV and AIDS patients in South Africa are available in a 
government publication: National antiretroviral treatment guidelines. Newer WHO 
guidelines are available for the treatment of HIV and AIDS patients. Updated 
guidelines have been developed but will only be available in January 2012 
(Telephone conversation between the author and ministerial representative E. 
Hadebe, 0795173333 on 27 October 2011). Some of the recommendations in the 
recent updates are: to discontinue stavudine as a first line treatment due to side 
effects of the drug. This recommendation is now implemented. Unfortunately the 
WHO recommendation to start antiretroviral treatment at a CD4 count below 350 
cells/mm3 was not adopted and remains at a CD4 count of ≤ 200 cells/mm3. The 
new guidelines recommended earlier treatment for four groups: 
 Person with WHO stage 4-disease (Table 2.4; WHO Clinical Staging of HIV 
and AIDS for Adults and Adolescents) regardless of CD4 count; 
 Person with HIV and TB and a CD4 count below 350 cells/mm3; 
 Pregnant women with CD4 count below 350 cells/mm3; and 
 Individuals with multi-drug resistance. 
 
The European guidelines to start with Antiretroviral (ARV) treatment are also 350 
cells/mm3 (EACS Guidelines 2011). The guidelines on when to start antiretroviral 
treatment (ART) in HIV-infected individuals are as important as the choice of 
treatment. The general recommendation is to start treatment already with a CD4 cell 
count of 500 cells or less per micro litre (Rossouw, Richter, Martin, Avenant, 
Spencer, 2011). 
 
Effective ART is usually made up of more than one drug, or even three drugs 
targeting different sites preventing the HIV to replicate (Coffey, 2011). Knowledge of 
the HIV lifecycle is used to develop treatment to inhibit viral host cell entrance, 
duplication and growth (HIV Lifecycle, 2011): 
 
30 
 
i) Fusion 
The HIV infects specifically immune cells (T-Helper cells) carrying a CD4 
molecule on its surface. The HIV enters the host cell by the binding of gp120 
molecule of the virus to the CD4 receptor of the host cell. After the initial binding 
the CCR5 and CXCR5 proteins are activated to complete the virus fusion with 
the host cell. Anti-retroviral medicine that block the fusion of the HIV is called 
fusion inhibitors. T-20 (enfuvitide, fuzeon) binds to the HIV and inhibits the fusion 
process. 
 
ii) Reverse transcription 
This process takes place after HIV fusion. Inside the host cell the genetic 
material (RNA) of the HIV is released inside the host cell. The viral enzyme 
(reverse transcriptase) translates the virus RNA into DNA. 
The three drugs in use to block this stage of HIV infection are: 
 Nucleoside reverse transcriptase inhibitors like AZT (zidovudine); 
 Non-nucleoside reverse transcriptase inhibitors like nevirapine 
(viramune); and 
 Nucleotide reverse transcriptase inhibitors like tenofovir (Viread). 
These drugs are also available in combination. 
 
iii) Integration 
After the forming of the DNA it is integrated with the DNA of the human host cell 
by means of a viral enzyme named integrase. This step prompts the human host 
cell to produce more HIV. The drug that acts on this stage of HIV infection is 
called integrase inhibitors, namely raltegravir (Isentress). Two potential areas to 
block viral duplication are with transcription (forming of messenger RNA) and 
translation (protein building blocks with messenger RNA). 
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iv) Viral assembly 
Finally, the production of the HIV can be inhibited by protease inhibitors. 
Protease enzyme divides the protein building blocks of the HIV into smaller 
particles that have the ability to repeat the duplication process. These new HIV 
buds off from the human host cell and are set free in the blood stream (about 
10.3 billion new viruses in persons not on anti-retroviral treatment). 
The protease inhibitors most commonly used are ritonavir (Norvir) and tipranavir 
(Aptivus). 
 
Recommended treatment regimes for HIV and AIDS in South Africa are as follows: 
(The South African antiretroviral treatment guidelines, 2013): 
 
2.4.4.1. First-line therapy for adults, including pregnant women 
Tenofovir (TDF) + Emtricitabine (FTC) (or Lamivudine (TC)) + Efavirenz 
(EFV) 
2.4.4.2. Second-line therapy (Failing on a TDF-first line regimen) 
Patients that continue to deteriorate virological and taking their medication correct 
will move on to the second–line therapy which includes zidovudine (AZT), 
Lamivudine (3TC) and lopinavir/ritonavir (LPV/r). 
 
Clinical and laboratory monitoring of individuals on ARV treatment is essential to 
prevent drug resistance and to treat adverse events and opportunistic infections. 
Individuals on treatment should visit the treating doctor or nurse at 4, 8 and 12 
weeks and then 3-monthly thereafter. CD4 counts and viral load have to be done 6-
monthly to monitor the success of the treatment (Grimwood, 2004). 
 
The prominence of lung disease and pulmonary infections associated with HIV 
infection demonstrates the severe effect that HIV has on host lung defenses of the 
HIV-infected individual (Beck, Rosen & Peavey, 2001). Recent studies in HIV-
infected individuals show that 31% to 64% presented with pulmonary symptoms and 
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8% to 21% showed airway obstruction with spirometry. The pulmonary host 
defenses are impaired by HIV infection by means of 
1) directly killing the cells directed to defenses, 
2) inducing defects in the metabolic and secretory functions of effector 
cells, 
3) shifting cell function products from immunostimulating to 
immunosuppressant, and 
4) reducing circulating lymphocytes, monocytes and neutrophils by 
migration to the alveolar spaces to clear pathogens (Beck, 2005). 
 
The direct infection of pulmonary cells by HIV alters the lung host defense because 
the CD4 molecule on the lymphocytes and monocytes serves as the primary cellular 
receptor for HIV-1, with a decrease in CD4 cell count (Beck, 2005). 
 
HIV breaks down the immune system and promotes nutritional deficiency in infected 
individuals (Campa & Baum, 2010). The optimal nutritional status of HIV-infected 
individuals is important, because malnutrition is associated with an increased death 
rate (Leah & Mascioly, 1995; Ockenga et al., 2006). HIV infection has a negative 
influence on the human metabolism even in the early stage of the infection when 
apparent clinical symptoms are not visible. 
 
 
2.5. NUTRITION AND HIV INFECTION 
To maintain optimal health a person needs energy-providing nutrients namely 
carbohydrates, fat and protein. In addition, water, minerals and vitamins (Spencer, 
Harman, Botha, Rollins, Labadarios, & Visser, 2008) play a vital role in this regard. 
This is even more important regarding HIV infection and AIDS as it impacts on 
nutritional status as a „wasting syndrome‟ (Leah & Mascioly, 1995; Lee & Nieman, 
2010). The nutritional effects of HIV infection include: An increase in resting energy 
expenditure (during infections), decreased food intake, depression, anorexia, 
malabsorption, decreased quality of life, decreased work productivity and less 
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dietary diversity, all contributing to the failure of gaining weight  (Sztam et al., 2010; 
Hemsworth, Hekmat & Reid, 2011). Food insecurity and increased nutritional 
vulnerability are major driving forces for nutritional care and support (NCS) 
programmes for HIV and AIDS infected individuals. The immune system requires 
the necessary micronutrients to maintain immunity. The immunity is compromised 
by HIV infection as it breaks down the immune system and promotes nutritional 
deficiency (Campa et al., 2010). 
 
2.5.1. Diet and nutrition in Southern Africa 
To achieve and maintain proper health an adult needs at least 2100 KJ per day, of 
which 10% - 20% should comprise of protein. Unfortunately protein intake makes 
out a very small portion of the daily diet of many communities in Southern Africa 
(Spencer et al., 2008). 
 
A study in Ga-Rankuwa in the Gauteng area, South Africa found that neither males 
nor females with HIV met the minimum prescribed daily energy intake through their 
diet and furthermore demonstrated a serious deficiency in micronutrient intake and 
dietary diversity (Venter, Gericke & Bekker, 2009). 
 
A study by Lategan and co-workers in the Northern Cape, South Africa, showed that 
25% of the 158 initial participants were malnourished and presented with a BMI less 
than 18.5 kg/m2 with enrolment into the study (Lategan et al., 2010). An 
investigation conducted in the Mangaung metropolitan indicated that HIV-infected 
women showed high energy intakes.  However, a recommendation was that these 
individuals should reduce their fat intake and increase the intake of other forms of 
energy sources, such as protein (Hattingh, Walsh, Veldman & Bester, 2006). 
 
Food for a healthy diet may represent about 30% of the total income of a family and 
is unaffordable for many South Africans. Interventions are necessary in South Africa 
to make available healthier and more affordable food (Temple & Steyn, 2011). To 
assess and improve the nutritional status of HIV and AIDS individuals an objective 
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measurement of anthropometry, clinical and biochemical status and dietary intake is 
necessary (Oketch et al., 2011). 
 
2.5.2. Micronutrients in HIV 
Micronutrients are essential for growth, immunity and psychomotor development as 
they catalyze body functions and are part of specific body tissues (De Pee & 
Semba, 2010). Cells require minerals and vitamins in small quantities to regulate 
important physiological processes of the human body. (Afacan, Fjell & Hancock, 
2012). 
 
Vitamins and minerals are organic substances that are not used to provide energy 
but assist the body to utilise fats, protein and carbohydrates for body building. In 
most instances vitamins act as coenzymes. With the exception of vitamin D and 
small amounts of vitamin B and vitamin K, produced by intestinal bacteria, all 
vitamins are obtained from food or by means of vitamin supplementation. Minerals 
are needed in moderate amounts and make up approximately 4% of the body 
weight (Marieb & Hoehan, 2010). 
Deficiencies of vitamins A, C, E, B6 and B12, as well as the minerals zinc and 
selenium have been shown to compromise the immune response (Campa et al., 
2010). Micronutrient deficiencies remain a major global problem, but especially in 
developing countries where such deficiencies contribute to impaired health and 
growth, neurobehavioral dysfunctions as well as defective immunity. It is also 
possible that certain micronutrient deficiencies may act as cofactor in HIV 
progression (Chen, Zhang, Li, Chen, Wei, Qu, Lui, 2011). In the Mangaung area 
(Free State, South Africa) HIV infection causes micronutrient deficiencies especially 
among HIV-infected children with glutathione, vitamin A, zinc and vitamin D being 
the most prominent ones (Steenkamp, Dannhauser, Walsh, Joubert & Veldman, 
2009). 
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2.5.2.1 Vitamins 
For the purpose of this study, a synopsis of specific vitamins and their respective 
functions relative to HIV are discussed. 
 
Vitamin A 
Vitamin A is present in the diet as all-trans retinol, beta carotene or retiyl esters. All-
trans retinol is stored in the liver after esterification to retinyl ester or bounded to 
protein as retinol to be transported to target tissues. All-trans retinol is then oxidised 
intracellular to all-trans retinal by retinol dehydrogenase (Cassani, Villablanca, De 
Calisto, Wang & Mora, 2012). 
 
Functions of vitamin A include maintenance of the epithelium, it acts as an 
antioxidant and helps to prevent damage to cell membranes (Yang, Yuan, Tao & 
Wang, 2011). Vitamin A deficiency will lead to increased susceptibility to lung and 
gastrointestinal infections, weak response to immunization and increased HIV 
progression (Marieb & Hoehan, 2010; Yang et al., 2011 & Cassani et al., 2012). The 
vitamin A metabolite, all-trans retinoic acid, regulates T and B cell immune 
responses (Cassani et al., 2012). 
 
Vitamin A supplementation reduces the incidence of measles and diarrhoea in HIV-
infected children (Imdad, Sadiq, & Bhutta, 2011) as well as diarrhoea and 
respiratory infection in unaffected children in South Africa (Chen, Yang, Yan, 2012). 
 
Vitamin A enhances cellular differentiation with an increase of the co- receptor 
CCR5 on CD4 cells that may imply that it enhances viral entry. Several trials and 
well documented observational studies demonstrated the benefits of vitamin A and 
other micronutrient supplementation (Metha et al., 2010). The recommended daily 
allowance of vitamin A (retinol) is 0.7 to 0.9 mg per day (Spencer et al., 2008). 
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Vitamins B Complex  
For the purpose of this study, the following B vitamins will be discussed: vitamin B1, 
B2, B3, B6 and B12. 
 
Thiamine (B1), riboflavin (B2) and Niacin (B3) 
Thiamine (B1), riboflavin (B2) and Niacin (B3) play important roles in the tricarboxylic 
acid cycle as coenzymes. This cycle is the main supplier of Adenosine triphosphate 
(ATP) in the human body and may be the cause of the lack of energy experienced 
even by asymptomatic HIV-infected individuals. Supplementation with the B group 
of vitamins improves the CD4 as well as the CD8 cell counts, with a longer delay 
and less rapid advancement of individuals to AIDS (Spencer et al., 2008). 
 
Vitamin B6 
Vitamin B6 deficiency is well documented amongst HIV-infected individuals and is 
associated with neurological manifestations such as memory loss, dementia, 
depression and cognitive abnormalities even before the manifestation of 
megaloblastic macrocytic anaemia (Campa et al., 2010). 
 
Vitamin B12 
Vitamin B12 is involved in protein and carbohydrate metabolism (Sviri, Khalaila, 
Bayya, Linton, Stav & van Heerden, 2012). Cobalamins, vitamin B12 derivates, are 
essential for the production of methylcobalamin and adenosylcobalamin, cofactors 
for mitochondrial-methylmalonyl-CoA mutase and cytosolic methinine synthase 
(Moreira, Barsch & Yun, 2011). Vitamin B12 deficiencies also occur in approximately 
27% of HIV-infected patients (Woods, Tang, Margo, Forrester, Jones, Hendricks, 
Ding & Knox, 2003). 
Vitamin B12 is important for red blood cell formation, neurological function and DNA 
synthesis. Low plasma levels of Vitamin B12 may result rather from absorption 
abnormalities than inadequate intake. Vitamin B12 first has to be released from the 
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ingested food protein by gastric hydrochloric acid and gastric proteases, after which 
it binds to cobalophins or haptocorns in the duodenum where it is released by 
hydrolysis.  
 
Free Vitamin B12 binds to intrinsic factor and is absorbed in the ileum. Vitamin B12 
deficiency is prevalent in chronic conditions like Crohn‟s disease and HIV. Vitamin 
B12 supplementation is necessary either in the form of fortified cereal or as a 
supplementation (Baer & St Peter, 2011). Specific supplementation with 
cyanocobalamin can protect individuals against oxidative stress-associates 
pathologies (Moreira et al., 2011). 
Vitamin C 
Vitamin C (ascorbic acid) is involved with the hydroxylation of carnitine, the 
conversion of tryptophan to neurotransmitters (serotonin and noradrenalin), the 
production of thyroxin and in the formation of collagen (Campa et al., 2010). Vitamin 
C is an antioxidant, with detoxification and assists with iron absorption (Paul, 2011). 
Vitamin C deficiency leads to scurvy, delayed wound healing and impaired immunity 
(Marieb & Hoehan, 2010; Dong & Imai, 2012). Studies showed that vitamin C 
supplementation delayed HIV progression and the onset of AIDS (Spencer et al., 
2008). 
Vitamin D 
Vitamin D exists in several forms including 25-hydroxyvitamin D and 1,25 
dihydroxyvitamin D [1,25(OH)2D]. Vitamin D is also obtained by exposing the skin to 
sunlight to convert 7- dehydrocholesterol to cholecalciferol and vitamin D3 (Dobnig, 
2011). Ingestible forms of vitamin D are vitamin D3 and D2 (Beard, Bearden & 
Striker, 2011). Classically the main role of vitamin D has been to be essential  for 
bone homeostasis, but recent research proves vitamin D to play an important role in 
modulating innate and adaptive immune function, due to the  presence of vitamin D 
receptors in most of the immune system cells (Baeke, Takiishi, Korf, Gysemans & 
Mathieu, 2010). Vitamin D is involved in innate immune system regulation. Vitamin 
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D-activating enzyme (CYP27B1) assist in linking monocytes and pathogen sensing 
mechanisms (Lagishetty, Lui & Hewison, 2011). 
 
Vitamin D, a fat soluble pre-hormone acts via metabolites like 1,25(OH)2D that 
binds to the nuclear vitamin D receptor (Gueli, Verrusio, Linguanti, Di Maio, 
Martinez,  Marigliano & Cacciafesta, 2012) and suppressed T-helper (Th1) CD4 
cells to enhance Th2 CD4 cell production. Toll-like receptors (TLRs) of monocytes 
and macrophages play an important role in innate immune response (Lagishetty et 
al., 2011). The stimulation of the TLRs in macrophages by anti-microbial peptides 
results in the conversion of vitamin D to its active form. The role of vitamin D is to 
assist with the induction of cathelicidin (protein with c-terminal cationic anti-microbial 
domain) to be released at the site of infection (Beard et al., 2011; Verrusio, 
Linguanti, Di Maio, Martinez, Marigliano & Cacciafesta, 2012). The major function of 
vitamin D is associated with the absorption of calcium from the intestine and the 
promotion of normal bone growth and mineralisation (Gueli et al., 2012). 
 
Lower than normal serum levels of vitamin D have been found in HIV-infected 
individuals, although there was no correlation between vitamin D levels and CD4 
cell count. It is well established that HIV treatment with protease inhibitors and non-
nucleoside reverse transcriptase inhibitors interferes with vitamin D metabolism 
(Wasserman & Rubin, 2010). An infected correlation was found between higher 
vitamin D levels and decreased mortality among HIV-infected individuals (Vilamor, 
2006). Vitamin D deficiency is increasing globally (Van Belle, Gysemans & Mathieu, 
2011) and vitamin D supplementation should be given routinely to HIV-infected 
individuals for periods longer than 12 months in individuals with low serum levels  
(Randall, Rutstein & Shah, 2011). Vitamin D cut-off points for serum levels are >75 
nm/L for sufficient, 50-70 nm/L for insufficient and, 50 nm/L for vitamin D deficiency 
(Makariou, Liberopoulos, Elisaf & Challa 2011; Van Schoor & Lips, 2011). 
According to the American Dietetic Association the Recommended Dietary 
Allowance (RDA) (assuming minimal sun exposure) for vitamin D should be 600 
IU/day for people 1-70 years of age (Ross, Manson, Abrams, Aloia, Brannon, 
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Clinton, Durazo-Arvizu, Gallagher, Gallo, JonesKovacs, Mayne, Rosen & Shapses, 
2011). 
 
 Vitamin E 
Vitamin E is considered to be the most important chain-breaking antioxidant in body 
tissue and represents the first line of protection against lipid peroxidation 
(Pekmezci, 2011). Vitamin E is a fat-soluble antioxidant that is involved in the 
regulation of cell signaling and gene expression (Dong et al., 2012). 
 
Vitamin E is necessary for the functioning of the immune system by increasing the 
cell-mediated and humeral immune response to antigens. Vitamin E enhances 
macrophage phagocytic function and resistance to viral infection (Campa et al., 
2010). The fast proliferating immune cells are easily damaged by peroxides thus 
vitamin E prevents damage to the cell membranes by reducing lipid peroxidation. 
Supplementation with vitamin E enhances humeral as well as mediated immunity in 
humans (Spencer et al., 2008; Marieb & Hoehan, 2010; Molano & Meydani, 2012). 
 
Although vitamin E protects the human body against cancer, ischemic heart disease 
and atherosclerosis, an elevated vitamin E concentration is associated with 
enhancing atherosclerosis in HIV-infected individuals (Falcone, Mangili & Tang, 
2010). The RDA for adults is 15 milligram of alpha tocopherol equivalents per day 
(Dong et al., 2012). 
 
2.5.2.2. Minerals 
Minerals are involved in most of the physiological functions of the body as a 
component of enzymes and/or as building blocks of tissue like bone and 
haemoglobin (Lee & Nieman, 2010). 
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Zinc 
Except for iron, zinc is the most abundant trace metal in the human body. An 
adequate intake of zinc is important for immune function and is essential for the 
hormone thymulin in the formation of T-lymphocytes. Zinc deficiency causes thymic 
atrophy, reduction in T- lymphocytes production and a reduction in macrophage 
activity to take up pathogens in the human body (Campa et al., 2010). Zinc is 
required for the regeneration of new CD4 cells as well as the maintenance of T4/T8 
ration and interleukin 2 levels (Metha et al., 2010). Zinc deficiency leads to a 
reduction in circulating T-cells as well as reduced tuberculin reactivity (Gupta,  
Gupta, Atreja, Verma, Vishvkarma, 2009).  Insufficient zinc serum levels occur in 
more than 50% of individuals infected with HIV (Baum, Lai, Sales, Page & Campa, 
2010). 
 
Supplementation with zinc shows a reduction in diarrhoea in HIV-infected 
individuals (Spencer et al., 2008; Irlam, Visser, Rollins & Siegfried, 2010) as well as 
a reduction in respiratory disease morbidity (Imdad et al., 2011). Zinc form part of 
the structural proteins of HIV and is necessary for effective reverse transcriptase 
enzyme activity (Spencer et al., 2008; Paul, 2011). This mineral is involved in more 
than 100 enzymatic processes in the body, assists with gene expression and 
protein folding (Saper & Rash, 2009) and serves as co-factor for 300 known 
enzymes (Quintero & Guidot, 2010). 
 
A low plasma level of zinc may occur when people consume a diet mainly 
consisting of maize and legumes. These food products are high in phytate that 
chelates the zinc in the diet (Mburu, Thurnham, Mwaniki, Muniu & Alumsas, 2010).  
Lower plasma zinc levels in patients with TB as a co-infection with HIV may be the 
result of lower a2-macroglobulin (zinc carrier protein) produced in the liver (Gupta et 
al., 2009). The RDA for zinc is 8 mg tot 11 mg per day (Marieb & Hoehan, 2010). 
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Selenium 
Selenium is an important component of the humeral immune repose through its role 
in interleukin-2 and cytokine action in the expression of T-Lymphocyte expansion 
(Campa et al., 2010). This trace element inhibits the progression and reduces the 
viral load of HIV by means of its antioxidant effect through glutathione peroxidase 
where it is an active component. Reduced selenium status is associated with an 
increase of HIV disease progression and mortality (Royal & Klebert, 2009; Irlam et 
al., 2010; Pitney, Stone, Kawai & Kupka, 2010).  Selenium is a chemo preventive 
mediator in HIV and supplementation may increase the defense systems of the 
human body (Campa et al., 2010) and specifically improves CD4 cell counts of HIV-
infected individuals (Stone et al., 2010). 
 
Magnesium 
The RDA for magnesium is 400 mg (Lee & Nieman, 2010). Magnesium is a 
component of certain co-enzymes in ATP and a lack of this macro mineral plays an 
important role in nervous system disturbances, muscle weakness and sudden 
cardiac death (Marieb & Hoehan 2010). 
 
Calcium 
Calcium is essential for several physiological functions in the human body. This 
mineral forms an important part of bone and tooth formation. Cell membrane 
integrity potential regulation of heart muscle contraction and clotting of blood are 
also influenced by this nutrient (Lee & Nieman, 2010; Marieb & Hoehan 2010). 
 
In people living with HIV and AIDS, lifestyle, hormonal factors, decreased physical 
activity, lower intake of calcium and vitamin D and depression lead to lower plasma 
calcium levels (Borderi, Gibellini, Vescini, De Crignis, Cimatti, Biagetti & Tampellini,   
2009; Campa et al., 2010).  Additional factors including lower BMI, lactic acidosis in 
addition to calcium deficiency usually lead to the loss of bone mass causing 
osteopenia and osteoporosis (Dobs & Brown, 2002). 
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2.5.3. Macronutrient in HIV 
Macronutrients include carbohydrates, fats and lipids, amino acids and proteins. 
Carbohydrates consist of monosaccharide, disaccharide, oligosaccharide and 
polysaccharides. The required digestible carbohydrates in the diet should be 45% to 
65% of the total calorie intake. Fats and lipids should not exceed 34% of the energy 
in the human diet. Protein requirement in diet is 0.8 gram of protein per kilogram of 
body weight. Protein intake should be 10% to 15% of the total daily energy dietary 
intake (Gallagher, 2012). 
 
2.5.4. Malnutrition in HIV-infected individuals 
The cause of malnutrition in HIV-infected individuals is multifaceted. Acute and 
chronic physiological changes associated with psychological, social and economic 
factors play an important role in every individual‟s nutritional status. These complex 
interactions often coexist geographically (Sztam et al., 2010). 
 
Good nutritional status of HIV-infected individuals is important as under nutrition is 
associated with an increased death rate (Ockenga, Grimble, Jonkers-Schuitema, 
Macallan, Melchior, Sauerwein & Schwenk, 2006). HIV infection has a negative 
influence on human metabolism even in the early stage of the infection when no 
apparent clinical signs are visible (Szetela & Gasiorowski, 2010). The chronic 
inflammation caused by infection increases the metabolic needs of the human body 
and may lead to the depletion of essential nutrients resulting in a malnourished 
person with reduced immunity. Reduced immunity is enhanced when oxidative 
stress becomes more prominent as nutritional reserves further decline. The immune 
changes in HIV-infected individuals including declines in the numbers as well as the 
ratio of CD4 cell count and CD8 cell count are also found in malnourished 
individuals due to the negative effect on the thymus gland cell proliferation. 
Malnutrition causes thymus atrophy affecting immature CD8 and CD4 cells 
contributing to impaired peripheral immune response (Savino & Dardenne, 2010). 
The increasing risk of death in a malnourished HIV-infected individual is 
independent from the viral load and CD4 cell count (Grimble, 2009). 
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To diagnose malnutrition, measurements such as BMI are necessary while blood 
analysis will help to confirm the diagnoses. Reductions in the following biochemical 
markers are typical of malnutrition: Albumins, haemoglobin, urea, creatinine, 
glucose, triglycerides, zinc, iron, selenium, vitamins A, B, D, folic acid (Szetela et 
al., 2010) and vitamin E (Mehta, Spie, About, Giovannucci, Msamanga, Hertzmark, 
Mugusi, Hunter & Fawzi, 2010). Signs and symptoms of malnutrition commonly 
include a: BMI below 18,5 kg/m2, cell mass loss (lean body mass) of more than 5% 
in three months, lack of weight gain, hormonal abnormalities and active 
opportunistic infections (Ockenga et al., 2006). 
 
Impaired and/or reduced nutritional status may be caused by a reduced intake and 
availability of food due to the effect of HIV and AIDS on the household income 
(Lemke, 2005; De Pee et al., 2010) and physiological symptoms like oral thrush; 
vomiting; appetite loss; reduced nutrient absorption due to diarrhoea and intestinal 
damage (Oketch et al., 2011). 
 
2.5.5. Nutritional supplementation and support for individuals living with HIV 
and AIDS 
A healthy, well balanced diet with all the necessary fluids, vitamins, minerals and 
other nutrients is the preferable way to supply all the body‟s needs. Dietary 
supplementation can help an individual to obtain additional micronutrients to boost 
the nutritional content of a diet. Supplementations are available in tablet, capsule, 
powder, or liquid form. Dietary supplementation may have side effects or interfere 
with medication and should therefore be taken with great care. According to Szetela 
and co-workers “Nutritional support for chronically ill patients is still perceived by 
medical professionals as a specialist field of expertise even though adequate 
supplementation of micro- and macro elements has been widely accepted as one of 
the key factors in successful treatment of chronic conditions like diabetes, renal, 
hepatic and intestinal diseases as well as HIV and AIDS. In all these cases 
prophylaxis of malnutrition and wasting has been proven to be cost-effective and in 
the case of HIV it has added value to ART alone in improving survival and quality of 
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life” (Szetela et al., 2010). The supplementation of nutrients like vitamin A has been 
found to lower respiratory infections as well as AIDS related deaths (Mehta & Fawzi, 
2007). A study done in the Northern Cape, South Africa, found that half the 
participants in the study gained significant weight after supplementation with 
enriched maize meal, a soy-based liquid and multivitamins. The author suggested a 
more aggressive supplementation programme to ensure a higher success rate in 
the treatment of weight gain (Lategan et al., 2010). As malnutrition is a global 
phenomenon and not only linked to illness, mineral and vitamin supplementation 
and food fortification should be done according to WHO guidelines taking in 
consideration local conditions (Tulchinsky, 2010). 
 
Supplementation with specific micronutrients like vitamin D will benefit HIV-infected 
individuals in particular to combat cardiovascular events (Choi, Lo, Mulligan, 
Schnell, Kalapus, Li, Hunt, Martin, Deeks, & Hsue, 2011) and restoring the immune 
homeostasis (Peelen, Knippenberg, Muris, Thewissen, Smolders, Tervaert, 
Hupperts & Damoiseaux, 2010). Vitamin D supplementation according to the U.S. 
food and drug administration should not be more than 2000 IU daily due to toxicity 
of this fat-soluble vitamin (Makariou et al., 2011). Nutritional addition of Beta-
sitosterol (naturally found in peanuts, sesame seeds and soybeans) supports the 
action of vitamin D to improve macrophage function. Macrophages produce 
cytokines and nitric oxide, an important defense mechanism against infection 
(Alappat, Valerio & Awad, 2010). 
 
Oral zinc supplementation will reduce viral activity and enhances wound healing 
(Kim, Bae & Lee, 2011). Vitamin A supplementation in high dosage is used as a 
child survival intervention in HIV-infected children (De Pee et al., 2010). 
Replenishment or additional provision of nutrients is able to enhance and restore 
cellular function such as phagocytosis and cytokine production of macrophages and 
neutrophils in individuals who suffered from mal nutrition (Afacan et al., 2012). 
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Spirulina (Spirulina plantensis) has been commercially available as a food 
supplement for more than 10 years. Spirulina contains essential fatty acids, beta-
carotene, minerals, vitamins and high quality protein. Spirulina potentiates the 
immune system, suppressing cancer development and viral infection (Hirahashi, 
Matsumoto, Hazeki, Saeki, Ui, Seya, 2002; Watanuki, Ota, Malina, Tassakka, Kato 
& Sakai, 2006). 
 
Most indigenous medicinal plants are sold on informal markets and by traditional 
healers. Some of these plants are now commercially produced. Several products 
have been standardised and are commercially available including the African 
potato (Van Wyk, 2011). The African potato (Hypoxis hemerocallidea) also known 
as “magic muthi”, yellow star, lotsane and inkomfe, is  widely utilized by the 
indigenous people in Southern Africa for cancer and HIV infection, as an emetic and 
a tonic (Philander, 2011). The anti-cancer and anti-HIV agent in African potato is 
rooperol: 4, 4‟ diglycoside (Beta-sitosterol) (Van Wyk, Van Oudshoorn & Gericke, 
1997). Beta-sitosterol and its glycoside exhibit anti-inflammatory, anti-neoplastic 
activities and enhance T-helper lymphocyte action to improve natural killer cell 
activity (Fraile, Crisci, Cordoba, Navarro, Osada & Montoya, 2012). However, 
clinical studies indicated bone marrow-failure and a drop in total lymphocyte count 
in some HIV-infected individuals using large quantities of African potato (Spencer et 
al., 2008). 
 
2.5.6. HIV-associated ‘Wasting’ and nutrition 
HIV wasting syndrome is defined by the CDC as: Involuntary weight loss of more 
than 10% of body weight; chronic diarrhoea (at least two loose stools a day for 30 
days or more) or chronic weakness; Constant or intermittent fever for 30 days or 
more; and the absence of a condition or illness other than HIV infection that might 
cause symptoms (Lee & Nieman, 2010). 
 
These symptoms are associated with clinical stage 4 of HIV infection, equivalent to 
AIDS (Singh & Singh, 2005). Wasting may be caused by decreased food intake, 
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increased nutrient requirement (hyper metabolism) and/or nutrient malabsorption. 
Decreased food intake may result from the loss of appetite (vomiting. nausea, 
altered taste, anorexia); chewing and swallowing problems (mouth and throat sores 
from Kaposi‟s sarcoma, infections like herpes, candidiasis, esophageal ulcers); 
decreased interest in eating (loneliness, depression); and not being able to prepare 
meals (poverty, weakness, AIDS induced dementia) (Dudgeon, Phillips, Carson, 
2006; Lee & Nieman, 2010). 
 
A severe increase in metabolism is also noted and may be caused by fever due to 
opportunistic infections and neoplastic origin. Hormone level changes such as 
increased cortisol levels due to chronic stress have a catabolic effect on the body by 
degrading skeletal muscle and slow down protein synthesis. A decrease in 
testosterone as well as insulin-like growth factor correlates with body mass loss and 
lean tissue mass loss. High levels of cytokines (proteins that produce inflammation) 
in Brown HIV infection affect the metabolism negatively as it causes the body to 
produce more fats and carbohydrates, but less protein (Dudgeon et al., 2006; 
Slama, Le Camus, Pialoux, Capeau & Gharakhanian, 2009; Brown, 2011; Falutz, 
2011). 
 
Malabsorption of nutrients is a major contributor to wasting due to diarrhoea and 
inflammation of the bowel mucosa occurs in more than 50% of individuals with AIDS 
(Lee & Nieman, 2010). 
 
The prevalence of osteoporosis and osteopenia is documented in HIV-infected 
individuals. Factors like gender, age, low body weight, sex hormones and 
malnutrition and calcium deficiency may contribute to bone loss. Cross-sectional 
studies showed a higher incidence of bone fractures amongst HIV-infected 
individuals (Briot, Kolta, Flandre, Boué, Ngo Van, Cohen-Codar, Norton, Delfraissy 
& Roux, 2011). 
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TB and HIV infection coincide in South Africa with more than 80% of the TB patients 
in KwaZulu-Natal, co-infected with HIV (Gandhi, Moll, Lalloo, Pawinski, Zeller, 
Moodley, Meyer & Friedland 2009). The high incidences of TB contribute to 
malnutrition and wasting in the HIV-infected community. The increased energy use 
in TB is due to an increased production of cytokines with lipolytic and protolytic 
activity (Gupta et al., 2009). 
 
 
2.6. THE IMMUNE SYSTEM AND HIV 
A highly complex and interactive group of cells and cell products in the body form 
the immune system with its unique properties (Kubena & McMurray, 1996). Self 
regulation of the immune system takes place by means of helper and suppressor 
cells as well as close communication with other body systems including the neuro 
endocrine functions. 
 
Humans are continuously confronted by intrusions from the environment, but the 
human immune system has evolved to render protection to the body against 
infectious microorganisms, which without the human being will not be able to 
survive (Coico,  Sunshine & Benjamini, 2003; Pratt, 2003). 
 
2.6.1 Classification of the immune system 
There are two distinctive immune responses in the human body namely innate 
immunity and specific immune responses. 
 
2.6.1.1 Innate immunity 
Innate immunity is a natural, non-specific defense mechanism present from birth. 
The innate immunity consists of a variety of mechanisms such as barriers (intact 
skin), surface secretions, ph changes, flushing actions (urine and tears) and 
resident bacterial population like normal flora. The main function of innate immunity 
is the prevention and containment of pathogen invasion as well as the production of 
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antigens by antigen-presenting cells (Pratt, 2003). The innate immune system 
actively protects the body without prior contact against a particular invader, but it 
lacks specificity. Granulocytes, natural killer cells and macrophages form part of the 
innate immune system (Van Belle et al., 2011). 
 
2.6.1.2 Specific immune responses (adaptive immune response) 
The specific immune response is also known as an adaptive immune response and 
provides permanent protection against the known pathogen in the body. The 
specific immune responses are: humeral and cellular immune responses: 
 
Humeral immunity 
Humeral immunity is the result of antibodies secreted into the serum by B-
lymphocytes after binding of the antigen to a specific immunoglobulin. The 
matured B-lymphocytes develop receptors on the surface named membrane 
immunoglobulin e.g.  IgA and IgM. The B-lymphocytes form 5%-15% of the 
circulating pool of lymphocytes, the remaining 85% are T-lymphocytes and 
natural killer cells (neutrophils and eosinophils (Pratt, 2003). Another major 
element of humeral immunity is the compliment system, activated by the 
interaction between antigens and antibodies. This immune activation causes 
early apoptosis of B- and T-lymphocytes to release apoptotic microparticles 
in the blood stream. The compliment system is a cascade of serum enzyme 
reactions resulting in the lyses and then the phagocytosis of intruder antigens 
by polymorphonuclear cells (Coico et al., 2003). 
 
Cellular or Cell-mediated immunity 
Cellular or Cell-mediated immunity is an antigen-specific immune response 
involving T-lymphocytes produced in the bone marrow and matured in the 
thymus gland.  The three types of T-lymphocytes are: T-cytotoxic (Tc) CD8 
cells, T-helper (Th) CD4 cells and T-suppressor cells (Coico et al., 2003; 
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Pratt, 2003). The CD4 and CD8 are co-receptors in the periphery of the T-
lymphocytes. The activation of the T-lymphocytes is by contact with antigen 
presenting cells like dendritic cells, macrophages and B-lymphocytes (Van 
Belle et al., 2011). The CD8 T-lymphocytes release lytic substances, 
granzyme B and perforin to kill identified cells directly. The CD4 T-
lymphocytes differentiate to produce interleukin, tumor necrosis factor and 
interferon. 
 
2.6.2 Host Cellular Immune response to HIV infection 
The early initial response of the innate and adaptive immune system occurs, but it is 
not in time to eliminate the HIV infection. The early immune response is responsible 
for the path the HIV uses to form mutations to escape detection in the human body. 
The presence of HIV viremia in the lymphoid tissue indicates systemic 
establishment of the virus in the body (Wendelsdorf, Dean, Hu, Nordone & Banks, 
2011). The formation of antibodies against the gp120 (Geha & Rosen, 2008) as well 
as gp41 envelope is an indicator of HIV infection (Tomaras, Yates, Lui, Li, Fouda, 
Chavez, Decamp, Parks, Ashley, Lucas, Cohen, Eron, Hicks, Charles, Hua-Xin, 
Self, Landucci, Forthal, Weinhold, Keele, Hahn, Greenberg, Morris, Karim, Blattner, 
Montefiori, Shaw, Perelson & Haynes, 2008). The attachment sites of the HIV that 
lock onto the receptors of the host cells are located in the gp120 envelope 
glycoprotein. The cell-surface receptor on T-lymphocytes as well as other immune 
system cells is the CD4 glycoprotein which is the main receptor for HIV. Other co-
receptors associated with CD4 molecules for HIV are chemokines (Pratt, 2003). 
 
Figure 2.5 explains the relationship between the CD4 cell count, viral load and 
clinical stages of disease progression. 
 
Initially there is a decrease in CD4 cells after infection, followed by a recovery of the 
CD4 count and a decrease in viral count (Crum-Cianflone, 2009; Trushin, Bren & 
Dabley, 2009). This initial antibody response does not provide protection against 
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infection, especially against infection with additional HIV strains. Eventually disease 
progression leads to decrease and depletion of CD4 cells with the loss of T cell 
function caused by the chronic persistent infection. The active CD8 cells without the 
presence of CD4 cells will with time loose the ability to respond to the HIV and the 
individual will develop AIDS (McCune, 2001; Boasso & Shearer, 2007; Green, 
Center & Cruikshank, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. The relationship between CD4 cell count, viral load and the clinical  
progression of HIV syndrome (Adapted from Living longer with HIV; new insight and 
issues, 2009). 
 
2.6.3 Nutrition and the immune system 
Macro- and micronutrients affect host defenses in a number of ways (Campa & 
Baum, 2010): 
 Cytokine and antigen receptor function can be negatively influenced by 
reduction of lipids and antioxidant vitamins which affect membrane 
structure. 
 The production of antibodies may be altered by limiting amino acids and 
reduced protein. 
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 Magnesium is directly associated with antibody formation and B-cell 
activation. Magnesium also influences the metabolism of other metabolites 
such as potassium, calcium and sodium. 
 Suppressed cell proliferation by limited nutrients such as zinc that 
modulates zinc-dependant enzymes. 
 Increased humeral immunity by selenium and vitamin A supplementation. 
 Increased antibody production and phagocytosis with vitamin E 
supplementation. 
 Zinc is necessary for proper thymus function, T-lymphocyte function and T 
cell dependent B-cell function. 
 
 
2.7 PULMONARY RESPONSE AND HIV 
Respiratory and pulmonary function abnormalities remain common in HIV-infected 
individuals especially before the introduction of combination antiretroviral (ARV) 
therapy. It is also speculated that ARV medication may be responsible for 
irreversible airway obstruction and that obstructive lung disease is likely under 
diagnosed (Gingo, George, Kessinger, Lucht, Rissler, Weinman, Slivka, McMahon, 
Wenzel, Sciurba & Morris, 2010). 
 
Since the first identification of HIV and AIDS, the pulmonary system has been the 
site mostly affected by the virus. Almost all patients develop lung complications 
during his/her history of HIV infection. Due to the administration of Pneumocystis 
prophylaxis and the introduction of highly active antiretroviral therapy (HAART) the 
epidemiology of lung infections has changed with a 50% decline in Pneumocystis 
pneumonia and bacterial pneumonia was recorded in patients treated with HAART 
(O‟Donnell, Bader, Zibrak, Jensen & Rose, 1988; Lazarous & O‟Donnell, 2007). In 
Africa lung infections are the most common reason for hospitalization, morbidity and 
mortality in people living with HIV and AIDS. Organisms such as pneumococcal 
pneumonia, Pneumocystis pneumonia and TB are most frequently reported (Benito, 
Moreno, Miro & Torres, 2011). In sub-Saharan Africa pneumonia remains the 
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leading cause of death and hospitalization especially amongst children (Gray & Zar, 
2010). To reduce this high occurrence of respiratory infections the treatment of 
HAART should be accompanied by the implementation of pneumococcal 
vaccination (Madeddu, Laura Fiori, Stella Mura, 2010). 
 
Pulmonary function test, particular spirometry is effective in diagnosing obstructive 
as well as restrictive respiratory diseases (Antwi, Gbekle, Cosmos, Ennin, 
Amedonu, Antwi-Boasiako, Clottey & Adzaku, 2011). HIV-infected individuals 
commonly have symptoms of airway disease associated with air trapping and 
significantly lower forced expiratory volume in one second (FEV1) and forced mid 
expiratory flow (FEF 50). These results suggest that small airways disease may be 
present in HIV-infected persons (Gelman, King, Neal, Pacht, Clanton & Diaz, 1999). 
Clinical studies confirmed that emphysematous lung disease is a lung complication 
of HIV and AIDS (Rubin & Luca, 2011). The damage to the lung tissue may be 
mediated by continuous immune activation and ongoing inflammation (Coffey, 
2011). 
 
Pulmonary function testing was done in 1988 on HIV-infected individuals by 
O‟Donnell and colleagues, who concluded that abnormally low forced expiratory 
flow rates frequently occurred in these individuals (O‟Donnell et al., 1988). 
Pulmonary function testing, such as the flow-volume curves indicate how the 
disease altered the physiological function and airflow dynamics of the lung. 
Measurements used to evaluate airway disease included forced expiratory volume 
in one second (FEV1) and vital capacity (VC). The ratio FEV1/VC is a parameter to 
demonstrate lower air flow in the lung (Takabatake, Sata, Abe, Inoue, Saito, Yuki, 
Shibata & Kubota, 2005; Cui, Carruthers, Mclvor, Smail, Thabane & Smieja, 2010). 
A decrease in the FEV1/VC was present in HIV-infected individuals. The abnormal 
airway function in HIV-infected individuals may by asthma like with bronchospasm 
and chest tightness (O‟Donnell et al., 1988), alveolitis, emphysema- like pulmonary 
disease (Diaz, Clanton, & Pacht, 1992) and inflammatory lung disease (Boyton, 
Smith & Ward, 2006). 
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The respiratory symptoms of a HIV-infected group of smokers were compared with 
a similar group of HIV negative smokers. The results showed that HIV-infected 
individuals are extremely affected by smoking and are more at risk to develop 
respiratory symptoms prior to AIDS related complications. The findings were as 
follows: the HIV-infected group results versus the HIV negative group results: 
Dyspnoea (41.6% vs. 7.7%), cough (40% vs. 25%) and phlegm production (41.9% 
vs. 23.1%). This may demonstrate the enhanced susceptibility to lung disease of 
people living with HIV and AIDS (Diaz, Wewers, Pacht, Drake, Ngaraja, Clanton, 
2003). Non-infective pulmonary diseases in HIV-infected individuals may include 
lymphocytic interstitial pneumonitis, malignancies like lymphoma and Kaposi 
sarcoma, interstitial lung disease. Non-infectious lung disease may present as 
COPD and in interstitial lung disease as restriction with decreased lung compliance 
(Theron, Andronikou, George, du Plessis, Goussard, Hayes, Mapukata & Gie, 2009; 
Hirani, Cavallazzi, Vasu, Pachinburavan, Kraft, Leiby, Short, Desimone, Squires, 
Weibel & Kane, 2011). 
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3.1. RESEARCH DESIGN 
The protocol design, study population, intervention (supplement), questionnaires, 
specific equipment and techniques used, measurements, and analysis of the data 
are discussed. 
 
3.1.1. Protocol design 
The trial is a quantitative, open-labeled, before-after clinical trial. 
 
3.1.2. Research site 
The present investigation was conducted in the University Clinic, Prosperitas 
Building, Central University of Technology, in Bloemfontein, Free State Province in 
the RSA. 
 
3.1.3. Scheduled planning outlay 
This investigation was divided into 2 phases each having their respective 
subdivisions and specified variables. These events are summarized in Figure 3.1. 
 
3.1.3.1. Phase 1 
During the initial phase a protocol was drafted and written approval was obtained 
from the Ethics Committee of the Faculty of Health Sciences, University of the Free 
State, Bloemfontein, before commencing with the project (ETOVS number: ETOVS 
142/05). 
 
3.1.3.2. Phase 2 (follow-up on phase 1 as specified). 
Baseline screening visits were followed by monthly screening visits extended over a 
period of one year. The first monthly visit was scheduled seven days after the 
baseline screening visit. Visit two was scheduled thirty days after visit one, followed 
by a thirty day waiting period to the next visit for a duration of one year (final visit). 
Deviations of ±2 days from the scheduled visits were allowed. 
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Figure 3.1. A summary of the research design and data collection of the specified      
variables. 
 
3.1.4. Procedures followed during screening visits 
Participants were seen at the clinic of the Central University of Technology (CUT) 
where specific procedures were adhered to on a monthly basis. 
 
3.1.4.1. Procedures followed during baseline screening 
Participants signed the consent form at their first visit after being informed. 
 
A registered dietician, researcher and local language interpreters interviewed the 
participants to complete the socio-demographic profile status questionnaire 
(SDPSQ) as well as a validated food-intake questionnaire (FIQ), (See 3.4). 
Physical and medical evaluations were performed on the participants by registered 
medical personnel to evaluate the health status of all participants. 
 
The researcher gathered information on bodyweight, height, as well as hip and 
waist circumferences to calculate anthropometric data (to calculate the BMI) by 
means of standard procedures (Lee & Nieman, 2010) and performed pulmonary 
function tests by means of spirometry (See 3.5.2.6). 
77 
 
Specialized medical personal took blood samples from all participants during each 
and every screening visit (see 3.5.2.2.) to gather information on haematological 
status and liver functions (3.5.2.3), immune status (see 3.5.2.4), and viral load (see 
3.5.2.5). Pathcare (private pathology laboratory) performed the laboratory analysis 
on all of these biochemical variables: The analytical methods applied are described 
in section 3.5.2: Laboratory investigations. 
 
3.1.4.2. Procedures followed during monthly screening 
The participants visited the clinic at the CUT on a monthly basis and all data was 
gathered by following the same procedures as outlined above (see 3.4.2.1.). Viral 
load and liver functions, however, were determined every 3 months during the 
follow-up screenings including the final screening. 
Compliance of the participants to adhere to the protocol and supplement intake was 
monitored throughout the trial (see 3.3.3 and 3.7.2). 
 
 
3.2. STUDY POPULATION 
The participants were HIV-positive volunteers living in the greater Mangaung 
Metropolitan. Recruitment was done by registered medical personnel, by word of 
mouth, transpiring in a snow-ball sampling effect. Both females and males in the 
age group of 18 to 65 years were included. None of the participants were on anti-
retroviral therapy or any form of chronic medication (Clinical category A 2). 
 
The baseline CD4/CD8-cell counts, viral load count and haematological data of the 
included participants were used as internal controls as no separate „control‟ group 
took part in this investigation because: 
 The immunological and nutritional status of people living with HIV and AIDS 
is different from those who are HIV-negative. It is believed that the response 
from HIV-negative people after supplementation may be very poor, thus 
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supplementation may not reflect a true influence of the nutritional 
supplement on the immune status of the HIV-negative group. 
 It is not ethical to use a HIV-positive control group, as they then would have 
been excluded from the use of medication (ART), treatment or discrimination 
in terms of gaining access to the possible benefits of the supplements. 
In accordance, all participants served as internal controls. 
 
3.2.1 Sample size 
A total of 132 participants pitched up for the initial baseline screening tests 
conducted over a period of 5 years (2006-2010). Participants who dropped-out due 
to withdrawal (see 3.2.2.3) or who did not comply with the terms and/or conditions 
set out in the research design, were replaced with individuals who met the inclusion-
exclusion criteria(see 3.2.2) in an attempt to raise the bar in terms of increasing the 
„power of the statistical outcomes‟. The final number of participants that met all 
requirements at 12 months was forty (40). 
 
3.2.2. Inclusion, exclusion and withdrawal criteria 
Strict inclusion, exclusion and withdrawal criteria ensured a homogeneous 
participant population with as little variation as possible: 
 
3.2.2.1. Inclusion criteria 
 HIV-positive male and female participants aged 18 to 65 years; 
 CD4-cell counts between 200–500 cells/mm3 ; 
 Medical history, physical evaluation, and laboratory results within 
the range of clinical acceptability, acknowledged by the clinical 
investigator; 
 Agreement to undergo a pre-study physical evaluation and pre- 
and post-study laboratory investigations; and 
 Ability to understand and willingness to sign the agreement of 
informed consent. 
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3.2.2.2. Exclusion criteria 
 History of psychiatric disorder, antagonistic personality, poor 
motivation to participate in this study or limited ability to comply 
with protocol requirements; 
 History of, or current compulsive alcohol abuse (>10 drinks 
weekly), or regular exposure to other substances of abuse; 
 Participation in another study with an experimental drug within 10 
weeks before the first administration of study supplement and/or 
screening visit; 
 History of hypersensitivity to the supplement; 
 Loss of blood equal to or exceeding 500 ml during the 10 weeks 
before the administration of study medication; 
 Heavy smoking (more than 20 cigarettes per day); 
 Pregnant women; 
 Diabetic HIV-positive participants; and 
 On anti-retroviral therapy or any treatment for chronic diseases. 
 
3.2.2.3. Withdrawal criteria 
Participants had the right to withdraw from the study at any time, irrespective of the 
reason, without detriment of their medical care. These participants were handled as 
drop-outs. Participants who dropped-out were replaced with individuals who met the 
inclusion criteria. The study had 92 drop-outs because of withdrawal or non-
compliance. 
 
3.2.3. Participant identification 
The following strategy for identification purposes during follow-up screening visits 
was implemented and adhered to: 
 Each enrolled participant received a specific number and retained 
this number throughout the trial. 
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 Each enrolled participant retained his/her initials obtained from a 
copy of his identification book (three digits); and 
 Each enrolled participant was identified by date of birth (six digits). 
 
3.2.4. Participant’s informed consent (see APPENDIX B) 
Before commencement of any of the screening procedures, the participants were 
given written notice and were also verbally informed by the researcher (with the 
help of language interpreters) of the nature, purpose and possible risks involved in 
the screening procedures as well as the purpose, procedures, restrictions, 
obligations, remuneration, insurance coverage and possible adverse supplement 
reaction relevant to the study. 
 
The participant information sheets and informed consent forms were available in 
English, Afrikaans and the language most often spoke in the area (Sotho). Each 
participant was provided with the participant information sheet and informed 
consent form in the language of his/her choice and retained copies of the participant 
information sheet and signed statement of informed consent. 
 
Both the informed consent discussion and the participant‟s written information were 
included to provide adequate information for the participants to understand and the 
participants in turn voluntarily accepted the terms of the study, and agreed to co-
operate in its conduct by signing the dated informed consent form. 
 
3.2.5. Restrictions on participants 
The following conditions prevailed: 
 
3.2.5.1. Medicines 
All concomitant medication was documented in clinical reference form (CRF) and 
the researcher notified if any additional medication was required during the study 
period. 
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3.2.5.2. Diet 
The participants continued with their normal diet similar to their baseline diet. 
 
3.2.6. Safety of the participants 
During all screening tests physical and medical evaluations (see 3.1.3. and 3.1.4) 
were adhered to in a professional and ethical manner (see 3.7). 
The supplement was ethically approved and is comprised of micronutrients and 
herbs only and contains no substances other than those specified substances (see 
3.3). 
The supplement was not used for purposes other than as directed in terms of the 
approved protocol. 
 
3.2.7. Financial implication for the participants 
There were no financial implications for the participants. The participants did not 
have to pay for their medical consultations or any of their clinical results. They 
received the treatment and supplement free of charge. The participants did not 
receive any remuneration for their participation in this study. 
 
 
3.3. SUPPLEMENT 
This section provides information on record keeping (inventory), formulation, and 
directions for use of the product (Bermins product). 
 
3.3.1. Inventory 
Administrative records were kept on whom, and when, a participant received the 
unit-package containing the supplement. On completion of the study, the remaining 
units (with exception of the retention samples) were returned to the sponsor. The 
retention samples were stored for a period of time in accordance with the sponsor‟s 
storage instructions. 
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3.3.2. Product formulation 
The product contains the following ingredients and quantities (Table 3.1). 
  Table 3.1. Composition of the supplement 
 
 
 
 
 
 
 
 
 
 
3.3.3. Directions for use 
The participants took one (1) tablet of the supplement once daily early in the 
morning and continued with their normal diet of the day. This procedure was 
followed throughout. Red Cross workers visited the participants on occasion in the 
afternoons to monitor that the number of pills were taken as prescribed. 
 
3.3.4. Supply, storage and dispensing 
A suitable number of units (plastic bottle containing 31 pills) to be used by the 
participants and for retention sample purposes were provided by the sponsor in 
bulk. The units were stored according to the storage instructions for the product in a 
confined enclosure at the institution (CUT). On clinic days and adhering to the 
administration procedures and purposes (see 3.1.3), each and every product-unit 
was labelled for each and every participant accordingly (see 3.2.2) i.e. the 
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participant number on the label corresponded to the number allocated for each 
participant. 
 
3.4. QUESTIONAIRES   
Two questionnaires namely a socio-demographic status questionnaire and a Dietary 
intake questionnaire were completed only at baseline. Local language interpreters 
were available to help avoid misunderstanding during the completion of the 
questionnaires. 
 
3.4.1. Socio-demographic status questionnaire (See APPENDIX C). 
Socio-demographic details including age, gender and residential area were 
obtained from each participant by means of a one-on-one interview to complete the 
questionnaire. The following information was collected by the researcher: Financial 
and employment status, level of education, marital status, monthly income, type of 
house, amount spent weekly or monthly on feeding, available cooking facilities, 
smoking habit, the number of children and the number of persons living in the 
house. 
 
3.4.2. Dietary intake 
At first visit a validated quantitative food frequency questionnaire (adapted from the 
Transition and Health During Urbanisation of South Africans (THUSA) study 
(Potchefstroom University) with a reliability of 90% was used to gather information 
on the habitual types and quantities of food and drink intakes by participants to 
determine the habitual intakes in terms of total energy, macronutrients and 
micronutrients (see APPENDIX D). 
 
The food frequency questionnaire (FFQ) was completed by a registered dietician 
appointed on a part time basis. 
 
Both traditional and western foods were included in the food frequency 
questionnaire.  
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Explanations were used to assist with the accuracy of the size of food portions 
described by the participants. Each participant was asked to demonstrate the 
quantity of a given food that he or she consumed on a daily, weekly or monthly 
basis. Local language interpreters were available to help avoid misunderstanding 
during the completion of the questionnaires. 
 
The portion sizes were estimated using house hold measures and converted to 
grams using the conversion figures in the Medical Research Council of South Africa 
Food Quantities Manual (Langenhoven, Kruger, Gouws & Faber, 1998). The 
quantities of food consumed on a daily basis were entered accordingly. The 
quantities of food stuff selected by the participants per day was calculated as food 
in grams consumed per week divided by 7 days or food in grams consumed per 
month divided by 30 days. The recorded food items were coded by means of food 
composition tables of the Medical Research Council of South Africa (Langenhoven 
et al., 1998). 
 
Complex dishes not appearing in the food composition tables were broken down 
into individual ingredients and weights and coded as such. The dietary data were 
analysed by means of a computer software programme, FoodFinder 3® (Medical 
Research Council, South Africa; June 2012; License Ernst Vermaak: C5997A8F) by 
a registered dietician. The energy intake was compared to the estimated energy 
requirement. Macro and micronutrient intake was compared with the recommended 
daily allowances (RDA) or Adequate Intake (AI). A value of <67% of the RDA/AI 
was considered to be inadequate for the individuals. 
 
 
3.5. MEASUREMENT INSTRUMENTS AND TECHNIQUES 
This section describes the kinds and types of physical and laboratory 
measurements made. 
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3.5.1. Anthropometry 
Anthropometry involves obtaining physical measurements of an individual, and 
relating these measurements to standards that also reflect their health and 
nutritional status such as malnutrition (Lee & Nieman, 2010). The following 
anthropometric data was obtained (see APPENDIX E): 
 
 Height 
Measured in centimetre with Seca, wall mounted stadiometer able to measure to 
the nearest 0.01 centimetres. The stadiometer is fitted with a right-angle headboard 
that can be moved up and down from a height of one meter to two meters. The 
stature or standing height of the participants was measured as follow: Bare feet flat 
on the floor and heels together against the wall. Arms at side of body with shoulders 
relaxed, head, shoulders and buttocks against the wall and the headboard resting 
on the crown of the head. The observer‟s eyes must be level with the headboard to 
avoid parallax errors (Lee & Nieman, 2010). 
 
 Weight 
Weight was measured in kilograms with a digital Tanita BWB 800 scale (able to 
measure 100g to 200kg). The scale was placed on a level, flat and hard surface and 
the scale was set to zero before the participant step onto the scale. The participant 
had to stand in the middle of the scale platform with weight equally distributed on 
both feet without touching anything (Lee & Nieman, 2010). 
 
 Body mass index (BMI) 
Body mass and height were used to calculate the BMI: 
 
 
The following BMI cut-off points were used (Lee & Nieman, 2010): 
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 Waist and hip circumferences 
Waist and hip circumferences were measured with a non-elastic, flexible tape with 
accuracy to the nearest 0.1 centimetre. The waist circumference was measured 
halfway between the lower rib line and iliac crest and the hip circumference on the 
iliac crest line (Lee & Nieman, 2010). 
 
During all of the measurement sessions, each participant stood with relaxed, arms 
comfortably placed to the side and feet held together, however, some 
measurements required the participants to place their feet apart. The participants 
presented themselves in minimal clothing to allow measurements to be done 
correctly and efficiently. The measurements were taken according to standard 
procedures (Lee & Nieman, 2010). 
 
Two trained researchers at a time did the measuring i.e. one measured and the 
second researcher noted the measurement. This ensured accuracy of site location, 
correct sequence of measurement sites and accurate reading. The recorder 
repeated the value as it was being recorded in order to enable the measurer to do 
an immediate check. The measurements were repeated 3 times at each site on 
each participant and the average value calculated and noted. 
 
3.5.2. Patient evaluations 
Laboratory investigations were limited to physical evaluation, blood sample analysis 
and pulmonary function testing. 
 
3.5.2.1. Medical evaluation 
A general physical evaluation was performed on each and every participant by a 
clinical physician during all monthly visits. All concomitant medications given to 
participants during the course of the study were documented in a clinical reference 
form (CRF) and specified for each and every individual. 
3.5.2.2. Blood sample collection 
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Blood samples were collected during the screening and monthly visits by registered 
medical personnel and transported to Pathcare (Pathology laboratory) for the 
analysis of the immune status, liver functions (health status), and haematological 
parameters as outlined in Figure 3.1. 
 
3.5.2.3. Pulmonary function tests 
The methods, standards and considerations for the pulmonary function testing were 
adopted from the American Thoracic Society‟s (ATS) task force document published 
in the European Respiratory Journal. This is to ensure that pulmonary function 
testing comply with the recently established international standards (Miller, 
Hankinson, Brusasco, Casaburi, Coates, Carpo, Enright, Van der Grinten, 
Gustafsson, Jensen, Johnson, MacIntyre, McKay, Navajas, Pedersen, Pellegrino, 
Viegi & Wanger, 2005). 
 
3.5.2.3.1. Spirometry 
Spirometry (meaning the measuring of breath) is the most common of the 
pulmonary function tests (PFTs), measuring lung function, specifically the amount 
(volume) in relation with the rate of air flow that can be maximally exhaled following 
maximum inhalation.  
 
The spirometry test is performed using a device called a spirometer which 
graphically displays a flow-volume loop (spirogram), which graphically depicts the 
rate of airflow on the Y-axis and the total volume inspired or expired on the X-axis 
(see Figure 3.2). 
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Figure 3.2. Adapted graphic illustration of a flow-volume loop depicting 
the relationship between rate of air flow on the Y-axis and the 
volume of air expired on the X-axis. (Adapted from Ruppel, 
G.L. 2003). 
 
Specific values for various and numerous specified parameters (as indicated in the 
spirogram) are also automatically calculated by the computerized software installed 
in the portable Jaeger lung function machine. The following pulmonary function 
variables are automatically calculated: 
 The forced vital capacity (FVC); 
 Forced expiratory volume in  0.5, 1.0 and 3.0 seconds (FEV 0.5, 1.0 and 3.0 ); 
 The FEV1 / FVC expressed as a percentage (FEV1 / FVC X 100);  
 The peak expiratory air flow rate (PEF); 
 Forced expiratory flow rate at 25%, 50% and 75% of the expired volume 
(FEF25%, 50% and 75%); and 
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 Forced inspiratory flow rate at 25%, 50% and 75% of the inspired volume 
(FIF25%,50% and 75%). 
 
The highest rate of flow (exhale / blow) is effort dependent and occurs at 25% of the 
expired volume. The flow-rate in the smaller airway is less effort dependent and is 
influenced by the elastic recoil of the lung and the integrity of the smaller airways. 
 
In terms of these variables a diagnosis regarding pulmonary function can be made. 
However, the flow-volume curve only gives a clear indication on how a specific type 
of disease has changed the shape, flow and volume values of the pulmonary 
system during maximal expiration following a maximal inspiration. To gain 
information on lung disease, the type of disease still have to be confirmed by means 
of a history of the participant, physical evaluation and other evaluations like 
radiography, bronchoscopy, microbiology and cytology. 
 
3.5.2.3.2. Requirements for the equipment 
The Spirometer must be capable of accumulating volume for ≥15 s and measuring 
volumes of ≥8 L (BTPS) with an accuracy of at least ±3% of reading or ±0.050 L, 
whichever is greater, with flows between 0 and 14 L/s-1. The total resistance to 
airflow at 14.0 L/s-1 must be ‹1.5 cmH2O/L-1/s-1 (0.15 kPa/L-1/s-1). The total 
resistance was measured with a tubing, valves, pre-filter, inserted between the 
participant and the Spiro meter. The filter is important for this study to prevent cross 
contamination of organisms that may infect participants performing a lung function 
test. 
 
The volume–time curve was plotted as hardcopy, the volume scale ≥10 mm/L-1 
(BTPS). For a screen display, 5 mm/L-1 is satisfactory. The time scale was ≥20 
mm/s-1. When the volume–time plot was used in conjunction with a flow–volume 
curve, the time scale requirement was reduced to 10 mm/s-1” ( Miller et al., 2005). 
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3.5.2.3.3. Quality control 
Calibration is a procedure for establishing the relationship between sensor-
determined values of flow and volume and the actual flow or volume to ensure 
reliable lung function results. The Spirometer is calibrated with a calibration syringe. 
The syringe discharged at least three times with a variation between the volumes 
less than 3% (Miller et al., 2005). 
 
3.5.2.3.4. Test procedure 
After the setup of the equipment and a quality check, the technologist instructs and 
demonstrates the test procedure to the participant. The maneuver consists of three 
distinct actions: 1) Deep and maximal inspiration; 2) a forced and maximal 
expiration performed like a hard blow of air; 3) continuation of exhalation till the air 
flow is zero for two seconds at least for six seconds (Enright, 2003). 
 
The participant was encouraged to do better after every effort by demonstration and 
exaggeration. At least three efforts are needed of which the sum of the forced vital 
capacity (FVC) and forced expiratory volume in one second (FEV1) of the three 
efforts do not vary more than five percent (5%) (Miller et al., 2005). 
 
3.5.3. Blood sample analysis 
Blood sample analysis and pulmonary function tests were performed. 
 
3.5.3.1. Haematological variables 
A Beckman Coulter machine was used to obtain information on the following 
haematological variables: 
 Red cell count; 
 Haemoglobin; 
 White cell count; 
 Differential count; 
 Hematocrit (packed cell volume); 
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 Mean cell volume (MCV); 
 Mean cell haemoglobin (MCH); 
 Mean cell haemoglobin concentration (MCHC); 
 Red cell distribution width (RDW), and 
 Platelet count. 
 
3.5.3.2. Immunological variables 
Purpose: To determine the immunological status of the participant: The CD4/CD8-
cell counts are essential measures of risk of contracting opportunistic infections and 
thus used as an indicator for instituting disease prophylaxis: 
 
Methodology of testing implemented 
The analysis was done by a pathology laboratory in Bloemfontein using the BD 
FACSCaliburTM flow pyrometer for cell enumeration (BD Biosience, 2350 Qume 
Drive, San Jose, CA 95131, USA). A BD TritestTM reagent kid was used for the CD4 
and CD8 cell counts. The immunofluorescent labelling of the whole blood 
lymphocytes using BD Tritest TM reagents follows: 
 The sodium citrate tube containing the peripheral whole blood sample of a 
participant was mixed for a few seconds on a vortex mixer to allow for proper 
mixing of the sample; 
 The sample was checked for clots with applicator stick and the applicator 
stick subsequently safely disposed; 
 20 µL of BD CD3/CD4/CD45 reagent was placed into a Trucount tube; 
 50 µL of participants‟ whole blood was added to the tube containing the BD 
reagent; 
 The same procedure was repeated with the Immuno-Trol control; 
 The tube was vortexed gently and incubated in the dark at room for 15 
minutes at 20-25oC; 
 450 ųL of IX BD FACS lysing solution was added to the mixture of antibody 
and blood and was vortex gently again; 
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 The tube was further incubated in the dark at room temperature for 15 
minutes; and 
 The specimen mixture was then analyzed with a flow cytometer. The stained 
lysed sample was stable for five (5) days. 
 
The CD4/CD8-cell counts were measured using a principal method called flow 
cytometry where blood cells are passed through a specially designed flow 
chambers and the physical characteristics of the cells (size and granularity) were 
measured with laser technology together with the detection of any surface markers 
such as CD4 which have been stained with fluorescent monoclonal antibodies. The 
four-colour direct immunofluorescence technique with a suitably equipped flow 
cytometer for CD3, CD4 and CD8-cell counts were used for this study supplied by 
Becton Dickinson (BD Ltd, South Africa). 
 
 Sensitivity: 
CD4 cells are measured relatively accurately when their number exceeds 50 
cells/ml but precautions prevail: Since CD4 cell counts can fluctuate due to 
extraneous factors, it should always be correlated with the CD4 cell% 
measurement. True increases/decreases in cell% were accompanied by 
corresponding increases/decreases in cell%. Single out-of-range results should be 
confirmed by re-testing. 
 
3.5.3.3. Liver functions 
 
An unicel DXC 880i Synchron access clinical system was used to obtain 
measurements that reflect liver functions (see APPENDIX F). These tests were 
done every 3 months to test toxicity of the supplement. In accordance, no results 
are shown and no statistical analysis on any of the numerous variables were 
analised statistically. 
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3.5.3.4. Viral load 
 
Purpose: Quantification of HIV count. This is the test for staging HIV disease and/or 
monitoring the efficacy of treatment. 
 
 Methodology of testing 
The Amplicor HIV-1 Monitor Test, v1.5, is used with plasma specimens only. Five 
(5) ml of blood was collected from each individual into a sterile EDTA sample tube. 
The plasma was separated from the whole blood by centrifugation at 800 
revolutions per minute for 20 minutes at room temperature. The separation took 
place within 6 hours after collection. Plasma specimens were stored at –800C 
before analyses. 
 
The Amplicor HIV-1 Monitor Test, v1.5 may be used with either of two specimen 
preparation procedures, the standard procedure or the Ultra Sensitive procedure. 
The standard procedure was used in the present investigation. In the standard 
specimen preparation procedure, HIV-1 RNA was isolated directly from plasma by 
lysis of virus particles with a chaotropic agent followed by precipitation of the RNA 
with alcohol. A known number of quantitation standard RNA molecules were 
introduced into each specimen with the lysis reagent. The HIV-1 quantitation 
standard was carried through the specimen preparation, reverse transcription, 
amplification and detection steps and used for the quantitation of HIV-1 RNA in the 
test specimen. 
 
The Amplicor HIV-1 Monitor Test, v1.5 is based on five major processes: 
i. Specimen preparation;  
ii. Reverse transcription of target RNA to generate complementary DNA 
(cDNA); 
iii. PCR amplification of target cDNA using HIV-1 specific complementary 
primers; 
94 
 
iv. Hybridization of amplified DNA to oligonucleic probes specific to the targets; 
and 
v. Detection of the probes bound amplified DNA by colorimetric determination. 
 
In the Amplicor HIV-1 Monitor Test, v1.5, the reverse transcription and amplification 
of HIV-1 and quantitation standard (QS) RNA occur simultaneously. The Master mix 
reagent contains a biotinylated primer pair specific for HIV-1 and QS target nucleic 
acid. 
 
The quantization of HIV-1 viral RNA was performed using the HIV-1 quantization 
standard (QS) (Tris HCL buffer: <0.001%, non-infectious in vitro transcribed RNA; 
microbial containing HIV-1 primer binding sequences) and a unique probe binding 
region (<0.005% Poly rA (synthetic), EDTA, Amaranth dye, 0.05% Sodium azide). 
The HIV-1 quantitation standard is a non-infectious RNA transcript that contains the 
identical primer binding sites as the HIV RNA target and a unique probe binding 
region that allows quantization standard amplicon to be distinguished from HIV-1 
amplicon. The quantization standard was incorporated into each individual 
specimen at a known copy number and is carried through the specimen 
preparation, reverse transcription, PCR amplification, hybridization and detection 
steps along with the HIV-1 target and was amplified together with the HIV-1 target. 
HIV-1 RNA levels in the test specimens was determined by comparing the HIV-1 
signal to the quantization standard signal for each specimen. The quantization 
standard compensates for effects of inhibition and controls for the amplification 
process to allow the accurate quantization of HIV-1 RNA in each specimen. 
Sensitivity Current generation tests measure from 20-50 RNA copies/ml and 
upwards. 
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3.6. STATISTICAL ANALYSIS 
The data obtained from this study was captured electronically in Microsoft Excel by 
the researcher. Any further analysis was done by an independent Biostatistician at 
the University of the Free State using SAS Version 9.2.1. For all the participants the 
following statistical analysis was done for all monthly visits. 
 
Continuous variables were summarised by means and standard deviations or 
medians and percentiles (where applicable). Categorical variables were 
summarised by frequencies and percentages. Some continuous variables were 
further classified into categories (normal values, less than normal or greater than 
normal values) and were also described by frequencies and percentages. 
 
The differences between the baseline screening visit and the screening at 6 months 
as well as the baseline screening visit and the screening at 12 months (final visit) 
were calculated for continuous variables and summarised by medians and 
percentiles. The paired median differences were compared using p-values obtained 
from the Wilcoxon Signed Rank test. Non-parametric confidence intervals for the 
paired median difference were also calculated. 
 
The change in categorical variables, classified according to normal ranges, from 
screening visit to final visit were summarised by contingency tables. The Chi-square 
statistic (or were applicable the Fisher‟s Exact Test) was used to calculate the p-
value to test for differences in proportions. 
 
The difference between the gender groups during the screening- and final visit were 
calculated. Gender differences for continuous variables were compared using p-
values obtained from Kruskal-Wallis test and 95% non-parametric confidence 
intervals were calculated. Gender differences for categorical variables were 
compared using p-values obtained from the Chi-Square statistic (or were applicable 
the Fisher‟s Exact Test).  
 
96 
 
The Spearman correlation-coefficient was calculated to investigate the relationship 
between some of the variables. 
 
The dietary intake was measured and calculated as discussed in Chapter 4 and 
described by medians and means. For all nutrients with an AI and RDA, the 
percentage of participants with intakes <67 percent or >67 percent of AI or RDA 
were calculated and summarised by frequencies and percentages. 
A significance level (α) of 0.05 was used throughout this study. 
 
 
3.7. SAFETY MEASURES 
The following safety measures were adhered to: 
 
3.7.1. Pre- and post study evaluation  
All data from the screening, monthly and final visits were documented in a study 
report by the clinical investigator. 
 
3.7.2. Adverse events 
The researcher carefully monitored each participant monthly by evaluating- and 
summarizing all the laboratory data and the physical evaluation data. Abnormal 
laboratory data were addressed immediately by the clinical investigator. In addition, 
information on adverse events was obtained from the participants by regular 
questioning of each participant by the clinical staff, although no leading questions 
were asked. When an adverse event occurred, the researcher decided whether to 
withdraw the participant from the study and/or initiate appropriate treatment. After 
withdrawal from the study, it was ensured that the participant received appropriate 
medical care. 
 
In the case of adverse events, the researcher instituted general supportive 
measures. The researcher reported all serious adverse events to the sponsor and 
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Ethics Committee by telephone or facsimile within 24 hours of becoming aware of 
the occurrence of such an event. The notification by telephone was followed by a 
detailed, written report within 48 hours after the initial notification or at latest on the 
following working day. All serious events were followed up until the outcome was 
known. 
 
The researcher ensured that the nature, date, time of onset, duration, intensity 
relationship to the study supplement, action taken, and outcome of all serious 
adverse events were documented and discussed in detail in the study report. 
 
No adverse event regarding the supplement was reported in any of the participants. 
 
The most common intervention applied, was the treatment of bacterial and fungial 
infection with appropriate medication prescribed by a medical doctor. 
 
3.7.3. Premature discontinuation of the study 
The sponsor or principal investigator had the right to discontinue the study at any 
time for medical and/or administrative reasons. 
 
3.8. ETHICAL ASPECTS AND CLINICAL PRACTISE COMPLIENCE 
The following ethical aspects and clinical practise compliance prevailed: 
 
3.8.1. Mandatory approval 
Written approval for the final version of the protocol was obtained from the Ethics 
Committee and the MCC before commencing the study (ETOVS number: ETOVS 
142/05). 
 
 3.8.2.  Good clinical practice (GCP)  
The trial was conducted in compliance with the protocol and the following 
recommendations and guidelines were adhered to: South African Good Clinical 
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Practice Guidelines, guidelines for good clinical practice in the conduct of clinical 
trials with human participants in South Africa. Department of Health: Pretoria, South 
Africa. 
3.8.2. Confidentiality 
All information obtained during the conduct of the study with respect to the 
participants identification and state of health was regarded as confidential. An 
agreement for disclosure of any such information was obtained in writing and is 
included in the informed consent. 
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ABSTRACT 
The aim of this part of the present investigation is to gain information on the 
Baseline dietary intake of 40 HIV-infected individuals living in Mangaung 
Metropolitan, Free State Province, South Africa. 
 
Dietary intake is determined using a validated Quantitative Food Frequency 
Questionnaire (adapted from the THUSA study, Potchefstroom University with a 
reliability of 90%) to determine the habitual types and quantities of food and liquid 
intakes for the period six months prior to subjecting the individuals to the 
intervention. The intake of both macronutrients and micronutrients are assessed by 
entering the data into a standard analytic program (FoodFinder 3, Medical Research 
Council). 
 
The results of the present investigation show that the mean and/or median Energy 
(kJ) intake is higher than the specified Estimated Energy Requirement (EER) in 
both groups (males and females). The macronutrient (total protein, carbohydrate 
and fat) intakes in both males and females are higher than the Recommended 
Dietary Intake (RDA) and/or Adequate Intake (AI) specifications. The majority of the 
respondents consumed adequate amounts of vitamins with the exception of Vitamin 
D where 83.3% of the males and 60.6% of the females (64.1% when combined,) 
consumed ≤67% in terms of the RDA specification. 
 
With the exception of Iodine, the dietary intake of minerals and trace element met or 
exceeded the specified RDA or applicable Adequate Intake (AI) specifications: 
Iodine intake in males is lower in terms of the mean (±SD) and median (inter-
quartile range) i.e. 66.2±27.1 and 60.5 (43-87) respectively when compared to the 
RDA of 150µg. Iodine intake in females is lower in terms of the mean (±SD) and 
median (inter-quartile range) i.e. 90.2±36.7 and 88 (65-110) respectively when 
compared to the RDA of 150 µg. In the male group 83.3% of the individuals and 
66.7% of the individuals in the female group consumed ≤67% of the RDA. When the 
groups are combined, 69.2% of the individuals consumed ≤67% of the RDA. 
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The present results suggest that an inadequate Vitamin D and Iodine intake 
appears to be the only limiting constraints observed in the present investigation. 
 
4.1 LITERATURE SURVEY 
Sub-Saharan Africa, housing 67% of the HIV-infected people worldwide and with 
Southern and East Africa where the prevalence of HIV-infected individuals probably 
exceeds 25% of the local population, are prone to food shortages that may 
contribute to malnutrition (Ahoua, Umutoni, Huerga, Minetti, Szumilin, Balkan, 
Olson, Nicholas & Pujades-Rodrigues, 2011). Food insecurity is defined as 
"Persistent lack of access to adequate food in needed quantities and quality." Food 
insecurity and increased nutritional vulnerability are major driving forces for nutrition 
care and support programs for HIV and AIDS-infected individuals (Ivers, Cullen, 
Freedberg, Block, Coates & Webb, 2009). The study by Ahoua and colleagues 
(2011) reported that 15% of HIV-infected individuals in sub-Saharan Africa require 
urgent nutritional rehabilitation. Nutritional therapy is therefore important in the 
clinical care of HIV-infected individuals and by sustaining optimal nutrition, 
complications and progression of HIV will be reduced (Somarriba, Neri, Schaefer & 
Miller, 2010). Impaired and/or reduced nutritional status may be caused by reduced 
intake and availability of food due to the effect of HIV and AIDS on the household 
income (Lemke, 2005), but also due to physiological symptoms such as oral thrush; 
vomiting; appetite loss; reduced nutrient absorption due to diarrhea and intestinal 
damage (Oketch, Paterson, Maunder & Rollins, 2011). 
 
Healthy males and females respectively need at least 12,881 KJ and 10,093 KJ per 
day (Nutrient Reference values for Australia and New Zealand, 2006), of which 
10%-20% should comprise protein. Unfortunately protein intake makes out a very 
small portion of the daily diet of many communities in Southern Africa (Spencer, 
Harman, Botha, Rollins, Labadarios & Visser, 2008). In order to maintain body 
weight and physical activity levels, a ten (10%) increase in energy requirement is 
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noted in asymptomatic HIV-infected individuals but is dependent on the stage of 
disease progression. 
 
Vitamins and minerals are substances that are not used to provide energy, but 
assist the body in utilizing macronutrients for anabolic and/or catabolic purposes. In 
most instances vitamins act as coenzymes. With the exception of vitamin D and the 
small amounts of vitamin B and vitamin K that are produced by intestinal bacteria, 
all vitamins are obtained from food or supplementation. Minerals are needed in 
relatively moderate amounts and make up approximately 4% of the body weight 
(Marieb & Hoehan, 2010). The reduction and deficiency of vitamins A, B6, B12, C 
and E as well as the minerals zinc and selenium have been shown to compromise 
the immune response (Campa & Baum, 2010). 
 
HIV breaks down the immune system and promotes nutritional deficiency in infected 
individuals (Campa & Baum, 2010).  The origin of malnutrition in HIV-infected indi-
viduals is multifaceted: Acute and chronic physiological changes associated with 
psychological, social and economic factors play an important role in every 
individual's nutritional status. These complex interactions often coexist 
geographically (Sztam, Awzi & Duggan, 2010). The optimal nutritional status of HIV-
infected individuals is important, because malnutrition is associated with an 
increased death rate (Leah & Mascioly, 1995; Ockenga, Grimble, Jonkers-
Schuitema, Macallan, Melchior, J-C., Sauerwein & Schwenk, 2006). HIV infection 
has a negative influence on the human metabolism even in the early stage of the 
infection when apparent clinical symptoms are not visible. Chronic inflammation 
caused by infection increases the metabolic needs of the human body and may lead 
to the depletion of essential nutrients transpiring in a malnourished person with 
reduced immunity (Szetela & Gasiorowski, 2010). 
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To maintain good health a person requires foodstuffs comprised of sufficient 
amounts of carbohydrates, fat and protein as well as water, minerals and vitamins 
(Spencer et al., 2008). HIV and AIDS relegate the nutritional status as being a 
“wastage syndrome”. In accordance, sufficient amounts of micro- and 
macronutrients intakes in healthy individuals could become insufficient in HIV-
infected and AIDS individuals at a later stage. Loss of body cell mass and muscle 
mass may be prevalent in the early course of HIV infection suggesting that the loss 
is due to the HIV infection and not opportunistic co-infections (Faintuch, Soeters & 
Osmo, 2006). The nutritional effects of HIV infection  coincides with an increase in 
resting energy expenditure (during infections), decreased food intake, depression, 
anorexia, malabsorption, decreased quality of life, decreased work productivity and 
less dietary diversity, all contributing to the failure to gain weight (Sztam et al., 
2010). Malabsorption of fats and carbohydrates is well documented in HIV-infected 
individuals. This, in turn, reduces the absorption of other nutrients such as fat-
soluble vitamins (A, D, E and K), endangering the immune system and aggravating 
the nutritional deficiency and the inflammatory reaction due to the HIV infection 
(Ivers et al., 2009). 
 
HIV and AIDS affect the metabolism of insulin and glucagon leading to muscle 
wasting (Ivers et al., 2009). Blood chemistry changes are reported in HIV-infected 
individuals with anthropometric indices and nutrient intake within normal limits. 
Lower blood levels of hemoglobin, high-density lipoprotein cholesterol, total 
cholesterol, triacylglycerols and albumin are reported (Faintuch et al., 2006). It has 
been reported that in HIV-infected individuals with CD4 counts below 400cells/mm3 
the blood levels of saturated fatty acids increase and the unsaturated fatty acids 
decrease (Faintuch et al., 2006). Reduced immunity is enhanced as oxidative stress 
becomes more prominent. The immune changes in HIV-infected individuals, such 
as a decline in numbers, as well as the CD4:CD8 ratio are also found in 
malnourished individuals. The increasing risk of death in a malnourished HIV-
infected individual is independent from the viral load and CD4 cell count (Grimble, 
2009). 
105 
 
Nutritional assessment and supplementation with both micro- and macronutrients 
may support the efficacy of medical treatment in HIV-infected individuals by 
improving the physiological function of the body (Somarriba et al., 2010). 
Supplements have to be administered with care as tolerable upper limits above 
RDA and AI exist (Monsen, 2000). All HIV-infected individuals should undergo a 
comprehensive nutritional assessment during their first visit to health care 
professionals. Proper nutritional intervention and ongoing monitoring should follow 
the initial assessment (Anabwani & Navario, 2005). Biochemical analysis will help to 
confirm the diagnoses: Reductions in the following biochemical markers are typical 
of malnutrition: albumin, hemoglobin, urea, creatinine, glucose, triglycerides, zinc, 
iron, selenium, vitamins A, B, D, folic acid, (Szetela & Gasiorowski, 2010) and 
vitamin E (Mehta, Spie, About, Giovannucci, Msamanga, Hertzmark, Mugusi, 
Hunter & Fawzi, 2010). It has been noted that selenium and vitamin A (antioxidants) 
are the first to decrease (Faintuch et al., 2006). Signs and symptoms of malnutrition 
commonly include: a BMI below 18.5 kg/m2, cell mass loss (lean body mass (Ivers 
et al., 2009) of more than 5% within three months, lack of weight gain, hormonal 
abnormalities and active opportunistic infections (Ockenga et al., 2006). 
 
 
4.2. METHODOLOGY 
The following section will provide information regarding the material and methods 
used. 
 
4.2.1. Study design and demographic information. 
Information based on the study design (see 3.1.1), study site (see 3.1.2), study 
population (see 3.2) and intervention (see 3.3) is described in Chapter 3. 
 
4.2.2. Measuring tool and variables 
The questionnaire that 40 HIV-infected individuals are subjected to is revealed in 
APPENDIX D. 
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4.2.3. Statistical analysis of Demographic and Absolute (measured) results 
The following variables were subjected to descriptive statistical analysis and  
elaborated on separately and specified for both genders separately (and pooled): 
 Baseline energy, macronutrient and cholesterol intake; 
 Baseline vitamin (fat- and water soluble) intake; and 
 Baseline mineral and trace element intake. 
 
The data is subjected to statistical analysis and the following calculations are 
implemented: 
 Percentage of individuals with a nutrient intake of ≤ 67% of the RDA/AI; 
 The mean (±standard deviation); and  
 Median (inter-quartile range). 
 
 
4.3. RESULTS 
This section reveals the demographic and relative results respectively. 
4.3.1 Demographic results 
A total of 132 HIV-infected individuals were enrolled into this investigation. One 
hundred and eight (108) individuals dropped out because of non-compliance to the 
protocol (not taking supplement correctly or missing appointments) (see Chapter 3: 
section 3.2.5). 
Seven of the 40 participants (17%) who completed the food frequency questionnaire 
were male and 33 of the 40 participants (83%) were female. 
 
4.3.2 Absolute (measured) results 
The mean (±standard deviation), median (inter-quartile range), RDA/AI, and the 
percentage of individuals with a nutrient intake of ≤ 67% of the RDA/AL are outlined 
for the following variables that will be elaborated on separately and specified for 
both genders separately (and pooled): 
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 Baseline energy, macronutrient and cholesterol intake; 
 Baseline vitamin (fat- and water soluble) intake; and 
 Baseline mineral and trace element intake. 
 
4.3.2.1 Baseline energy, various macronutrients and cholesterol intake 
The results for Baseline energy, the various macronutrients and cholesterol are 
summarized and presented in Table 4.1. Each and every variable is discussed 
separately. 
 
Baseline energy 
The mean (±SD) and median (inter-quartile range) for the total energy intake for 
males are 20,318.7±7,602.0 and 22,583. (12,358.0 – 25,870.0 respectively). The 
mean (±SD) and median (inter-quartile range) for the total energy intake for females 
are 21,293.8±6,220.9 and 22,328.0 (17,632.0 – 26,255.0) respectively. Both 
genders exceeded the respective average RDA/AI 
 of 12,881 and 10,093. 
 
Total protein intake 
The mean (±SD) and median (inter-quartile range) for the total protein intake for 
males are 160.8±67.3 and 146.5 (113.9-201.5) respectively. The mean (±SD) and 
median (inter-quartile range) for the total protein intake for females are 180±66.6 
and 174.7(140.5-225.9) respectively. Both genders exceeded the average. In both 
of the male and female groups the median and mean total protein intake exceeded 
the RDA of 46 g/day. 
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  Table 4.1. Baseline energy, macronutrient and cholesterol intake of HIV- 
infected individuals in Mangaung (n=40) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     a
 = EER indicates Estimated Energy Requirement 
     b
 = RDA indicates Recommended Dietary Intake 
     c
 = AI indicates Adequate Intake 
     d
 = Recommended guideline 
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Fat intake 
The mean (±SD) and median (inter-quartile range) for the total fat intake for males 
are 188.4±81.7 and 180.3 (113.1-262.7) respectively. The mean (±SD) and median 
(inter-quartile range) for the total fat intake for females are 213.1±81.5 and 
210.5(163.4-262.7) respectively. The total fat intake of both groups (male and 
female) is higher than the recommended intake of less than 30% of the total daily 
energy intake (Gallagher, 2012). 
 
Carbohydrate intake 
The mean (±SD) and median (inter-quartile range) for the total carbohydrate intake 
for males are 572.5±223.4 and 588.8 (352.3-758.9) respectively. The mean (±SD) 
and median (inter-quartile range) for the total carbohydrate intake for females are 
559.7±171.4 and 581.9(479.4-660.1) respectively. The mean and median total 
carbohydrate intake of both groups is more than 4 times the RDA of 130 g/day. 
 
Fiber intake 
The mean (±SD) and median (inter-quartile range) for the total fiber intake for males 
are 48.7±21.2 and 60.1(30.6-63.4) respectively. The mean (±SD) and median (inter-
quartile range) for the total fiber intake for females are 46.7±17.7 and 46.8(37.4-
59.7) respectively. 
 
In the male group 16.7% and 6.1% of the female group consumed ≤67% of the 
respective recommended 38g and 25g of fiber per day. 
 
Cholesterol 
The mean (±SD) and median (inter-quartile range) for the total cholesterol intake for 
males are 420±281.5 and 324.5(203-668) respectively. The mean (±SD) and 
median (inter-quartile range) for the total cholesterol intake for females are 
822.4±470.4 and 781(559-1101) respectively. 
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On average the total dietary intake of cholesterol in both the male and female 
groups is more than the recommended guideline of <300 mg/day for both genders. 
 
4.3.2.2. Baseline vitamin (fat- and water soluble) intake 
The results for the various Baseline fat- and water soluble vitamin intakes for males 
and females are summarized and presented in Table 4.2. A holistic approach is 
followed and only differences below or above the RDA/AL is discussed. 
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               Table 4.2.     Baseline fat- and water soluble vitamin intake of HIV-infected  
     individuals in Mangaung (n=40) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  *AI indicates Adequate Intake 
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Fat soluble vitamins 
The present results show that, except for vitamin D, other fat soluble vitamin intakes 
on average met or exceeded the RDA/AI. Vitamin D intake in males is lower in 
terms of the mean (±SD) and median (inter-quartile range) i.e. 7.0±3.7 and 7.1(3.3-
9) respectively when compared to the RDA of 15 µg. Vitamin D intake in females is 
lower in terms of the mean (±SD) and median (inter-quartile range) i.e. 9.8±5.9 and 
9.1(6.2-11.8) respectively when compared to the RDA of 15 µg. In the male group 
83.3% of the individuals and 60.6% of the individuals in the female group consumed 
≤67% of the RDA. When the groups are combined, 64.1% of the individuals 
consumed ≤67% of the RDA. 
 
Water soluble vitamins 
Analysis of the present results shows that on average all water soluble vitamin 
intakes met or exceeded the RDA/AI. 
 
A reduced Folate intake is observed in 33.3% of the males and 18.2% of the 
females (combined: 20.5%) consuming ≤67% in terms of the RDA. 
 
4.3.2.3. Baseline mineral and trace element intake. 
The results for the various Baseline mineral and trace element intakes for males 
and females are summarized and presented in Table 4.3. A holistic approach is 
followed and only differences below the RDA/AL are discussed. 
 
The present results show that, except for Iodine, all mineral and trace element 
intakes on average met or exceeded the RDA/AI. Iodine intake in males is lower in 
terms of the mean (±SD) and median (inter-quartile range) i.e. 66.2±27.1 and 
60.5(43-87) respectively when compared to the RDA of 150µg. Iodine intake in 
females is lower in terms of the mean (±SD) and median (inter-quartile range) i.e. 
90.2±36.7 and 88(65-110) respectively when compared to the RDA of 150 µg. In the 
male group 83.3% of the individuals and 66.7% of the individuals in the female 
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group consumed ≤67% of the RDA. When the groups are combined, 69.2% of the 
individuals consumed ≤67% of the RDA. 
 
    Table 4.3.     Baseline mineral and trace element intake of HIV-infected  
     individuals in Mangaung (n=40) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    *AI indicates Adequate Intake 
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4.4. DISCUSSION 
The results of the present investigation reflect information based on a sub-
population in the Mangaung Metropolitan. 
 
The structure-layout for the report-back and discussion of the present findings is 
presented in the following format: 
 Section on results pertaining to Baseline energy, macronutrient and 
cholesterol intake; 
 Section on results pertaining to Baseline fat- and water soluble vitamin 
intake; 
 Section on results pertaining to Baseline mineral and trace element intake; 
and 
 Synopsis of the main findings. 
 
In order to elaborate on additional phenomena/attributes that relate to the present 
findings, cross-reference between these aforementioned sections is made where 
deemed appropriate. The present results are also compared to the results stated by 
other researchers. 
 
4.4.1 Baseline energy, macronutrient and cholesterol intake (Refer to Table 
4.1) 
The present findings show that the mean and median energy intakes for both male 
and female HIV-infected individuals are higher than the Estimated Energy 
Requirement (EER). A similar finding pertaining to higher energy intakes is reported 
by Oguntibeju, Van den Heever and Van Schalkwyk (2005) in a trial conducted over 
a period of 3 months in the same region (Mangaung Metropolitan). 
 
The higher energy intake (kJ) of the HIV-infected individuals might be explained by 
means of the staple food that the individuals mainly consume i.e. high portion of 
maize intakes per se and/or coinciding in combination with a relatively small (6%) 
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increase above the specified 30% level of energy derived from fat. The mean and 
median carbohydrate intake of both male and female HIV-infected individuals 
exceeded the RDA of 130 g/day more than four-fold. This could possibly explain the 
relative contribution of carbohydrate towards high energy intake of the individuals. 
 
Carter (2012) states that high energy intake may reduce the possibility of muscle 
wasting and promotes the well-being of HIV-infected individuals. This view, 
however, should be appreciated within the notion put forward by Ivers et al., (2009) 
i.e. that HIV and AIDS affect the metabolism of insulin and glucagon leading to 
muscle wasting. A decrease in insulin could impact on anabolic growth and 
catabolic (energy yielding) processes. A decrease in glucagon could negatively 
impact on plasma blood glucose levels. 
 
The total mean protein intake of both groups is much higher than the specified RDA 
of 46 g/day, with males exceeding the RDA with 114.8 g/day and females with  
134 g/day. A higher intake of dietary protein than the RDA is also reported by Kim, 
Rimm & Gorbach (2001) and Oguntibeju (2004). 
 
The mean and median plant protein intake is lower compared to the animal protein 
intake for both groups of individuals: Expressed in terms of a percentage the 
differences are 36% (51%) and 51% (49%) respectively. No comparable report-
back in this regard is noted in the literature. 
 
The total fat intake of 188.4 g/day for males and 213.1 g/day for the females is 6% 
higher (i.e. 36%) when compared to the recommended and specified <30% daily 
energy intake for healthy persons. However, it should be noted that specified fat 
requirements for HIV-infected individuals are non-existent (National Guidelines on 
Nutrition for people living with HIV, AIDS, TB and other Debilitating Conditions, 
2007). 
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The median and mean fiber intake of both the male and female group exceeded the 
AI.  Only 16.7% of the male group and 6.1% of the female group displayed a fiber 
intake of ≤67% of the AI. 
 
The median and mean cholesterol intakes in all individuals are higher than the 
recommended guideline. In accordance none of the individuals showed a 
cholesterol intake of <300 mg/day. 
 
4.4.2. Baseline fat- and water soluble vitamin intake (Refer to Table 4.2) 
Reductions in the following biochemical markers are typical of malnutrition: albumin, 
hemoglobin, urea, creatinine, glucose, triglycerides, zinc, iron, selenium, vitamins A, 
B, D, and folic acid, (Szetela & Gasiorowski, 2010) and vitamin E (Mehta et al., 
2010). In accordance, the rationale for analyzing the micronutrient composition of 
foodstuff intakes, relates to their respective physiological functions within the body. 
 
A brief description on some of these functions for the various micronutrients follows 
and should be viewed with the present results relating to each and every one of 
these micronutrients: 
 
Fat soluble vitamins 
Recent research shows that vitamin D plays an important role in modulating innate 
and adaptive immune function, due to the presence of vitamin D receptors in most 
of the immune system cells (Baeke, Takiishi, Korf, Gysemans & Mathieu, 2010). 
Vitamin D is involved in innate immune system regulation. The vitamin D-activating 
enzyme, CYP27B1, assists in linking monocytes and pathogen-sensing 
mechanisms (Lagishetty, Lui & Hewison, 2011). Vitamin D, a pre-hormone, acts via 
metabolites like 1,25(OH)2D that binds to the nuclear vitamin D receptor (Gueli, 
Verrusio, Linguanti, Di Maio, Martinez, Marigliano & Cacciafesta, 2012) and 
suppresses T-helper (Th1) CD4 cells to enhance CD4 cell production. Toll-like 
receptors (TLRs) of monocytes and macrophages play an important role in innate 
immune response (Lagishetty et al., 2011).  The stimulation of the TLRs in 
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macrophages by anti-microbial peptides results in the conversion of vitamin D to its 
active form. An additional role of vitamin D is to assist with the induction of 
cathelicidin (a protein with c-terminal cationic anti-microbial domain) to be released 
at the site of infection (Beard, Bearden & Striker, 2011; Verrusio, Linguanti, Di Maio, 
Martinez, Marigliano & Cacciafesta, 2012). 
 
The present results show that, except for vitamin D, other fat soluble vitamin intakes 
on average met or exceeded the RDA/AI. Vitamin D intake in males is lower (±50%) 
in terms of the mean (±SD) and median (inter-quartile range) i.e. 7.0±3.7 and 
7.1(3.3-9) respectively when compared to the RDA of 15 µg. Vitamin D intake in 
females is also lower (±35%) in terms of the mean (±SD) and median (inter-quartile 
range) i.e. 9.8±5.9 and 9.1(6.2-11.8) respectively when compared to the RDA of 15 
µg. In the male group 83.3% of the individuals and 60.6% of the individuals in the 
female group consumed ≤67% of the RDA. When the groups are combined, 64.1% 
of the individuals consumed ≤67% of the RDA. 
 
In terms of the numerous aforementioned functions of Vitamin D, surely, continuous 
exposure to inadequate Vitamin D intake could impact negatively on the health 
status of the individuals in many ways. It has already been noted that in people 
living with HIV and AIDS, lifestyle, hormonal factors, decreased physical activity, 
lower intake of calcium and vitamin D as well as lower plasma calcium levels, all 
contribute to the progression of the disease (Borderi, Gibellini, Vescini, De Crignis, 
Cimatti, Biagetti & Tampellini, 2009; Campa & Baum, 2010). 
 
The interactions of Vitamin D and Calcium as well as the interactions between 
Calcium and high protein intake are discussed in section 4.4.3. 
 
Functions of Vitamin A include maintenance of the epithelium; acts as an 
antioxidant and helps to prevent damage to cell membranes (Yang, Yuan, Tao & 
Wang, 2011). Vitamin A deficiency leads to increased susceptibility to lung and 
gastrointestinal infections, weak response to immunization and increased HIV 
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progression (Cassani, Villablanca, De Calisto, Wang & Mora, 2012; Yang et al., 
2011). The vitamin A metabolite, all-trans retinoic acid, regulates T and B cell 
immune responses (Cassani et al., 2012).   
 
In the male group only 16.7% showed an intake of vitamin A ≤67% of the RDA. This 
figure is higher than the figure of 12.5% determined by Oguntibeju (2004). The 
present results show that Vitamin A intake in males is higher (±300%) in terms of 
the mean (±SD) and median (inter-quartile range) i.e. 3,051.8±1813.9 and 
3489.5(1.419-4,500) respectively when compared to the RDA/AI of 900µg. Vitamin 
A intake in females is even higher (700%) in terms of the mean (±SD) and median 
(inter-quartile range) i.e. 4,798±3426.7 and 3,939(2088-7120) respectively when 
compared to the RDA of 700µg. In the male group only 16.7% of the individuals and 
3% of the individuals in the female group consumed ≤67% of the RDA. When the 
groups are combined, 5% of the individuals consumed ≤67% of the RDA. 
 
In terms of the numerous functions of Vitamin A and according to the present 
results, the dietary intake of Vitamin A appears to be non-deficient and physiological 
function could remain intact. 
 
The mean and median intake of Vitamin E and Vitamin K are higher than the RDA 
or AI. In accordance specific functions ascribed to these two vitamins should remain 
intact. 
 
Vitamin E is necessary for the functioning of the immune system by increasing the 
cell-mediated and humeral immune response to antigens in HIV-infected 
individuals. This vitamin enhances macrophage phagocytic function and resistance 
to viral infection (Campa & Baum, 2010). The fast proliferating immune cells are 
easily damaged by peroxides, thus vitamin E prevents damage to the cell 
membranes by reducing lipid peroxidation. Supplementation with vitamin E 
enhances humeral as well as mediated immunity in humans (Spencer et al., 2008; 
Molano & Meydani, 2012). 
119 
 
Vitamin K is produced by the normal bacterial flora that resides in the intestines of 
a person and from foods – mainly green leafy vegetables. This vitamin is involved in 
the carboxylation of glutaminic acid, necessary for blood coagulation. In HIV, 
vitamin K also plays a role in the regulation of inflammation (Gallagher, 2012). 
 
Water soluble vitamins 
The B vitamins act as coenzymes in the tricarboxylic acid cycle. Deficiencies in this 
group of vitamins result in lack of energy commonly present in HIV-infected 
individuals, even during the early asymptomatic stage (Campa & Baum, 2010). 
 
Vitamin C is an antioxidant with detoxification properties and assists with iron 
absorption (Paul, 2011).  In HIV, deficiency of this vitamin will lead to impaired 
immunity (Dong & Imai, 2012).  HIV is known to increase oxidative stress markers 
that damage tissue and CD4 cells. It has been reported that vitamin C 
supplementation delayed HIV progression and the onset of AIDS (Spencer et al., 
2008). 
 
Folate and vitamin B12 are necessary for DNA synthesis, with folate acting as a 
coenzyme (tetrahydrofolate and dihydrofolate) used in DNA and protein synthesis. 
Folate converts homocysteine into cystine to prevent oxidative damage to the blood 
vessels (Campa & Baum, 2010). 
 
The present results show that on averages mean (±SD) and median (inter-quartile 
range); all water soluble vitamin intakes met or exceeded the RDA/AI. 
 
A reduced Folate intake is observed in 33.3% of the males and 18.2% of the 
females (combined: 20.5%) consuming ≤67% Folate in terms of the RDA/AI. This 
did not impact on the mean or median in any significant way. However, it should be 
stated that Herbert, Fong & Gulle (1990) reported that 33% of HIV-infected 
individuals presented with low serum folate levels and a negative folate balance. 
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4.4.3 Baseline mineral and trace element intake (Refer to Table 4.3) 
Calcium is not just important for good bone health but could also have an effect on 
weight management, weight loss, and visceral fat and fat loss: Analysis of national 
survey data as well as small clinical studies shows an inverse relationship between 
calcium intakes and body fatness i.e. the higher the calcium intake, the lower the 
body fatness. An adequate dietary Calcium intake may help prevent excessive fat 
accumulation by stimulating hormonal action that targets the breakdown of stored 
fat (Melanson, Sharp, Schneider, Donahoo, Grunwald & Hill, 2003). Cell membrane 
integrity, potential regulation of heart muscle contraction and clotting of blood are 
influenced by this nutrient (Lee & Nieman, 2010; Marieb & Hoehan, 2010). 
 
Inadequate calcium significantly contributes to the development of osteoporosis. 
Low intakes of calcium and inadequate vitamin D status often cluster with higher 
prevalence rates of obesity (Soares, Murhadi, Kurpad, Piers. 2012). 
 
In people living with HIV and AIDS, lifestyle, hormonal factors, decreased physical 
activity, lower intake of Calcium and Vitamin D as well as lower plasma calcium 
levels all contribute to the progression of the disease (Borderi, et al., 2009; Campa & 
Baum, 2010). 
 
On the contrary, and at first sight, the present findings show that the mean and 
median intake for Calcium is relatively higher than the specified RDA of 1,000 
mg/day for both genders, does not exceed the and the upper limit is 2500mg per 
day (Curtiss & Johnson, 2007) and in effect, accordingly, raises no concern. 
However, a link between vitamin D and calcium absorption from the alimentary tract 
exists: Calcium is better absorbed when taken in combination with Vitamin D. Lack 
of the simultaneous intake of Calcium and Vitamin D intake in the diet impedes on 
the formation of the hormone calcitriol (known as the “active vitamin D”). This in turn 
leads to insufficient calcium absorption from the diet. In this situation, the body must 
take calcium from its stores in the skeleton, which weakens existing bone and 
prevents the formation of strong, new bone (Anderson, 2008). Although the present 
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results show sufficient intake of Calcium, a decrease in Vitamin D intake is 
observed and, accordingly, could impact on the health status of the individuals with 
low vitamin intake. 
 
Furthermore, it should also be stated that although a balanced diet aids calcium 
absorption, high levels of protein and sodium (salt) in the diet are thought to 
increase calcium excretion through the kidneys. Excessive amounts of these 
substances should be avoided, especially in those with low calcium intake (Rolfes, 
Whitney, & Pinna, 2009). 
 
The present results indicate a relatively high protein intake: The mean (±SD) and 
median (inter-quartile range) for the total protein intake for males are 160.8±67.3 
and 146.5 (113.9-201.5) respectively. The mean (±SD) and median (inter-quartile 
range) for the total protein intake for females are 180±66.6 and 174.7(140.5-225.9) 
respectively. Both genders exceeded the average in both male and female groups 
the median and mean total protein intake exceeded the RDA of 46 g/day. 
 
In accordance, interactions between micronutrients and macronutrients exist and 
should not be viewed as single entities per se: Calcium intake appears to be 
sufficient but low Vitamin D intake could impact on Calcium metabolism in various 
and numerous physiological ways. 
 
The baseline intakes for Iron, magnesium, zinc, copper and chromium are higher 
than the RDA and AI respectively. In accordance, the following physiological 
functions could probably remain intact: Magnesium, zinc and copper are cofactors 
and components of more than 300 enzyme systems. Magnesium is widely present 
in green vegetables; zinc in food like meat, fish and poultry. Copper is available 
from organ meat, seafood, nuts and seeds.  Magnesium deficiency may lead to 
neuromuscular defects, anorexia and weight loss. Zinc depletion results in 
endogenous zinc loss resulting in diarrhea, reduced appetite and impaired immune 
response. Copper deficiency results in hyperchromic anemia, leucopenia, 
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neutropenia and may negatively affect the cardiovascular and immune systems. 
Chromium is associated with glucose metabolism and a deficiency enhances 
diabetes and cardiovascular disease (Nutrient Reference values for Australia and 
New Zealand, 2006). 
 
The intake of selenium is inadequate in 33.3% of males and 18.2% of females i.e. 
values less than ≤67% of the specified RDA standard measured. In accordance, the 
following physiological functions could be strained: 
Selenium is an important component of the humeral immune repose through its 
active role in interleukin-2 and cytokine action in the expression of T-Lymphocyte 
expansion. Furthermore, selenium inhibits the progression and reduces the viral 
load of HIV by means of its antioxidant effect through the enzymes glutathione 
peroxidase and thioredoxin reductase where selenium functions as an active 
component in the processes involved. These enzymes reduce oxidized molecules, 
thereby protecting cells from oxidative stress caused by reactive oxygen radicals 
Campa & Baum (2010). Reduced selenium status is associated with an increase of 
HIV disease progression and mortality (Pitney, Royal & Klebert, 2009; Irlam, Visser, 
Rollins & Siegfried, 2010; Stone, Kawai & Kupka, 2010). Selenium is a chemo 
preventive mediator in HIV that may increase the defense systems of the human 
body, reduce viral load (Campa & Baum, 2010) and specifically improves CD4 cell 
counts of these individuals (Stone et al., 2010). 
 
Iodine is a trace element and micronutrient required in the synthesis of thyroid 
hormones, triiodothyronine (T3) and thyroxine (T4). Thyroid hormones play a major 
role in the metabolic processes of the body (Leung, Braveman & Pearce. 2012). It is 
involved in the regulation of macronutrient metabolism and basal metabolic rate 
(Bougma, Aboud, Harding & Marquis, 2013). Iodine deficiency may lead to low 
levels of thyroid hormones resulting in full-blown hypothyroid syndrome 
(myxedema). Symptoms include mental sluggishness, edema and low metabolic 
rate (Marieb & Hoehan, 2013). 
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The high concentration of iodine in the thymus supports the role of this element in 
the immune system. Leukocyte myeloperoxidase enzymes in cell-mediated 
immunity use iodine to produce iodine-free radicals. Iodine also increases 
immunoglobulin-G production in human lymphocytes. The non-endocrine effects of 
iodine include increase in the movement of granulocytes into areas of inflammation 
and improve phagocytosis ability of the granulocytes. The immune deficiency in 
iodine-deficient individuals may be restored by oral administration of iodine (Venturi, 
2009). According to Beltran, Lescure, El Esper, Schmit and Desailloud (2006), 
iodine deficiency in HIV-infected individuals may contribute towards 
hypothyroidism. 
 
Iodine intake in males is lower in terms of the mean (±SD) and median (inter-
quartile range) i.e. 66.2±27.1 and 60.5(43-87) respectively when compared to the 
RDA of 150µg. Iodine intake in females is lower in terms of the mean (±SD) and 
median (inter-quartile range) i.e. 90.2±36.7 and 88(65-110) respectively when 
compared to the RDA of 150 µg. In the male group 83.3% of the individuals and 
66.7% of the individuals in the female group consumed ≤67% of the RDA. When the 
groups are combined, 69.2% of the individuals consumed ≤67% of the specified 
RDA standard. 
 
4.4.4 Reflection of the findings in terms of the composition of the 
supplement. 
The researcher had no indication or any insight knowledge on the baseline dietary 
intake levels of the 40 HIV-infected individuals prior to the formulation of the 
product. Furthermore, the researcher did not participate in formulating the product 
and viewed the formulation as being an arbitrary concoction of „nutritional 
substances‟ where claims are made in terms of the „beneficial effects‟ ascribed to 
use of the supplement by HIV-infected individuals. The primary goal is to evaluate if 
the supplement impact on various and numerous variables indicative of the health 
status of HIV-infected individuals (see chapter 5). 
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The ingredients and their respective quantities that comprise the product are 
revealed in Chapter 3: 3.3.2. 
 
In retrospect/hindsight, and at this point in time, it appears to be easy to predict 
what the possible outcome in terms of the presence of the micronutrient 
components of formulation should entail i.e. the present results show a decrease in 
the intake of Vitamin D and Iodine and should have been present (not absent) in the 
formulation. All other micronutrients on average (mean and median) met or 
exceeded the RDA/AI and one could consider supplementation as being an 
unnecessary additive/venture. In terms of the ingredients other than micronutrients, 
i.e. Biociden, Colostrum, and Spirulina lend elaboration will merely lend itself to 
speculation only. The nutritional requirements of HIV-infected individuals are most 
probably higher than the recommendation for healthy persons. 
 
 
4.5 CONCLUSION 
The main findings of the present investigation suggests that the eating pattern of 
this urbanized group of individuals reflects a high dietary intake of proteins and 
carbohydrate coinciding with a decrease in Vitamin D and Iodine intake in a 
significant number of individuals. 
 
 
REFERENCES 
Ahoua, L., Umutoni, C., Huerga, H., Minetti, A., Szumilin, E., Balkan, S., Olson, 
D.M., Nicholas, S. & Pujades-Rodrigues, M.  2011.  Nutrition outcomes of HIV 
malnourished adults treated with ready-to-use therapeutic food in sub-Saharan 
Africa: a longitudinal study.  Journal of the International AIDS Society, 14:2-9. 
 
Anabwani, G. & Navario, P.  2005.  Nutrition and HIV and AIDS in sub-Saharan 
Africa: an overview.  Nutrition, 21(1):96-99. 
 
125 
 
Anderson, J.J.B. 2008. The Nutrition and Bone Health. In Krause’s Food & Nutrition 
Therapy by Mahan LK, Escott-Stump S. 12th edition. United States of America: 
Lippencott Williams & Williams: 614-635. 
 
Baeke, F., Takiishi, T., Korf, F., Gysemans, C. & Mathieu, C.  2010.  Vitamin D: 
modulator of the immune system.  Current Opinion in Pharmacology, 10(4):482-
496. 
 
Beard, J.A., Bearden, A. & Striker, R. 2011. Vitamin and the anti-viral state. Journal 
of Clinical Virology, 50(3):194-200. 
 
Beltran, S., Lescure, F.X., El Esper, I., Schmit, J.L. & Desailloud, R.  2006.  
Subclinical hypothyroidism in HIV-infected patients is not an autoimmune disease.  
Hormone Research, 66:21-26. 
 
Bougma, K., Aboud, E.A., Harding, K.B., Marquis, G.S. 2013. Iodine and mental 
development of children 5 years old and under: A systematic review and meta- 
analysis. Nutrients, 5(4): 1384-1416. 
 
Borderi, M., Gibellini, D., Vescini, F., De Crignis, E., Cimatti, L., Biagetti, C. & Tam-
pellini, L.  2009.  Metabolic bone disease in HIV infection.  AIDS, 23(11):1297-1310. 
 
Campa, A. & Baum, M.K.  2010. Micronutrients and HIV infection. HIV Therapy, 
4(4):437-468. 
 
Carter, M.  2012.  Obesity is a risk factor for co-occurring chronic health problems in 
patients with HIV.  HIV & AIDS Information. Available: http://www.aidsmap.com, 
[2012, 6 October]. 
 
Cassani, B., Villablanca, E.J., De Calisto, J., Wang, S. & Mora, J.R.  2012.  Vitamin 
A and immune regulation L Role of retinoic acid in gut-associated dendritic cell 
126 
 
education, immune protection and tolerance. Molecular Aspects of Medicine, 
33(1):63-76. 
 
Curtiss, D.H. & Johnson L.K. 2007. Calcium requirements: new estimations for men 
and women by cross-sectional statistical analyses of calcium balance data from 
metabolic studies. The American Journal of Clinical Nutrition, 86(4):1054 - 1063. 
 
Dong, K.R. & Imai, C.M.  2012.  Medical nutrition therapy for HIV and AIDS, In: Ma-
han, L.K., Escott-Stump, S. & Raymond, J.L. Krause's food & the nutrition care pro-
cess.  13th ed.  St.  Louis, Missouri: Elsevier Sanders.  864-883. 
 
Faintuch, J., Soeters, P.B. & Osmo, H.G.  2006. Nutritional and metabolic 
abnormalities in pre-AIDS HIV infection.  Nutrition, 22(6):683-690. 
 
Gallagher, M.L.  2012.  Intake: the nutrients and their metabolism, In: Mahan, L.K., 
Escott-Stump, S. & Raymond, J.L. Krause's food & the nutrition care process.  13th 
ed.  St.  Louis, Missouri: Elsevier Sanders.  32-128. 
 
Grimble, R.F.  2009.  Basics in clinical nutrition: immunonutrtion – nutrients which 
influence immunity: effect and mechanism of action. e-SPEN, The European e-Jour-
nal of Clinical Nutrition and Metabolism, 4(1):e10-e13. 
 
Gueli, N., Verrusio, W., Linguanti, A., Di Maio, F., Martinez, A., Marigliano, B. & 
Cacciafesta, M. 2012. Vitamin D; drug of the future. A new therapeutic approach. 
Archives of Gerontology and Geriatrics. 54(1):222-227. 
 
Herbert, V., Fong, W. & Gulle, V.  1990.  Low holotranscobalamin II is the earliest 
serum marker for subnormal vitamin B12 absorption with AIDS.  American Journal 
of Hematology, 34:132-139. 
127 
 
Ivers, L.C., Cullen, K.A., Freedberg, K.A., Block, S., Coates, J. & Webb, P.  2009.  
HIV/AIDS, Undernutrition and food insecurity. Clinical Infectious Disease, 49(7): 
1096-1102. 
 
Irlam, J.H., Visser, M.M., Rollins, N.N. & Siegfried, N.  2010. Micronutrient supple-
mentation in children and adults with HIV infection.  Cochrane Database of Systems 
Reviews, 8(12):Article no. CD003650. 
 
Kim, J.H.S., Rimm, E. & Gorbach, S.  2001. The correlates of dietary intake among 
HIV-positive adults.  American Journal of Clinical Nutrition, 74(6):852-861. 
 
Lagishetty, V., Lui, N.Q. & Hewison, M.  2011. Vitamin D metabolism and innate 
immunity. Molecular and Cellular Endocrinology, 347(1-2):97-105. 
 
Leah, M. & Mascioly, E.A. 1995. Nutrition and HIV infection.  Nutritional Biochemi-
stry, 6(1):2-11. 
 
Lee, R.D. & Nieman, D.C. 2010. Nutritional assessment. 5th ed. New York: McGraw 
Hill Companies Incorporate. 326-357. 
 
Leung, M.A., Braveman, L.E., Pearce, E.N. 2012. History of U.S. iodine fortification 
and supplementation. Nutrients, 4(11):1740-1746. 
 
Marieb, E.N. & Hoehan, K. 2010. Human anatomy & physiology. 8th ed. San Fran-
cisco: Pearson Education. 661-693. 
 
Marieb, E.N. & Hoehan, K. 2013. Human anatomy & physiology. 9th ed. San 
Francisco: Pearson Education. 591-630. 
 
Melanson, L., Sharp, T.A., Schneider, J., Donahoo, W.T., Grunwald, G.K., Hill, J.O. 
2003. Relation between calcium intake and fat oxidation in adult humans. 
International Journal of Obesity, 27:196-203. 
128 
 
Mehta, S., Spie, D., About, S., Giovannucci, E.L., Msamanga, G I., Hertzmark, E., 
Mugusi, F.M., Hunter, D.J. & Fawzi, W.W. 2010. Lipid-soluble vitamins A,D, and E 
in HIV-infected pregnant woman in Tanzania. European Journal of Clinical Nutrition, 
64(8):808-817. 
 
Molano, A. & Meydani, S.N.  2012. Vitamin E, signalosomes and gene expression in 
T cells.  Molecular Aspects of Medicine, 33(1):55-62. 
 
Monsen, E.R.  2000.  Dietary Reference Intakes for the antioxidant nutrients: 
vitamin D, vitamin E, selenium, and carotenoids. Journal of the American Dietetic 
Association, 100(6):637-640. 
 
Nutrient Reference values for Australia and New Zealand, 2006.  Available: 
http://www.nhmrc.gov.au , [2012, 1 November]. 
 
Ockenga, J., Grimble, R., Jonkers-Schuitema, C., Macallan, D., Melchior, J-C., 
Sauerwein, H.P. & Schwenk, A.  2006.  ESPEN guidelines on enteral nutrition: 
wasting in HIV and other chronic infectious diseases.  Clinical Nutrition, 25(2):319-
329. 
 
Oguntibeju, O.O.  2004.  The influence of a multiple combination liquid product on 
the immune status of HIV-positive/AIDS patients.  Doctor Technologiae thesis.  
Bloemfontein: Central University of Technology, Free State. 
 
Oguntibeju, O.O., Van den Heever, W.M.J., & Van Schalkwyk, F.E.  2005.  An 
analysis of the baseline dietary intake of HIV-positive/AIDS patients.  Medical 
Technology SA, 19(2):3-9. 
 
Oketch, J.A., Paterson, M., Maunder, E.W. & Rollins, N.C.  2011.  Too little, too late: 
comparison of nutritional status and quality of life of nutrition care and support reci-
129 
 
pients and non- recipients among HIV positive adults in KwaZulu-Natal, South 
Africa.  Health Policy, 99(3):267-276.  
 
Paul, L.  2011. Diet, nutrition and telomere length.  Journal of Nutritional Biochemis-
try, 22(10):895-901. 
 
Pitney, C.L., Royal, M. & Klebert, M.  2009. Selenium supplement in HIV-infected 
patients: Is there any potential clinical benefit? Journal of the Association of Nurses 
in AIDS Care, 20(4):326-333. 
 
Rolfes, S.R., Whitney, E & Pinna K. 2009. Understanding normal and Clinical 
Nutrition. 8th edition. United States of America: Thomson Wadsworth: 416. 
 
Soares, M.J., Murhadi, L.L., Kurpad, A.V., Piers, L.S. 2012. Mechanistic roles for 
calcium and vitamin D in the regulation of body weight. PubMed [online], 13(7):592-
605. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22385576 [Accessed 9 
October 2013] 
 
Somarriba, G., Neri, D., Schaefer, N. & Miller, T.L.  2010.  The effect of aging, nutri-
tion and exercise during HIV infection. HIV/AIDS – Research and Palliative Care, 
2:191-201. 
 
Spencer, D.C., Harman, C., Botha, C., Rollins, N., Labadarios, D. & Visser, M.  
2008.  Nutritional guidelines for HIV-infected adults and children in South Africa: 
meeting the needs (section 3-6).  The Southern African Journal of HIV Medicine, 
29:34-59. 
 
Stone, C.A., Kawai, K. & Kupka, R.  2010.  Role of selenium in HIV infection.  
Nutrition Reviews, 68(11):671-681. 
 
130 
 
Szetela, B. & Gasiorowski, J.  2010.  Nutritional support for patients living with HIV 
or AIDS.  HIV & AIDS Review, 9(3):79-82. 
 
Sztam, K.A., Fawzi, W.W. & Duggan, C.  2010.  Macronutrient supplementation and 
food prices in HIV treatment.  The Journal of Nutrition, 140(1):213S-223S. 
 
Venturi, S. 2009. Iodine, thymus and immunity. Nutrition, 25: 977-979. 
 
Verrusio, N.G.W., Linguanti, A., Di Maio, F., Martinez, A., Marigliano, B. & Caccia-
festa, M.  2012.  Vitamin D: drug of the future.  A new therapeutic approach.  Arc-
hives of Gerontology and Geriatrics, 54(1):222-227. 
 
Yang, Y., Yuan, Y., Tao, Y. & Wang, W.  2011.  Effects of vitamin A deficiency on 
mucosal immunity and response to intestinal infection in rats.  Nutrition, 27(2):227-
232. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
CHAPTER 5 
 
 
INFLUENCE OF NUTRITIONAL SUPPLEMENT INTAKE ON THE 
HAEMATOLOGICAL STATUS, IMMUNE STATUS AND VIRAL LOAD IN HIV-
INFECTED INDIVIDUALS LIVING IN THE MANGAUNG METROPOLITAN 
 
 
 
ABSTRACT          132 
5.1. INTRODUCTION        133 
 
5.2. METHODOLOGY        136 
5.2.1. Protocol design demographic information.    136 
5.2.2. Measuring tool, variables and analysis of data   136 
5.2.3. Statistical analysis of data      137 
 
5.3. RESULTS         137 
5.3.1. Demographic results       138 
5.3.2. Relative results        138 
5.3.2.1. Results for the Entire Study Population (ESP)   138 
5.3.2.2. Results for the Sub-Population Groups (SPG)   143 
 
5.4. DISCUSSION        145 
 
5.5. CONCLUSION        150 
 
REFERENCES         150 
132 
 
ABSTRACT 
The aim of the investigation was to determine if supplementation with a mixture 
comprised from specific minerals, vitamins and herbs over a period of one year, 
affect the viral load, immune and Haematological status in forty (40) HIV-infected 
individuals living in the Mangaung Metropolitan. 
 
The study commenced with a screening visit for inclusion purposes, followed by a 
baseline evaluation on numerous variables. Participants received the supplement 
with their monthly clinic visits for a period of 12 months. Blood samples were 
obtained, clinical assessment and pulmonary function tests performed during all 
monthly visits. 
 
The results show statistical significant median difference (p<0.0001) decreases in 
the mean viral load values of the study population i.e. from 51,040 RNA copies per 
milliliter plasma to 43,107 RNA copies per milliliter plasma over the first 6-month 
period and 37,307 RNA copies per milliliter plasma over the 12 month period 
respectively. 
 
From all of the haematological variables the only statistical significant changes 
observed are increases in the median ESR (p=0.0219) and MCHC (p=0.0245) and 
a decrease in viral load (p=0.0001) after 6 months. At 12 months a statistical 
significant decrease in the median CD/CD8 ratio (p<0.0048), median Hematocrit 
concentration (p<0.0312), median MCV (p<0.0359), and median RDW (p<0.0273) 
accompanies the significant decrease in the median viral load (p<0.0001). The only 
variable(s) that show a statistical significant increase is the MCHC (p<0.0003) at 12 
months. 
 
The study population was divided into two (2) sub-populations demarcated to 
present positive responders (i.e. decrease in viral load) and non-responders (no 
change or increase in viral load). At 6 months 89% (CI95%: 73%;96%) of the 
individuals show a decrease in viral load counts with a median percentage change 
133 
 
of 34% (CI95%: 73%;96%). At 12 months 85% [CI95%: 68% ; 94%] of the individuals 
show a decrease in viral load counts with a median percentage change of 62.9% 
(CI95%: 50%;78.6%) following the intake of the supplement. In terms of the decrease 
in viral load and the number of individuals showing a decrease in viral load following 
use of the supplement, the present results suggest that those measurable clinical 
advantages are not related to chance/coincidence. 
 
5.1 INTRODUCTION 
Nutritional metabolism and human immunity are complex biological systems that 
have to function in a synergistic fashion to sustain and preserve life. Any disruption 
of the nutritional status of any individual will be detrimental to the ability of the 
immune system to protect the human body against infection. A reduction in immune 
system activity will also impact negatively on the nutritional status of the immune 
compromised individual (Afacan, Fjell & Hancock, 2012). The immune system 
requires essential nutrients to produce needed defense mechanisms and defense 
cells (Carter, 2011). An inadequate intake of specific micronutrients, suppresses the 
immune system by reducing the innate T-cell response leading to deregulation of 
the host immune response (Wintergerst, Maggini & Hornig, 2007). 
 
HIV is known to break down the immune system and promotes nutritional deficiency 
in infected individuals (Campa & Baum, 2010). HIV changes the production of T-cell 
precursors that impair CD4 cell response resulting in opportunistic infections and 
AIDS (De Biasi, Pinti, Nasi, Gibellini, Bertoncelli, Manzini, Mussini & Cossarizza, 
2011). The weeks that follow the initial infection are associated with prompt damage 
to the immune cells due to direct viral cell toxicity (McMichael, Borrow, Tomaras, 
Goonetilleke & Haynes, 2010).  
 
The first stage of HIV infection is the attachment of HIV glycoprotein envelope to the 
primary cellular receptor, CD4 cells. This binding leads to viral and host membrane 
fusion with viral capsid entrance into the host cells (Friedrich, Dziuba, Li, Endsley, 
Murray & Ferguson, 2011). HIV enters the host cell also by means of endocytosis 
134 
 
by binding to the lectins on the cell surface. After the viral core is released into the 
cytoplasm of the host cell, reverse transcriptase converts the virus RNA to DNA 
(Yan & Lieberman, 2011).  
 
The human innate immune response is first activated by HIV and then the adaptive 
immune response is triggered. The innate immunity is activated by the recognition 
of pathogen-associated molecular patterns (Yan & Lieberman, 2011).  
The CD8 cells are vital to control viral replication by secreting interferon gamma that 
induces the production of antiviral proteins and immune response that destroys 
infected cells. This implies that a strong cytotoxic T-Lymphocyte reaction is 
associated with improved virus control and delayed disease development during 
early HIV-infection (Kim, Lee, Hong & Kim, 2010).  
 
HIV escape from the CD8 cell response may occur very quickly, even within 10 
days of lymphocyte recognition. This commences with viral cell reservoirs and 
antibody escaped viral mutants emerge in the host plasma that may lead to the 
activation of uninfected CD4 cells and death by apoptosis, causing immune 
suppression. Up to 80% of the host CD4 cells can be depleted in the first three 
weeks of HIV infection (McMichael et al., 2010). The majority of untreated HIV-
infected individuals develop uncontrolled viremia with progressive immune 
destruction and ultimately AIDS and death (Théze, Chakrabarti, Vingert, Porichis & 
Kaufmann, 2011). 
 
Significant weight loss and underweight are widely present among HIV-infected 
adults in sub-Saharan Africa. This compromised nutritional status may result from 
reduced food intake due to the impact of HIV on the health of the infected individual. 
The weight loss in HIV-infected individuals is potentiated by elevated tumor necrosis 
factor alpha, interleukin-1 and interleukin-6 (Koethe, Chi, Megazzini, Heimburger & 
Stringer, 2009).  
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The compromised immune function leads to opportunistic infections such as oral 
thrush and diarrhoea leading to reduced nutritional intake. Other factors include 
fatigue, nausea, vomiting, appetite loss, skin infection and prolonged fever. Food 
insecurity also contributes towards malnourishment of HIV-infected individuals 
(Oketch, Paterson, Maunder & Rollins, 2011). 
 
Malnutrition has a negative effect on the innate, adaptive as well as cellular immune 
response leading to reduced host defense and increased pathogen virulence. In 
turn, the infection negatively impacts on the micronutrient status of the body by 
reducing nutrient intake, interfering with metabolic pathways and excessive loss of 
nutrients (Wintergerst et al., 2007). A study by Afacan and associates (2012) 
suggests that viruses modify the metabolic processes of infected cells by increasing 
aerobic glycolysis, resulting in a shift of the cellular metabolism to enhance energy 
promotion over cell biosynthesis. 
 
A study regarding the nutritional status of HIV-infected individuals show that 
malnutrition contributing to weight loss in HIV-infected individuals plays a predictive 
roll in disease progression regardless indicators such as low CD4 cell count 
(Venter, Gericke & Bekker, 2009). Malnutrition in impaired immunity interrupts 
recovery from disease and increases complications associated with the infection 
(Cawood, Elia & Stratton, 2012).  
 
Research conducted in the Mangaung Metropolitan show that micronutrient 
deficiencies occurred in the majority of HIV-infected children in care centers 
(Steenkamp, Dannhauser, Walsh, Joubert & Veldman, (2009). The prominent 
deficient micronutrients are zinc, Vitamin A, Vitamin D and glutathione and the 
researchers recommend vigorous macro- and micronutrient supplementation in an 
attempt to eliminate these nutrient deficiencies. The first line of defense against 
pathogenic invasion is the innate immune system. Evidence by Lagishetty, Lui and 
Hewison (2011) show that Vitamin D is involved in innate immune system 
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regulation. Vitamin D-activating enzyme (CYP27B1) assists in linking monocytes 
and pathogen sensing mechanisms (Lagishetty, Lui & Hewison, 2011). 
 
The importance of nutrient supplementation is highlighted by many HIV and AIDS 
programmes in sub-Saharan Africa that started to include nutritional assistance in 
addition to medical treatment to reduce malnutrition and improve the outcome in 
HIV-infected individuals (Tirivayi & Groot, 2011). The improvement of the nutritional 
status of HIV-infected individuals improves their physiological and psychological 
status with better quality of life (Oketch et al., 2011).  
 
The aim of the investigation was to determine if supplementation with a mixture 
comprised from specific minerals, vitamins and herbs over a period of one year, 
affect the haematological status, immune status and/or viral load in forty (40) HIV-
infected individuals living in the Mangaung Metropolitan. 
 
 
5.2. METHODOLOGY 
The following section will provide information regarding the material and methods 
used. 
 
5.2.1. Protocol design demographic information. 
Information based on the study design (see 3.1.1), study site (see 3.1.2), study 
population (see 3.2) and intervention (see 3.3) is described in Chapter 3. 
 
5.2.2. Measuring tool, variables and analysis of data 
Information pertaining to the apparatus used and the various haematological and 
immunological variables including the viral load are made by means of using 
standard accredited laboratory and technological procedures and is disclosed in 
Chapter 3 section 3.5.2. 
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5.2.3. Statistical analysis of data 
The data is subjected to statistical analysis categorized into two populations: 
1. A study population where the following statistical formulations are applied: 
 Percentages and corresponding 95% confidence intervals for these 
percentages (descriptive statistics); 
 Mean and corresponding standard deviations; 
 Median and 95% confidence intervals for the mean; and 
 Corresponding p-values for median differences and 95% confidence 
intervals for these mean differences. 
 
2. A study subpopulation category demarcated as responders and non-responders 
in terms of changes in viral load is drafted where the following statistical 
formulations are applied: 
 Percentages and corresponding 95% confidence intervals for the 
percentages; 
 Median percentage change and 95% confidence intervals for the .median 
percentage change and 
 Corresponding p-values for median differences and 95% confidence 
intervals for these mean differences. 
 
Baseline levels are obtained for all variables and compared to the various 
corresponding levels at 6 months and 12 months respectively.  
 
 
5.3. RESULTS 
The following sections reflects the demographic, absolute and relative results. 
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5.3.1. Demographic results 
A total of 132 HIV-infected individuals were enrolled into present investigation but 
due to dropouts the study is completed with a final total of 40 individuals. The 
relatively high dropout figure can be ascribed to noncompliance with the protocol 
design i.e. not taking the supplement correctly or missing appointments–see 
Chapter 3 section 3.5.2. Seven (17%) of the 40 participants are male while 33 
(83%) are female.  
 
5.3.2. Relative results 
Relative results refer to calculated values derived from specific measurements. The 
results obtained for two (2) populations are revealed i.e. entire study population and 
the two sub-populations. 
 
5.3.2.1. Results for the Study Population category (SP) 
Table 5.1 indicates the normal values, mean, standard deviation, median and p-
values (statistical significant differences highlighted in red) for viral load, 
haematological, and immunological variables at baseline, six (6) months, and twelve 
months (12) for the entire population. 
 
The results show statistical significant median difference (p<0.0001) decreases in 
the mean viral load values of the study population i.e. from 51,040 RNA copies per 
milliliter plasma to 43,107 RNA copies per milliliter plasma over the first 6-month 
period and 37,307 RNA copies per milliliter plasma over the 12 month period 
respectively. From all of the haematological variables the only statistical significant 
changes observed are increases in the median ESR (p=0.0219) and MCHC 
(p=0.0245) and a decrease (in Viral load (p=0.0001) after 6 months. At 12 months a 
statistical significant decrease in the median CD/CD8 ratio (p<0.0048), median 
Hematocrit concentration (p<0.0312), median MCV (p<0.0359), and median RDW 
(p<0.0273) accompanies the significant decrease in the median viral load 
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(p<0.0001). The only variable(s) that show a statistical significant increase is the 
MCHC (p<0.0003) at 12 months. 
   
  Table 5.1.  Haematological and immunological variables and viral load of the HIV-
infected individuals at baseline, 6 months, and final visit at 12 months 
(n=40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     *Signed Rank Test for median differences for dependent data. 
     RBC Red cell count                              
     MCV Mean corpuscular volume  
     MCH Mean corpuscular Hemoglobin 
     MCHC Mean corpuscular Hemoglobin concentration 
     RDW Red cell distribution width             
     WCC White cell count                                
     Std Dev Standard deviation   
     ESR    Erythrocyte sedimentation rate 
     p<0.05   Statistical significant difference 
 
Seven of the most prominent variables regarded as being important in the 
progression of HIV-infected individuals, are selected from Table 5.1 and is 
presented in Table 5.2 (see the specified variables in the column specified as 
„VARIABLES‟).  
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The statistical analysis performed emphasise the number of individuals that show a 
change [expressed as a percentage (%:CI95%)] and the „size of change‟ [expressed 
as the median percentage change (%:CI95%)] indicating the type of change 
(increase; decrease; no change) when baseline values are compared to the 
corresponding and respective values obtained for the specified variables at six (6) 
and twelve (12) months. Relatively large changes are highlighted in red. 
 
  Table 5.2. The percentage of HIV-infected individuals with change in  
haematological and immunological values and viral load, 
at baseline, six months, and final visit at 12 months (n=40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Each and every variable is discussed separately: 
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Hemoglobin 
At six months, 40%(CI95%: 24% ; 57%) of the individuals show a median 4.1% (CI95%: 
2.9% ; 11.2%) increase in hemoglobin concentration, while 55% (CI95% [38% ; 71%])  
show a decrease of 4.5% (CI95% [1.4% ; 8.8%]). Five per cent of the individuals 
show no change in hemoglobin concentration. 
At 12 months 42% (CI95%  [27% ; 59%]) of the individuals show a 4.3% (CI95% [1.5% 
; 12.4%]) increase in hemoglobin concentration, while 55% (CI95%[38% ; 71%])  
show a decrease of 4.5%(CI95%[1.4% ; 8.8%]). Three per cent of the individuals 
show no change in hemoglobin concentration 
 
Hematocrit 
At six months, 29% (CI95%[16% ; 46%]) of the individuals show a 5.6%(CI95% [2.6% ; 
14.3%]) increase in hematocrit, while 55% (CI95%[38% ; 71%]) show a decrease of 
5.6%(CI95%[4.5% ; 9.5%]). Sixteen per cent of the individuals show no change. 
 
At 12 months 26% (CI95%[14% ; 43%]) of the individuals show a 7.1% (CI95%[2.6% 
;12.5%])  increase in hematocrit, while 63% (CI95%[46% ; 78%]) show a decrease of 
5.1% (CI95%[4.5% ; 8.2%]). Eleven per cent of the individuals show no change. 
 
 White cell count (WCC) 
At six months, 53% (CI95%[31% ; 64%]) of the individuals show a 20.1% (CI95% 
[5.7% ; 38.4%])  increase in WCC, while 47%(CI95% [31% ; 64%]) show a decrease 
of 13.4% (CI95%[12.0% ; 31.4%]). No individuals show unchanged WCC. 
 
At 12 months 45% (CI95% [29% ; 62%]) of the individuals show a 14.6% (CI95% 
[10.9% ; 27.8%])  increase in WCC, while 45% (CI95%[29% ; 62%]) show a decrease 
of 14.3%(CI95% [5.8% ; 23.4%]). Ten per cent of the individuals show no change in 
WCC. 
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CD4 count 
At six months, 53% (CI95%[31% ; 64%])  of the individuals show a 21.8% (CI95% 
[5.7% ; 38.4%]) increase in CD4 count, while 47% (CI95%[36% ; 69%]) show a 
decrease of 18.5%(CI95%). No individual show an unchanged CD4 count. 
 
At 12 months 34%(CI95%) of the individuals show a 21.6% (CI95%) increase in CD4 
count, while 66%(CI95% [48% ; 80%]) show a decrease of 18.2% (CI95% [9.7% ; 
21.1%]) No individual show an unchanged CD4 count. 
 
CD8 count 
At six months, 57% (CI95%[40% ; 73%])  of the individuals show a 14.8% 
(CI95%[7.5% ; 34.9%]) increase in CD8 count, while 43% (CI95%[27% ; 60%]) show a 
decrease of 22.8%(CI95%[9.8% ; 31.2%]). No individual show an unchanged CD8 
count. 
 
At 12 months 59%(CI95% [42% ; 75%]) of the individuals show a 10.9% (CI95%[3.5% ; 
27.7%]) increase in CD8 count, while 41% (CI95%[24% ; 58%]) show a decrease of 
26.7% (CI95%[7.0% ; 38.1%]). No individual show an unchanged CD8 count. 
 
CD4/CD8 ratio 
At six months, 29% (CI95%[16% ; 46%]) of the individuals show a 14.3%(CI95%[8.3%; 
35.7%]) increase inCD4/CD8 ratio, while 61%(CI95%[43% ; 76%]) show a decrease 
of 14%(CI95%[9.5% ; 17.9%]). Ten (10) per cent of the individuals show no change in 
the CD4/CD8 ratio. 
 
At 12 months 26%(CI95% [14% ; 43%]) of the individuals show a 12.9%(CI95% [3.4%; 
26.7%]) increase inCD4/CD8 ratio, while 66% (CI95%[49% ; 80%])  show a decrease 
of 14.3% (CI95%[11.1% ; 20.7%]). Eight (8) per cent of the individuals show no 
change in CD4/CD8 ratio. 
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Viral load 
At six months, 11% (CI95%[4% ; 27%]) of the individuals show a 62%(n is too small) 
increase in viral load, while 89% (CI95%[73% ; 96%]) show a decrease of 34% (CI95% 
[21.3% ; 55.2%]). Five (5) per cent of the individuals show no change in viral load. 
 
At 12 months 15%(CI95%[6% ; 32%])  of the individuals show a 136% (n is to small) 
increase in viral load, while 85% (CI95% [68% ; 94%]) show a decrease of 62.9% 
(CI95%[50.0% ; 78.6%]).  
 
5.3.2.2. Results for the Sub-Population category (SPG) 
The entire study population is sub-divided into two (2) sub-groups demarcated to 
present positive responders (i.e. decrease in viral load) and non-responders (no 
change or increase in viral load). 
 
Table 5.3 indicate the actual measured raw data values, median difference and the 
respective corresponding p-values for the median difference for the specified 
haematological and immunological variables when baseline values are compared to 
the values obtained at 6 and 12 months for the non-responders (A) and responders 
(B) separately. 
 
Non-responders (n=4)  
No statistical significant changes in haematological or immunological values of HIV-
infected individuals with a viral load increase, at baseline, six months, and final visit 
at 12 months are indicated (Table 5.3 A). 
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  Table 5.3 Median haematological and immunological values at baseline, six months, and 12          
                          months in non-responders (n=4) and responders (n=36) after exposure to the              
                          intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   RBC Red cell count; MCV Mean corpuscular volume;  
   MCH Mean corpuscular Hemoglobin; 
   MCHC Mean corpuscular Hemoglobin concentration; RDW Red cell distribution width 
   WCC White cell count;  P<0.05 Statistical significant difference. 
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Responders (n=36) 
According to Table 5.2 an average decrease of 89% (CI95%: 73%; 96%) of the 
individuals show decreased viral load counts with a median degree of change of 
34% (CI95%: 73%; 96%) at 6 months and 85% [CI95%: 68%; 94%] of the individuals 
show lower values with a median degree of change of (CI95%: 50%; 78.6%) at 12 
months compared to baseline values. 
 
Statistical significant changes occurred in the following variables coinciding with a 
decrease in viral load (see red highlighted figures in Table 5.3 B). 
 
The hematocrit decreased from 0.41l/l to 0.39l/l (P=0.0316) from baseline to 12 
months. The MCHC increased from 3.25g/dl to 33.0g/dl (P=0.0384) from baseline to 
6 months and is unchanged after 12 months. The RDW decreased from 14.35 to 
13.9 (P=0.0020) after 12 months. A decrease in the monocyte count from 0.49 
x109/l to 0.44 x109/l (P=0.0248) is recorded after 6 months. Plasma Viscosity 
(ESR) is reduced from 38.0 mm/h to 37.5 mm/h (P=0.0351) after 12 months and the 
CD4/CD8 ratio decreased from 0.31 to 0.30 (P=0.0057) at 12 months. 
 
 
5.4 DISCUSSION 
The impact of the HIV on the human body is multi faceting, the virus affect the 
physiological function and the altered functions in turn causes further pathological 
changes. It is associated with an increase in renal, immune system, liver, 
cardiovascular and neurocognitive disorders. Haematological system disorders are 
common amongst HIV-infected individuals, the appearance are varied and prevail 
throughout the course of the disease. Anemia is a frequent complication of HIV 
infection (Mathews, Srivastava, Yadav & Sharma, 2013). 
 
HIV infection has a negative influence on metabolism even in the early stages of the 
infection when no apparent clinical signs are visible (Szetela & Gasiorowski, 2010).  
The chronic inflammation caused by infection increases the metabolic needs of the 
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human body and poor absorption may lead to the depletion of essential nutrients 
resulting in a malnourished person with reduced immunity (Duggal, Chugh & 
Duggal, 2012). 
 
The supplement used in the present investigation contained plant sterols, 
antioxidants and vitamins crucial to cell metabolism (Chapter 3 section 3.6). HIV 
infection results in activation of the immune system and local systemic oxidative 
stress. Although antioxidant protection is available in the body, it is proclaimed to be 
insufficient to contain the damage caused by reactive oxygen species (Coaccioli, 
Carpa, Fantera, Del Giorna, Standoli, Frongillo, Biondi & Puxeddu, 2010).  
 
However any explanation pertaining to the exact mechanism involved due to the 
individual and/or synergistic role(s)/effect(s) of the ingredients on haematological 
and immunological function, do not fall within the realm/ambit of the present 
investigation. 
 
Anemia is a well-known and frequent complication in HIV-infected individuals 
(Obinkorang & Yeboah, 2009; Marti-Carvajal, Sola, Pena-Marti & Comunian-
Carrasco, 2011; Takuva, Maskew, Brennan, Sanne, MacPhail & Fox, 2013). 
Mathews and associates (2013) established that normocytic, normochromic anemia 
is prevalent in more than 40.1% of the HIV-infected individuals in their research 
study. 
 
In this regard the present results show no significant alterations in hemoglobin 
levels or red blood cell count (see Table 5.2). The present results, however, 
show a decrease (p=0.0312) in hematocrit in 55% (CI95%38%; 71%) at six months 
and 63% (CI95%27%; 59%) at 12 months (Table 5.2). A decrease (p=0.0359) in the 
MCV is observed at 12 months. The reason(s) for these findings remain 
unexplained. 
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Plasma Viscosity (Table 5.1) is a useful marker indicative of inflammation in 
several conditions including HIV infection (Feldman, Aziz, Kang, Opondo, Belz & 
Sellers, 2013). The normal value for plasma viscosity is 3-12 mm/h. The plasma 
viscosity for the participants at baseline is 53.70 mm/h. The result of the high 
plasma viscosity caused rouleau formation of the red blood cells. In their study the 
participants show plasma viscosity levels of more than four times the normal value 
which is an indication of the level of inflammation present. In contrast, the present 
findings show a significant increase (p=0.0219) at 6 months but a significant 
decrease (p=0.0351) at 12 months in the responder group. 
 
The white cell count (WCC) (Table 5.1) did not show significant changes during 
the investigation period. The more important component of the WCC is the 
lymphocyte count which includes the CD4 and CD8 cells. A lymphocyte count of <1 
200 109/l (Cells) indicates an increase in disease progression and mortality (Sen, 
Vyas, Sanghi, Shanmuganandan, Gupta,  Kapila, Praharaj, Kumar &  Batra,  2011) 
In the present investigation the lymphocyte count decreased from 2.11 X 109/l to 
1.90X 109/l over the 12 month period. This decrease is close (p=0.0563) to the 95% 
confidence interval level and is way above the critical count level specified by Sen et 
al. (2011). 
 
The immune changes in HIV-infected individuals, including declines in the numbers 
as well as the ratio of CD4 cell counts and CD8 cell counts, are also found in 
malnourished individuals due to the negative effect on the thymus gland cell 
proliferation (Savin & Dardenne, 2010). Malnutrition causes thymic atrophy affecting 
immature CD8 and CD4 cells contributing to impaired peripheral immune response 
(Savin & Dardenne, 2010). 
The pathogenicity of HIV is associated with its heterogeneity and is the end result of 
numerous abnormalities such as errors in enzyme reverse transcriptase and 
recombination at a rate of approximately 2% per kilobase per replication cycle 
results in selective immune pressure with negative affect on CD4 and CD8 cells. 
The reduction in CD4 and CD8 cells is contributed to oxidative cell activity 
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enhanced by insufficient nutrition (Momoh, Muhamed, Agboke, Akpabio & Osonwa, 
2012). 
 
The increase of HIV-RNA levels is associated with a decrease in T-cell count and 
function, as well as haematological variables such as hemoglobin concentration 
(Langford, Ananworanich & Cooper, 2007). Although the increasing risk of death in 
a malnourished HIV-infected individual is independent from the viral load and CD4 
cell count (Grimble, 2009). Fauce, Yang and Effros (2007) reveal that the CD8 cell 
response is strategic in controlling HIV-replication and coincides with a strong anti-
viral activity. Kim and associates (2010) state that the CD8 cells are vital to control 
viral replication by secreting interferon gamma that induces the production of 
antiviral proteins and immune response that destroys infected cells.  
 
Pertaining to the present findings no statistical significant changes in CD4 and CD8 
cell counts occurred in the entire study population (Table 5.1) or sub-populations 
(Table 5.3) over the entire duration of the trial period. 
 
It is known that absolute CD4 cell counts per se to be inconsistent and may be 
misleading, for diagnostic purposes and the ratio of CD4 cell to CD8 cell count 
therefore to be considered a more reliable variable (Gaurav, Keerthilantha & 
Archna, 2011). Serrano-Villar, Gutiérrez, Vallejo, Hernandéz-Nova, Diaz, 
Fernandéz, Madrid, Dronda, Zamora, Munzo-Fernandéz, and Moreno (2013) state 
that an inverted CD4/CD8 ratio is associated with immune activation and increased 
disease progression and mortality regardless of the reduction of virus replication. 
The CD4/CD8 ratio is independently linked with T-cell activation even with long-term 
viral suppression (Serrano-Villar et al., 2013). Furthermore, that lack of correlation 
even between a very small size of proviral DNA reservoir and T-cell activation in 
HIV-infected individuals with a continuous undetectable viral load for 10 years, are 
indicated (Poizot-Martin, Faucher, Obry-Roguet, Nicolino-Burnet, Ronot-Bregigeon, 
Dignat-George, & Tamalet, 2013).  
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Although CD4 and CD8 cell counts appears to be unaltered in the present 
investigation, a statistical significant decrease in the CD4/CD8 ratio (p=0.0048) is 
observed at 12 months. The only explanation for the decrease in the CD4/CD8 ratio 
could lie within the notion that a relatively small insignificant decrease in CD4 count 
in combination with a relatively small insignificant increase in the CD8 count in 
combination could significantly impact on the ratio and render a significant inverse 
relationship. 
 
Research by Fauci, Pantaleo, Stanley and Weissman (1996) show that the viral 
load in HIV-infected individuals starts to rise after nine to 12 weeks after being 
infected and may increase to more than 108 RNA copies per milliliter plasma within 
12 years. The plasma viral load of the HIV correlates with the rate of virus 
production in the lymphoreticular tissues. High levels of HIV copies in the plasma 
have been associated with rapid CD4 reduction and increased disease progression 
(Swanson, 1997). 
 
The study of Oguntibeju (2004) reveals the short term effect of daily nutritional 
supplementation on the haematological variables, immune status and viral loads of 
HIV-infected individuals in the Free State province in South Africa. His results 
support the decrease in viral load that is indicated in the present study i.e. a 
statistical significant decrease load (p=0.0001) at both 6 months and 12 months 
following supplementation (see Table 5.1). The supplement taken by the HIV-
infected individuals in this study contained several elements that combat oxidative 
stress and possibly contributed to the lower viral loads (See Chapter 3, section 
3.3.2 for supplement content). Elements like zinc, magnesium and selenium inhibit 
intracellular HIV replication (Sepulveda & Watson, 2002) and possibly contributed 
towards the decrease in viral load. 
 
The present results suggest that in terms of viral load and the number of individuals 
showing a decrease in viral load following use of the supplement, measurable 
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advantages in terms of clinical relevance that could not be ascribed/related to 
chance/coincidence, exist. 
 
 
5.5 CONCLUSION 
In terms of the primary aim of the present investigation the results suggest that a 
significant measurable decrease in viral load in HIV-infected individuals can be 
obtained by means of subjecting individuals to a nutritional fortification supplement 
strategy. 
 
Due to the severity of the epidemic (in 2011, 10.6% (5.38 million) of the total 
population of the Republic of South Africa is HIV-infected) it seems possible that 
Southern Africa and particularly the rest of sub-Saharan Africa known to have 
limited access to quality nutritional recourses, could benefit from a well-balanced 
and carefully compiled nutritional supplement fortification regime but the compilation 
of the supplement could be specific for various specified regions. 
 
Nutritional supplementation may delay the onset of AIDS and it furthermore, 
remains tempting to state that individuals receiving ARV could benefit from this 
practice as well.  
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ABSTRACT 
The aim of the present investigation is to determine if a nutrient supplement 
(comprised of selected minerals, vitamins and herbs) administrated for a period of 
one year impact on pulmonary function in forty (40) HIV-infected individuals living in 
the Mangaung metropolitan. 
 
Participants received the supplement with their monthly clinic visits for a period of 
12 month. Blood samples were obtained, clinical assessment and pulmonary 
functions tests were performed during all monthly visits.  
 
The main findings of the present investigation suggest that statistical significant 
changes in the median of the pulmonary function variables are evident for the PEF 
at six months and FEF75 at twelve months only: The significant increase (p=0.0302) 
in the median PEF from 6.09 l/sec to 6.62 l/sec coincides with a mean (CI95%) of 
68% (50%-81%) of the individuals showing a median (LQ - UQ) increase of 16.9% 
(11.5%;36.1%) in the Peak Expiratory Flow (PEF). The significant decrease 
(p=0.0484) in the median FEF75 from 1.35 l/sec to 1.17 l/sec coincides with a mean 
(CI95%) of 70% (53%-83%) of the individuals showing a median (LQ - UQ) decrease 
of 28.1% (14%; 35.3%) in the FEF75.after 12 month of exposure to the supplement. 
No statistical significant changes are observed for FVC, FEV1, FEV1/FVC and 
FEF50. 
 
The present results suggest that an improvement in air flow in the upper conductive 
airways of the lungs (trachea and bronchi) occurred after supplementation for six 
months but that the status deteriorated in the following six months. Airflow in the 
bronchioles (smaller airways) deteriorated at 12 months. 
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6.1 INTRODUCTION 
The introduction of highly active antiretroviral therapy (HAART) dramatically 
reduced HIV related morbidity and mortality since 1990, resulting in HIV-infected 
people living much longer and even beyond middle age. The prolonged lifespan and 
reduced AIDS deaths created an interest in the long-term health of HIV-infected 
individuals (Mani, Haigentz & Aboulafia, 2012). 
 
Early studies concluded that the lung is a major target for a variety of infections, 
immune defects and tumors in HIV-infected individuals (Mayaud & Cadranel, 2001). 
Pulmonary disease associated with HIV infection is an important co-morbidity with 
high mortality regardless effective treatment with HAART (Estébanez-Munoz, Soto-
Abénades, Rios-Blanco & Arribas, 2012; Kynyk, Parsons, Para, Koletar, Diaz & 
Mastronarde, 2012).  
 
The risk of lung cancer is greater in HIV-infected individuals compared with the non 
HIV-infected population (Silverberg, Choa, Leyden, Xu, Tang, Horberg, Klein, 
Quesenberry, Towner & Abrams, 2009). The incidence of lung cancer is two to four 
times higher in HIV-infected individuals than in the general population (Mani et al., 
2012). Lung cancer is currently the primary cause of non-AIDS related deaths in 
HIV-infected individuals, though the incidence of neoplasms such as non-Hodgkin 
lymphoma and Kaposi‟s sarcoma has decreased due to HAART (Estébanez-Munoz 
et al., 2012). Histological, adenocarcinoma is most common in HIV-infected 
individuals (D‟Jaen, Pantanowitz, Bower, Buskin, Neil, Greco, Cooly, Henry, Stem, 
Dezube, Stebbing & Abouiafia, 2010) followed by squamous-cel cancer (Engels, 
Brock, Chen, Hooker, Gillisom & Moore, 2006). HIV related factors that promote 
lung cancer may include the oncogenic properties of the HIV, recurrent respiratory 
infections, immunosuppression, reduced immune surveillance and increased 
susceptibility to carcinogens (Mani et al., 2012). 
 
To prevent the spread of pathogenic microbes into the pulmonary tract, the airways 
and lungs are protected first by the innate defense system encompassing the 
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epithelial cells, ciliary clearance, factors like antibacterial peptides and complement 
proteins. Cell support involves: macrophages, neutrophils, mast cells, natural killer 
cells, monocytes, and dendritic cells. The adaptive immune system is also involved 
with CD4 and CD6 cells prominent in both the airway and alveolar space (Brusselle, 
Joos & Bracke, 2011).  With reduced immune protection opportunistic respiratory 
infections are associated with HIV-infected individuals (Estébanez-Munoz et al., 
2012). 
 
Mycobacterial, bacterial and fungal, as well as viral lung infections are well 
described and persistent in HIV-infected individuals (Moja, Jalil, Perol, Quesnel, 
Cotte, Livrozet, Boibieux, Chamson, Vergnon, Lucht, Tran, Pozzetto & Genin, 1997; 
Rasheed & Thajuddin, 2011; Cunha, Syed & Hage, 2012). Tuberculosis (TB) and 
HIV and AIDS are closely linked. TB is the primary opportunistic infection amongst 
HIV-infected individuals (Raghavan, Alagarasu & Selvaraj, 2012). HIV is recognised 
as a risk factor for attracting TB disease. South Africa is the most affected country in 
the world where 73% of all diagnosed TB cases are co-infected with HIV (Daftary, 
2012). Patients with TB experience anatomical lung changes secondary to the TB 
infection. It includes bronchiectasis, emphysematous as well as fibrotic changes. To 
measure these changes and impairment, pulmonary function tests are used. A 
present investigation by Vecino and co-workers found that the mentioned lung 
changes occur as early as 20 weeks after TB infection and that early diagnosis and 
treatment are important to prevent lung damage (Vecino, Pasipanodya, Slocum, 
Bae, Munguia, Miller, Fernandez, Drewyer & Weis, 2011).  
 
Pulmonary function tests performed to measure lung impairment due to TB infection 
are: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), 
FEV1/FVC ratio and peak expiratory flow (PF) (Di Naso, Pereira, Schuh & Unis, 
2011). Other organisms involved in respiratory infections in HIV-infected individuals 
include: Pneumocystis jiroveci, Cryptococcus neoformans, (Javier, Llovras, 
Santiago & Alcides, 2012), Mycobacterium avian (Bussone, Brossier, Roudiere, 
Bille, Sekkal, Charlier, Gilquin, Lanternier, Lecuit, Lortholary & Catherinot, 2012), 
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moulds like aspergillus, zygomycetes and pseudallescheria (Tammer, Tintelnot, 
Braun-Dullaeus, Mawrin, Scherlach, Schluter & Koning, 2011). Any human 
pathogenic organism may be the source of lung infection in HIV-infected individuals 
due to reduced immune protection (Rasheed et al., 2011). 
 
Obstructive lung disease includes chronic obstructive pulmonary disease (COPD), 
asthma and bronchitis (Hirani, Cavallazzi, Vasu, Pachinburavan, Kraft, Leiby, Short, 
Desimone, Squires, Weibel & Kane, 2011). COPD and asthma are on the increase 
in HIV-infected individuals. Recent studies demonstrate that 31% to 64% of HIV-
infected individuals have pulmonary symptoms and that 6% to 21% presented with 
obstructive airway disease as measured with spirometry. Pre-bronchodilator and 
post-bronchodilator spirometry on HIV-infected individuals in an outpatient setting 
demonstrated that the pulmonary functions of 10% of the participants improved with 
10%, suggesting that airway hypersensitivity might be a notable cause of airway 
obstruction in HIV-infected individuals (Gingo, Wenzel, Steele, Kessinger, Lucht, 
Lawther, Busch, Hillenbrand, Weinman, Slivka, McMahon, Zhang, Sciurba & Morris, 
2012). Chest radiographic scoring by Desai and co-workers demonstrated chronic 
airway disease in HIV-infected individuals not linked to the usual chronic lung 
disease, suggesting that HIV infection does target the lungs independently (Desai, 
Copley, Barker, Elston, Miller, Wellsa, MInyati, Nathoo, Corbett & Ferrand, 2011).  
 
Noninfectious lung conditions, especially emphysema, are appearing more 
frequently in HIV-infected individuals. Smoking is a contributing factor for increased 
COPD in HIV-infected individuals, as 40%-50% are current smokers. The 
prevalence of COPD among HIV-infected individuals who never smoked is also 
higher than individuals without HIV infection who are smoking (Hirani et al., 2011). 
Additional predictive factors for the development of irreversible obstructive 
respiratory symptoms are: history of bacterial pneumonia, the use of intravenous 
drugs and HAART (Estébanez-Munoz et al., 2012). HIV induced COPD contributes 
to skeletal muscle wasting which is recognised as an important extra pulmonary 
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manifestation of COPD contributing to increased morbidity and reduced quality of 
life (Ju & Chen, 2012). 
 
An investigation by Gingo and co-workers (2012) determined that asthma is the 
most frequent diagnosed chronic pulmonary disease in HIV-infected individuals. 
Asthma associated symptoms are: wheezing, bronchodilator airway obstruction 
reversibility and increased medication use. Kynyk and co-workers (2012) found that 
HIV-infected individuals had increased respiratory symptoms, are more sensitive to 
bronchus-provocation and demonstrated elevated IgE which are indicative to 
asthma (Kynyk et al., 2012). The inflammatory pathways leading to asthma related 
to TH2-inflammation in HIV-infected individuals are cytokines IL-4, IL-5, and IL-13. In 
addition, the interaction between corticosteroids for the treatment of asthma and 
protease inhibitors used in some antiretroviral therapies may increase the peripheral 
corticosteroid levels. 
 
Inhaled corticosteroids lessen the immune capability of the lungs to reduce airway 
inflammation, but increase the risk of pneumonia and TB infection (Calverley, 
Anderson, Celli, Ferguson, Jenkins, Jones, Yates & Vestbo, 2007). Siberry and co-
workers (2012) established that HIV-infected individuals undergoing immune 
reconstruction with HAART resulting in immune activation may develop bronchial 
asthma after immune restoration (Siberry, Leister, Jacobson, Foster, Seage, 
Lipshultz, Paul, Purswani, Colin, Scott & Shearer, 2012). 
 
The respiratory system is uniquely located to be constantly exposed to the external 
environment as well as the entire blood circulation of the human body (Kovach & 
Standiford, 2011). The diverse immune defects in HIV-infected individuals lead to a 
10 times higher susceptibility to pulmonary infections compared to the general 
population (Rasheed et al., 2011). Non-infectious lung conditions, such as 
emphysema, asthma (Hirani et al., 2011) and lung cancer are becoming ever more 
prominent as HIV-infected individuals life span increases (Mani et al., 2012). The 
compromised, deregulated immunity, and disrupted lymphocyte development of 
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HIV-infected individuals leading to pulmonary hypersensitivity need close scrutiny to 
avoid permanent lung damage (Siberry et al., 2012). 
 
In this chapter the focus is mainly based on spirometry (flow-volume curve 
measurements). 
 
 
6.2. METHODOLOGY 
Information based on the study design (see 3.1.1), study site (see 3.1.2), study 
population (see 3.2), intervention (see 3.3), pulmonary function testing (see 3.5.2.6) 
and analysis of data (see 3.6) was described in Chapter 3 as indicated. 
 
 
6.3. RESULTS 
This section reveals the demographic and relative results for two (2) populations 
categories. Baseline levels are obtained for all variables and compared to the 
various corresponding levels at 6 months and 12 months respectively.  
 
6.3.1 Demographic results 
A total of 132 HIV-infected individuals were enrolled but due to dropouts the study 
was completed with a final total of 40 individuals. The relatively high dropout figure 
can be ascribed to noncompliance with the protocol design i.e. not taking the 
supplement correctly or missing appointments–see Chapter 3: section 3.2. 
Seventeen (17%) of the 40 participants are male while 33 (83%) are female. 
 
6.3.2. Relative results 
Relative results refer to calculated values derived from specific measurements. The 
results obtained for two (2) populations are revealed i.e. entire study population 
(ESP) and a sub-population (SP). 
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6.3.2.1. Results for the entire Study Population category (ESP) 
Table 6.1 indicates the normal values, mean, standard deviation, median and p-
values for the specified pulmonary function variables at baseline, 6 and 12 months. 
Only statistical significant changes for a specified variable will be discussed. It is 
argued that if a statistically non-significant change is indicated, the researcher 
cannot form a scientifically validated opinion to make any statement pertaining to 
„change‟ or „difference‟ since these „changes‟ or „differences‟ could be related to 
„chance‟. 
 
Table 6.1 Pulmonary function variables of the HIV- infected individuals at  
baseline, 6 months, and final visit at 12 months (n=40). 
 
 
 
 
 
 
 Std Dev  Standard deviation  
 FVC  Forced vital capacity 
 FEV  Forced expiratory volume in I second 
 FEV  FVC: Forced expiratory volume in 1 second / Forced vital capacity ratio 
 PEF  Peak expiratory flow 
 FEF50  Forced expiratory flow at 50% of the total expired volume 
 FEF75  Forced expiratory flow at 75% of the total expired volume 
 p≤0.05:  Variables demonstrate a statistical difference. 
 (l)  Litre 
 (l/sec)  Litre / second 
 
The median Peak Expiratory Flow (PEF) demonstrated a statistical significant 
increase (p=0.0302) between baseline values and the values obtained at six 
months (see red figure in Table 6.1). The values of all other variables show no 
statistical significant changes (i.e. p>0.05) between baseline values and the values 
obtained at 6 months. The FEF75 (Forced expiratory flow at 75% of the total expired 
volume) show a significant reduction (p=0.0484) between baseline values and the 
values obtained at 12 months (see red figure in Table 6.1-bottom of the last 
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column). The values of all other variables show no statistical significant changes 
(i.e. p>0.05) between baseline values and the values obtained at 12 months. 
 
6.3.2.2. Results for the Sub-Population category (SP) 
The pulmonary function variables outlined in Table 6.1 are subjected to an 
additional statistically analyses to express the mean percentage (CI95% based on 
this mean) of individuals showing a median percentage change (LQ - UQ) for each 
and every variable (see Table 6.2). 
 Table 6.2. The percentage of HIV-infected individuals with change lung 
function variables, at baseline, 6 months, and 12 months (n=40) 
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At six months 68% (50%-81%) of the individuals show a median increase 
(p=0.0302) of 16.9% (11.5%; 36.1%) in the Peak expiratory flow (PEF). Over the 
period of twelve (12) months, 70% (53%-83%) of the individuals show a median (LQ 
- UQ) decrease (p=0.0484) of 28.1% (14%; 35.3%) in the FEF75 (see highlighted red 
figures in Table 6.2).  
 
These two variables are the only variables where the changes measured could not 
be related to chance/coincidence. 
 
 
6.4. DISCUSSION 
Early studies concluded that the lung is a major target for a variety of infections, 
immune defects and tumors in HIV-infected individuals (Mayaud & Cadranel, 2001). 
Mycobacterial, bacterial and fungal, as well as viral lung infections are well 
described and persistent in HIV-infected individuals (Moja, et al., 1997). In 
accordance, it is to be expected that deterioration in pulmonary function over a 
period of 12 months could be a possibility. 
 
The main findings of the present investigation suggest that no statistical significant 
changes are observed for FVC, FEV1, FEV1/FVC and FEF50 over the period of 12 
months when the supplement is used. Statistical significant changes in the median 
of the various pulmonary function variables are evident for the PEF at six months 
and FEF75 at twelve months only i.e. increase (P=0.0302) in the median PEF from 
6.09 l/sec to 6.62 l/sec coincides with a mean (CI95%) of 68% (50%-81%) of the 
individuals showing a median (LQ - UQ) increase of 16.9% (11.5%;36.1%) in the 
Peak Expiratory Flow (PEF) and the decrease (p=0.0484) in the median FEF75 from 
1.35 l/sec to 1.17 l/sec coincides with a mean (CI95%) of 70% (53%-83%) of the 
individuals showing a median (LQ - UQ) decrease of 28.1%(14%;35.3%) in the 
FEF75 after 12 months of exposure to the supplement is observed. 
166 
 
The PEF is the first part of air forcefully exhaled during maximal expiration following 
a maximal inspiration and represents/reflects the happenings in the upper 
conductive airways of the lungs (trachea and bronchi). The attempt is effort 
dependent with expiratory muscles and mechanism implicated (Enright, 2003). An 
improvement in the PEF could be due to an improvement in the function of 
expiratory muscles and mechanism implicated [HIV induced COPD contributes to 
skeletal muscle wasting which is recognized as an important extra pulmonary 
manifestation of COPD (Ju & Chen, 2012) and/or a decrease in air flow in the upper 
airways due to lumen diameter changes in the upper (trachea and bronchi) 
conductive airways brought about by chronic obstructive pulmonary disease 
(COPD), asthma and bronchitis (Hirani, et al., 2011). 
 
The FEF75, represents the air flow in the bronchioles (smaller airways) near end of 
maximal expiration (Ruppel, 2003) and a decrease in the FEF75 is indicative of the 
integrity of the bronchioles. In HIV-infected individuals a decrease in the FEF75 may 
be due to bronchiolitis (Gingo et al., 2012) (at the time of measurement) or chronic 
bronchiolitis per se (Hirani, 2011). 
 
 
6.5. CONCLUSION 
In the first six (6) months individuals show an increase in the Peak expiratory flow 
(PEF). In accordance, it appears that improved function in terms of the happenings 
in the upper conductive airways of the lungs (trachea and bronchi) which are effort 
dependent with expiratory muscles and mechanism implicated, is evident. 
 
At 12 months individuals show a decrease in the FEF75. In accordance it appears 
that the integrity of the bronchioles is tarnished. This could be due to lost in the 
elasticity of the lung parenchyma and/or swelling of the bronchioles transpiring in air 
trapping reflected by the decrease in the flow rate of air (FEF75) in bronchioles i.e. 
small airways disease due to HIV progression. 
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These two variables are the only variables where the changes measured could not 
be related to chance/coincidence. 
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7.1. INTRODUCTION 
In 2011, 10.6% (5.38 million) of the total population of the Republic of South Africa 
was HIV-infected. Any disruption of the nutritional status of any individual will be 
detrimental to the ability of the immune system to protect the human body against 
infection. The immune system requires essential nutrients to produce needed 
defense mechanisms and defense cells (Carter, 2011). Not only will the inadequate 
intake of specific micronutrients suppresses the immune system (Wintergerst, 
Maggini & Hornig, 2007) but a reduction in immune system activity will also impact 
negatively on the nutritional status of the immune compromised individual (Afacan, 
Fjell & Hancock, 2012).  
 
The importance of nutrient supplementation is highlighted by many HIV and AIDS 
programmes in sub-Saharan Africa that started to include nutritional assistance in 
addition to medical treatment to reduce malnutrition and improve the outcome in 
HIV-infected individuals (Tirivayi & Groot, 2011). The improvement of the nutritional 
status of HIV-infected individuals improves their physiological and psychological 
status with better quality of life (Oketch, Paterson, Maunder & Rollins, 2011).  
 
 
7.2. PURPOSE 
The purpose of this section of the Thesis is to integrate and align the main findings 
on baseline dietary intake, haematological status, immune status, viral load and 
pulmonary function following intake of a supplement. Furthermore, to state mutual 
tangent points (or differences) with the comparable findings of other researchers in 
this field of study. 
 
 
7.3. MAIN FINDINGS OF THE PRESENT INVESTIGATION 
The main findings on baseline dietary intake, haematological status, immune status 
and pulmonary function is stated and weighted. 
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7.3.1. Baseline dietary intake 
The results of the present investigation show that the mean and/or median Energy 
(kJ) intake is higher than the specified Estimated Energy Requirement (EER) in 
both groups (males and females). The macronutrient (total protein, carbohydrate 
and fat) intakes in both males and females are higher than the Recommended 
Dietary Intake (RDA) and/or Adequate Intake (AI) specifications. Similar finding 
pertaining to higher energy intakes is reported by Oguntibeju, Van den Heever and 
Van Schalkwyk (2005) in a trial conducted over a period of 3 months in the same 
region (Mangaung Metropolitan). 
 
The majority of the respondents consumed adequate amounts of micronutrients 
with the exceptions of Vitamin D and Iodine. The dietary intake of minerals and 
trace element met or exceeded the specified RDA or applicable Adequate Intake 
(AI) specifications. Research conducted in the Mangaung Metropolitan show that 
micronutrient deficiencies occurred in the majority of HIV-infected children in care 
centers (Steenkamp, Dannhauser, Walsh, Joubert & Veldman, 2009). The 
prominent deficient micronutrients were zinc, vitamin A, vitamin D and glutathione. 
These authors recommended vigorous macro- and micronutrient supplementation 
to eliminate these nutrient deficiencies. 
 
7.3.2. Haematological variables 
From all of the haematological variables the only statistical significant changes 
observed between baseline data and the data at 6 months are increases in the 
median ESR (p=0.0219) and MCHC (p=0.0245) coinciding with a decrease 
(p=0.0001) in viral load. At 12 months a statistical significant decrease in the 
median CD/CD8 ratio (p<0.0048), median Hematocrit concentration (p<0.0312), 
median MCV (p<0.0359), and median RDW (p<0.0273) accompanies a significant 
decrease in the median viral load (p<0.0001). The only variable(s) that show a 
statistical significant increase is the MCHC (p<0.0003) at 12 months. 
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A mean decrease of 89% (CI95%: 73%;96%) of the individuals show a decrease in 
viral load counts with a median percentage change of 34% (CI95%: 73%;96%) at 6 
months. At 12 months a mean decrease of 85% [CI95%: 68%; 94%] of the individuals 
show a decrease in viral load counts with a median percentage change of 62.9% 
(CI95%: 50%;78.6%) following the intake of the supplement. 
 
Plasma Viscosity is a useful marker indicative of inflammation in several conditions 
including HIV infection (Feldman, Aziz, Kang, Opondo, Belz & Sellers, 2013). In 
their study the participants show plasma viscosity more than four times the normal 
value which is an indication of the level of inflammation present. In contrast, the 
present findings show a significant increase (p=0.0219) at 6 months but a significant 
decrease (p=0.0351) at 12 months in the responder group. 
 
The white cell count of <1 200 109/l (Cells) indicates an increase in disease 
progression and mortality (Sen, Vyas, Sanghi, Shanmuganandan, Gupta,  Kapila, 
Praharaj, Kumar, and  Batra, 2011) In the present investigation the lymphocyte 
count decreased from 2.11 X 109/l to 1.90X 109/l over the 12 month period. This 
decrease is close (p=0.0563) to the 95% confidence interval level but is way above 
the critical count level specified by Sen et al. (2011). 
 
The immune changes in HIV-infected individuals, including declines in the numbers 
as well as the ratio of CD4 cell counts and CD8 cell counts is evident (Savin & 
Dardenne, 2010). Malnutrition causes thymic atrophy affecting immature CD8 and 
CD4 cells contributing to impaired peripheral immune response (Savin & Dardenne, 
2010). Pertaining to the present findings no statistical significant changes in CD4 
and CD8 cell counts was observed for the entire study population or sub-
populations during the entire trial period.  
 
It is known that absolute CD4 cell counts per se to be inconsistent and may be 
misleading, for diagnostic purposes and the ratio of CD4 cell to CD8 cell count 
therefore to be considered a more reliable variable (Gaurav, Keerthilantha & 
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Archna, 2011; Serrano-Villar, Gutiérrez, Vallejo, Hernandéz-Nova, Diaz, Fernandéz, 
Madrid, Dronda, Zamora, Munzo-Fernandéz, Moreno, 2013). Lack of correlation 
even between a very small size of proviral DNA reservoir and T-cell activation in 
HIV-infected individuals (CD4/CD8 ratio) with a continuous undetectable viral load 
for 10 years, are indicated (Poizot-Martin, Faucher, Obry-Roguet, Nicolino-Burnet, 
Ronot-Bregigeon, Dignat-George & Tamalet, 2013). Although CD4 and CD8 cell 
counts appears to be unaltered in the present investigation, a statistical significant 
decrease in the CD4/CD8 ratio (p=0.0048) is observed at 12 months. The only 
explanation for the decrease in the CD4/CD8 ratio could lie within the notion that a 
relatively small insignificant decrease in CD4 count in combination with a relatively 
small insignificant increase in the CD8 count in combination could significantly 
impact on the ratio and render a significant inverse relationship. 
 
The plasma Viral load in HIV-infected individuals starts to rise after nine to 12 
weeks after being infected and may increase to more than 108 RNA copies per 
milliliter plasma within 12 years (Fauci, Pantaleo, Stanley & Weissman, 1996). High 
levels of HIV copies in the plasma have been associated with rapid CD4 reduction 
and increased disease progression (Swanson.1997). On the contrary, 89% (CI95%: 
73%;96%) of the individuals show a decrease (p=0.001) in viral load counts with a 
median percentage change of 34% (CI95%: 73%;96%) at 6 months. At 12 months 
85% [CI95%: 68%; 94%] of the individuals show a decrease in viral load counts with a 
median percentage change of 62.9% (CI95%: 50%;78.6%) following the intake of the 
supplement. These findings suggest that in terms of viral load and the number of 
individuals showing a decrease in viral load following use of the supplement, 
measurable advantages in terms of clinical relevance exist and could not be 
ascribed to chance or be related to coincidence. A measureable decrease in viral 
load following supplementation was also observed in another trial with a different 
supplement, conducted by Oguntibeju (2004) in the same Metropolitan. In 
accordance it seems to be appropriate to state that supplementation can decrease 
viral load. 
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7.3.3. Pulmonary function 
Pulmonary function test, particular spirometry is effective in diagnosing obstructive 
as well as restrictive respiratory diseases (Antwi, Gbekle, Cosmos, Ennin, 
Amedonu, Antwi-Boasiako, Clottey & Adzaku, 2011). Abnormally low forced 
expiratory flow rates frequently occur in HIV-infected individuals (O‟Donnell, Bader, 
Zibrak, Jensen & Rose, 1988). 
 
In the first six (6) months the only change observed for all variables is an increase in 
the Peak expiratory flow (PEF). In accordance, it appears that improved function in 
terms of the happenings in the upper conductive airways of the lungs (trachea and 
bronchi) which are effort dependent with expiratory muscles and mechanism 
implicated, is evident. 
 
HIV-infected individuals commonly have symptoms of airway disease associated 
with lower forced expiratory air flow in one second (FEV1) and forced mid expiratory 
flow (FEF50) (Gelman, King, Neal, Pacht, Clanton & Diaz, 1999). The present results 
show no significant change in the FEV1 or FEF50  At 12 months individuals showed a 
decrease in the FEF75. The FEF75, represents the air flow in the bronchioles (smaller 
airways) near end of maximal expiration (Ruppel, 2003) and a decrease in the 
FEF75 is indicative of the integrity of the bronchioles. In HIV-infected individuals a 
decrease in the FEF75 may be due to bronchiolitis (Gingo, Wenzel, Steele, 
Kessinger, Lucht, Lawther, Busch, Hillenbrand, Weinman,  Slivka, McMahon, 
Zhang, Sciurba & Morris,  2012) (at the time of measurement) or chronic 
bronchiolitis per se (Hirani, Cavallazzi, Vasu, Pachinburavan, Kraft, Leiby, Short, 
Desimone, Squires, Weibel & Kane, 2011). In accordance it appears that the 
integrity of the bronchioles is tarnished. This could be due to lost in the elasticity of 
the lung parenchyma and/or swelling of the bronchioles transpiring in air trapping 
reflected by the decrease in the flow rate of air (FEF75) in bronchioles i.e. indicative 
of small airways disease. Small airways disease is frequently present in HIV-
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positive individuals (Gelman et al., 1999). The damage to the lung tissue may be 
mediated by continuous immune activation and ongoing inflammation (Coffey, 
2011). 
 
7.4. INTEGRATED INTERACTIONS AND POSSIBLE CONSEQUENCES 
The impact of the HIV on the human body is multi faceting, the virus affect the 
physiological function and the altered functions in turn causes further pathological 
changes. It is associated with an increase in renal, immune system, liver, 
cardiovascular and neurocognitive disorders (Meir-Shafrir & Pollack, 2012) 
Haematological system disorders are common amongst HIV-infected individuals, 
the appearance are varied and prevail throughout the course of the disease. 
Anemia is a frequent complication of HIV infection (Mathews, Srivastava, Yadav & 
Sharma, 2013). 
 
7.4.1. Baseline dietary intake and anthropometric aspects 
Significant weight loss and underweight are widely present among HIV-infected 
adults in sub-Saharan Africa. The nutritional status of the individual can impact on 
the BMI. In the present investigation the weight range for the group is considered to 
be normal weight (see Chapter 3: 3.5.1) i.e. a baseline median BMI of 24.5 and 24.0 
after 12 months is observed and no statistical significant chance (p=0.6805) was 
calculated (see APPENDIX F). Poverty can impact not only on nutrient intake but 
also the type of food ingested. Furthermore, the impact of HIV-infection per se, can 
also impact on food intake. 
 
Information on the EER, macronutrient and micronutrient intake was briefly 
discussed in section 3.1. No significant changes are observed for any of the 
anthropometric parameters i.e. BMI; and circumferences [indicative of health and 
nutritional status such as malnutrition and/or progression of the syndrome/disease 
per se (Gibson, 1998; Lee & Nieman, 2010). These findings were not discussed but 
the findings are stated in APPENDIX F. In accordance, it could be possible that the 
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relatively high energy intake (Carter, 2011) and/or a relatively high protein intake 
(after Kim, Rimm & Gorbach, 2001; Oguntibeju, 2004) may have prevented the 
phenomena surrounding muscle wastage. This view, however, should be 
appreciated within the notion put forward by Ivers, Cullen, Freedberg, Block, Coates 
and Webb (2009) i.e. that HIV and AIDS affect the metabolism of insulin and 
glucagon leading to muscle wasting. A decrease in insulin could impact on anabolic 
growth and catabolic (energy yielding) processes. A decrease in glucagon could 
negatively impact on plasma blood glucose levels. 
 
7.4.2. Baseline dietary intake and immunological aspects 
The majority of the respondents consumed adequate amounts of micronutrients 
with the exceptions of Vitamin D and Iodine. 
 
7.4.2.1. Vitamin D deficiency and immune function 
Vitamin D deficiency could impact on homeostasis in many ways: Lagishetty, Lui & 
Hewison (2011) show that vitamin D is involved in the regulation of the innate 
immune system (see Chapter 2: 2.6.1.1): Toll-like receptors (TLRs) of monocytes 
and macrophages plays an important role in innate immune response (Lagishetty, 
Lui & Hewison. 2011). The stimulation of the TLRs in macrophages by anti-
microbial peptides results in the conversion of vitamin D to its active form. The role 
of vitamin D is to assist with the induction of cathelicidin (protein with c-terminal 
cationic anti-microbial domain) to be released at the site of infection (Beard, 
Bearden & Striker, 2011; Verrusio, Linguanti, Di Maio, Martinez, Marigliano & 
Cacciafesta, 2012). 
 
Vitamin D, a fat soluble pre-hormone acts via metabolites like1,25(OH)2D that binds 
to the nuclear vitamin D receptor (Gueli, Verrusio, Linguanti, Di Maio, Martinez, 
Marigliano & Cacciafesta, 2012) and suppressed T-helper (Th1) CD4 cells to 
enhance Th2 CD4 cells production. Vitamin D-activating enzyme (CYP27B1) assists 
in linking monocytes and pathogen sensing mechanisms. 
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It has already been noted that in people living with HIV and AIDS, lifestyle, 
hormonal factors, decreased physical activity, lower intake of calcium and vitamin D 
as well as lower plasma calcium levels, all contribute to the progression of the 
disease (Borderi, Gibellini, Vescini, De Crignis, Cimatti, Biagetti & Tampellini, 2009; 
Campa & Baum, 2010). The present findings show that the mean and median 
intake for Calcium is relatively higher than the specified RDA of 1,000 mg/day for 
both genders, but Calcium intake did not exceed the upper limit of 2500mg per day 
(Curtiss & Johnson, 2007) and raises no concern. However, a link between vitamin 
D intake and calcium absorption from the alimentary tract exists: Calcium is better 
absorbed when taken in combination with Vitamin D. Lack of the simultaneous 
intake of calcium and Vitamin D intake in the diet impedes on the formation of the 
hormone calcitriol (known as the “active vitamin D”). This in turn leads to insufficient 
calcium absorption from the diet. In this situation, the body must take calcium from 
its stores in the skeleton, which weakens existing bone and prevents the formation 
of strong, new bone. Although the present results show sufficient intake of Calcium, 
a decrease in Vitamin D intake is observed and, accordingly, could impact on the 
health status of the individuals with low Vitamin D intake. 
 
7.4.2.2. Iodine deficiency and immune function 
Iodine is required in the synthesis of thyroid hormones, triiodothyronine (T3) and 
thyroxin (T4). Thyroid hormones play a major role in the metabolic processes of the 
body. It is involved in the regulation of macronutrient metabolism and basal 
metabolic rate. Iodine deficiency may lead to low levels of thyroid hormones 
resulting in full-blown hypothyroid syndrome (myxedema). Symptoms include 
mental sluggishness, edema and low metabolic rate (Marieb & Hoehan, 2013). 
The high concentration of iodine in the thymus supports the importance of this 
element in the immune system. Leukocyte myeloperoxidase enzymes in cell-
mediated immunity (See Chapter 2: 2.6.1.2) use iodine to produce iodine-free 
radicals. Iodine also increases immunoglobulin-G production in human 
lymphocytes. The non-endocrine effects of iodine include increase in the movement 
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of granulocytes into areas of inflammation and improve phagocytosis ability of the 
granulocytes. 
The immune deficiency in iodine-deficient individuals may be restored by oral 
administration of iodine (Venturi, 2009). According to Beltran, Lescure, El Esper, 
Schmit and Desailloud (2006), iodine deficiency in HIV-infected individuals may 
contribute towards hypothyroidism. 
 
7.4.2.3. Vitamin D deficiency and pulmonary function 
Growing evidence exist that Vitamin D (especially vitamins D2 and D3) are involved 
in respiratory infections and immune function in asthma due to its 
immunomodulatory function (Huang, Porpodis, Zarogoulidis, Domvri, Giouleka, 
Papaiwannou,  Primikyri, Mylonaki, Spyratos, Hohenforst-Schmidt, Kioumis &  
Zarogoulidis. 2013). Vitamin D modifies the airway responsiveness by reducing 
airway inflammation (Rance, 2013). In accordance, the reduced intake of vitamin D 
may contribute to the reduction in the integrity of the smaller airways. 
 
Supplementation with specific micronutrients like vitamin D will benefit HIV-infected 
individuals in particular to combat cardiovascular events (Choi, Lo, Mulligan, 
Schnell, Kalapus, Li, Hunt, Martin, Deeks, & Hsue, 2011) and restoring the immune 
homeostasis. Vitamin D supplementation according to the U.S. food and drug 
administration should not be more than 2000 IU daily due to toxicity of this fat-
soluble vitamin (Makariou, Liberopoulos, Elisaf & Challa 2011; Van Schoor & Lips, 
2011). Nutritional addition of Beta-sitosterol (naturally found in peanuts, sesame 
seeds and soybeans) supports the action of vitamin D to improve macrophage 
function. Macrophages produce cytokines and nitric oxide, an important defense 
mechanism against infection. Dietary supplementation of vitamin D as an anti-
inflammatory nutrient may improve the immune function and the pulmonary function 
of the body (Ng, Niti, Yap, & Tan. 2013). 
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7.4.3. Baseline dietary intake and haematological aspects 
Anemia is a well-known and frequent complication in HIV-infected individuals  
(Takuva, Maskew, Brennan, Sanne, MacPhail, & Fox. 2013; Mathews et al., 2013). 
Hemoglobin values are associated with reduced intake of protein and essential 
nutrients in HIV-infected individuals. This and other factors such as change in 
cytokine production and decreased erythropoietin concentration lead to anemia 
associated with the progression of AIDS and shorter survival of HIV-infected 
individuals. Mathews and associates (2013) established that normocytic 
normochromic anemia is prevalent in more than 40.1% of the HIV-infected 
individuals in their research study. This may explain why the reduction in median 
hemoglobin value in this- investigation showed no statistical significant alterations.  
 
In this regard the present results show no significant alterations in hemamaglobin 
levels or red blood cell count (see Table 5.2). The present results show a decrease 
(p=0.0312) in hematocrit in 55% (CI95%38%; 71%) of the participants at six months 
and 63% (CI95%27%; 59%) of the participants at 12 months. 
 
7.4.4. Viral load 
Viral load in HIV-infected individuals starts to rise after nine to 12 weeks after being 
infected and may increase to more than 108 RNA copies per milliliter plasma within 
12 years (Fauci, et al., 1996). It also appears that the plasma viral load of the HIV 
correlates with the rate of virus production in the lymphoreticular tissues and is 
associated with rapid CD4 reduction and increased disease progression 
(Swanson.1997). On the contrary, 89% (CI95%: 73%; 96%) of the individuals show a 
decrease (p=0.001) in viral load counts with a median percentage change of 34% 
(CI95%: 73%;96%) at 6 months. At 12 months 85% [CI95%: 68%; 94%] of the 
individuals show a decrease in viral load counts with a median percentage change 
of 62.9% (CI95%: 50%;78.6%) following the intake of the supplement. These findings 
suggest that in terms of viral load and the number of individuals showing a decrease 
in viral load following use of the supplement, measurable advantages in terms of 
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clinical relevance exist and could not be ascribed to chance or be related to 
coincidence. A measureable decrease in viral load following supplementation was 
also observed in another trial conducted by Oguntibeju (2004) in the same 
Metropolitan. In accordance it seems to be appropriate to state that 
supplementation can decrease viral load. 
 
The increase of HIV-RNA levels is associated with a decrease in T-cell count and 
function, as well as haematological variables such as hemoglobin concentration 
(Langford, Ananworanich & Cooper, 2007). The present results suggest that an 
inverse relationship between these variables also seems to exist i.e. decrease in 
viral load coincides with no alterations in T-cell count and hemoglobin 
concentration. 
 
Although the increasing risk of death in a malnourished HIV-infected individual is 
independent from the viral load and CD4 cell count (Grimble, 2009), other 
researchers state that the CD8 cells are vital to control viral replication by secreting 
interferon gamma that induces the production of antiviral proteins and immune 
response that destroys infected cells (Kim, Lee, Hong & Kim, 2010). It is known that 
absolute CD4 cell counts per se to be inconsistent and may be misleading, for 
diagnostic purposes and the ratio of CD4 cell to CD8 cell count therefore to be 
considered a more reliable variable (Gaurav, et al., 2011). Although CD4 and CD8 
cell counts appears to be unaltered in the present investigation, a statistical 
significant decrease in the CD4/CD8 ratio (p=0.0048) is observed at 12 months. 
The only explanation for the decrease in the CD4/CD8 ratio could lie within the 
notion that a relatively small insignificant decrease in CD4 count in combination with 
a relatively small insignificant increase in the CD8 count in combination could 
significantly impact on the ratio and render a significant inverse relationship. 
Furthermore, it appears that the CD4/CD8 ratio is independently linked with T-cell 
activation even with long-term viral suppression (Serrano-Villar et al., 2013). 
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7.4.5. Supplement 
The researcher had no indication or any insight knowledge on the baseline dietary 
intake levels of the 40 HIV-infected individuals prior to the formulation of the 
product. Furthermore, the researcher did not participate in formulating the product 
and viewed the formulation as being an arbitrary concoction of „nutritional 
substances‟ where claims are made in terms of the „beneficial effects‟ ascribed to 
use of the supplement by HIV-infected individuals. 
 
The primary goal of the present investigation was to evaluate if the supplement 
impact on viral load and gather information pertaining to various and numerous 
variables indicative of the health status of HIV-infected individuals (see chapter 5). 
 
The ingredients and their respective quantities that comprise the product are 
revealed in Chapter 3: section 3.3.2. The addition of Spirulina to the mixture does 
not reflect the actual amounts of specific additional essential fatty acids, beta-
carotene, minerals, vitamins and high quality protein added to the formulation as 
specified in the formulation. However, Spirulina per se potentiates the immune 
system, suppressing cancer development and viral infection (Watanuki, Ota, Malina, 
Tassakka, Kato & Sakai, 2006). The same argument could be put forward for the 
non-specified compositions for other substances (Biociden and Colostrum) specified 
in the formulation. 
 
In retrospect/hindsight, and at this point in time, it appears to be easy to predict 
what the possible outcome in terms of the presence of the micronutrient 
components of formulation should entail i.e. the present results show a decrease in 
the intake of Vitamin D and Iodine and should have been present (not absent) in the 
formulation. In terms of baseline dietary intake, all other micronutrients on average 
(mean and median) met or exceeded the RDA/AI and one could consider 
supplementation as being an unnecessary dietary additive. In terms of the findings 
pertaining to the viral load, the venture, however, holds water. 
 
184 
 
Research conducted in the Mangaung Metropolitan show that micronutrient 
deficiencies occurred in the majority of HIV-infected children in care centers 
(Steenkamp et al., 2009). The prominent deficient micronutrients were zinc, vitamin 
A, vitamin D and glutathione. These authors recommended vigorous macro- and 
micronutrient supplementation to eliminate these nutrient deficiencies. 
 
The study of Oguntibeju (2004) reveals the short term effect of daily nutritional 
supplementation on the Haematological variables, immune status and viral loads of 
HIV-infected individuals in the Free State province in South Africa. His results 
support the decrease in viral load that is show in the present study i.e. a statistical 
significant decrease load (p=0.0001) at both 6 months and 12 months following 
supplementation.  
 
The supplement taken by the HIV-infected individuals in this study contained 
several elements that combat oxidative stress (although not tested in this study) and 
possibly contributed to the lower viral loads (see Chapter 3 section 3.6.1 for 
supplement content). Elements like zinc, magnesium and selenium inhibit 
intracellular HIV replication (Sepulveda & Watson. 2002) and possibly contributed 
towards the decrease in viral load. The exact mechanisms involved, however, 
remains unresolved. 
 
 
7.5. LIMITATIONS OF THE PRESENT INVESTIGATION AND 
RECOMMENDATIONS 
 
 It could be argued that although the stage of disease progression was known 
when the participants enrolled, the study population is comprised of 
individuals covering a broad spectrum of diverse immune-respons states. 
The diversity in the immune-respons states between and amongst 
individuals transpires in relatively large standard deviations for numerous 
variables in the study population. Although statistical significant changes 
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with corresponding confidence intervals for numerous specific variables 
were noted, the final sample size (n = 40) could be rendered insufficient if 
relatively small changes pertaining to any specified variable coincide with 
large standard deviations. To combat this constraint sample size must 
increase. The relatively small sample size was mainly brought about by the 
unpredicted high dropout numbers/rates (i.e. 40/132). This could have 
affected the statistical power of the present findings where small changes 
occurred.  
 
 The present findings cannot be extrapolated to be representative of similar 
results being obtained in the population of all HIV-infected individuals in any 
other regions/country elsewhere. The results only relate to the present 
specified study population in the Mangaung Metropolitan. In accordance, 
baseline dietary intake information for example, should be determined for 
various regions/countries in order to formulate the composition of a specific 
supplement for that region/country. 
 
 The plasma levels for all comparable substances pertaining to measurable 
baseline dietary intake levels of micronutrients should be determined. This 
recommendation could give information on the absorption rates and 
fractions in terms of the Baseline dietary intake levels; 
 
 The present findings relate to an intervention where a nutritional supplement 
comprised of vitamins, minerals and herbs is administered to HIV-infected 
individuals. No clarity exists to state which substance or combination of 
substances that comprise the product is responsible for the observed 
changes in the variables stated. 
 
 CD4 counts, CD8 counts and the CD4:CD8 ratio play major roles in 
immunity. However, no statistical significant changes was observed for 
these variables except for the statistical significant decrease in the CD4/CD8 
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ratio (p=0.0048) observed at 12 months. Cell counts says something but not 
all. It is recommended that cell activity levels for these specified cell counts 
should also be determined in order to elaborate on the immune status in a 
holistic manner.  
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APPENDIX B 
 
 
 
HIV/AIDS Nutrition Project 
 
        Date: ------------------ 
 
CONSENT TO PARTICIPATE IN RESEARCH 
 
 
You have been asked to participate in a research study. 
 
You have been informed about the study by ………………………………………. . 
 
You may contact Prof E van den Heever-Kriek at 082 770 5356 any time if you have 
questions about the research or if you are injured as a result of the research. 
 
You may contact the Secretariat of the Ethics Committee of the Faculty of Health Sciences, 
UFS at telephone number (051) 4052812 if you have questions about your rights as a 
research subject. 
 
Your participation in this research is voluntary, and you will not be penalized or lose 
benefits if you refuse to participate or decide to terminate participation.   
 
If you agree to participate, you will be given a signed copy of this document as well as the 
participant information sheet, which is a written summary of the research. 
 
The research study, including the above information has been verbally described to me.   
I understand what my involvement in this study means.  I also understand that my patient 
information will be regarded as confidential, that my participation is voluntary and that I 
could withdraw at any time. 
 
 
_____________________   __________________ 
Signature of Participant   Date 
 
 
 
_____________________   __________________ 
Signature of Translator   Date 
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INFORMATION DOCUMENT 
 
STUDY TITLE: The influence of a liquid nutritional supplement on the immune– and 
health status of HIV-positive/AIDS patients in the Bloemfontein region. 
 
Dear participant, we are inviting you to be part of this clinical trail and would be very 
thankful if you could see your way open to be part of this study. Below you will find all the 
information about this study and your responsibilities as participant. 
 
INTRODUCTION 
Several vitamins and minerals are critical for fighting HIV infection because they are 
required by the immune system and major organs to attack infectious pathogens.  
Research indicates that in the early period of HIV infection, weight gain or maintenance 
might be achieved through nutrition.  Data on the prevalence of malnutrition, dietary intake 
and / or supplementation in HIV-infected persons in industrialized countries, is widely 
available.  However, this information is often scarce in Africa where endemic malnutrition 
and lack of nutrition management are common.  Therefore, study to evaluate the role of 
nutritional supplementation in HIV-positive patients becomes necessary, especially in a 
developing country such as South Africa.  This clinical trail is set up to investigate the 
efficiency of a liquid nutritional supplement on the immune system of HIV/AIDS patients 
with a suppressed immune system. 
 
STUDY DESIGN 
This study will be divided into 4 phases: 
1 Initial phase 
2 Screening/baseline visit 
3 Monthly visits  
4 Final visit 
 
During the initial phase of the project written approval for the protocol will be obtained from 
the Ethics Committee of the Faculty of Health Sciences, University of the Free State, 
Bloemfontein, before the first administration of study supplement. The training of staff and 
field workers will also take place during this phase. 
 
The rest of the study consists of a screening visit and monthly visits over a period of one 
year.  The first monthly visit will be scheduled seven days after screening.  Visit two will be 
scheduled thirty days after visit one, etc.  A deviation of –2 and +2 days from schedule 
visits will be allowed.  Figure 1 below is a summary of the study visits and data collection of 
the project. 
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Figure1.  A summary of the study visits and data collection of the project. 
 
Visit Procedures  
Respondents will be transported to the Medi Inn Centre monthly.  The respondents will sign 
the consent form at their first visit.  Researchers will interview the respondents to determine 
the demographic profile and food consumption patterns of the respondents.  Compliance 
will also be measured at the end of the study, using a standardized questionnaire. 
 
The researchers will perform Anthropometric- and baseline biochemical measurements.  
Anthropometric measurements will include:  Bodyweight, height, hip circumference, waist 
circumference, percentage fat, skin-fold thickness, and BMI. 
 
Registered medical personnel will draw blood specimen from patients before, during and 
after supplementation for a period of one year.  Blood samples will be collected during the 
screening and monthly visits by registered medical personnel and send to Pathcare 
(Pathology laboratory) for the analysis of the immune status, health status, viral load (very 3 
months), haematological parameters and liver functions (every 3 months). 
 
STUDY POPULATION  
Fifty volunteers living with HIV will be selected after the screening visit, who fulfilled the 
inclusion criteria, did not meet any of the exclusion criteria, and who gave written informed 
consent, will be entered into the study. 
 
Inclusion Criteria 
 Male and female subjects from 18 to 65 years of age that are HIV/AIDS 
positive. 
 CD4+T-cell counts 200 – 350 cells/mm3 
Nutritional and immune Status of HIV –positive/AIDS patience 
 Consent form 
 Socio demographic 
profile questionnaire 
 Dietary Intake 
questionnaire 
 Anthropometry 
 Medical examination 
 Haematological 
parameters  
 Immune status 
 Viral load  
 Haematological 
parameters  
 Medical examination 
 Immune status 
 Anthropometry 
 Viral load  (every 3 
months) 
 Liver function (every 
3 months) 
 Anthropometry 
  Medical examination 
  Haematological 
parameters 
  Immune status 
  Viral load 
 Dietary intake 
questionnaire 
 Screening 
visit 
  Monthly visit 
         (Months 1-11) 
  Final visit 
         (Month 12) 
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 Findings within the range of clinical acceptability in medical history and 
physical examination, and laboratory results acknowledged by the clinical 
investigator. 
 Willingness to undergo a pre-study physical examination and pre- and post 
study laboratory investigations. 
 Ability to comprehend and willingness to sign the statement of informed 
consent. 
 
Withdrawal criteria 
Subjects have the right to withdraw from the study at any time, irrespective of the reason, 
without detriment of their medical care.  These patients will be handled as drop-outs.  Drop-
outs to whom the study supplement was administrated will be requested to undergo the 
post-study evaluation. 
The following may also lead to withdrawal: 
6.3.2.1  Adverse events as a result of taking the study supplement, at the discretion of the 
clinical investigator.   
6.3.2.2   Protocol violation by subjects, at the discretion of the clinical investigation. 
 
Subject identification 
 Each enrolled subject will receive a number (01 – 50) and will retain this number 
throughout the study.  
 Each enrolled subject will retain his initials obtained from a copy of his identification 
book (i.e. three digitals) 
 Each enrolled subject will be identified by date of birth (six digits). 
 
Participation is voluntary, and refusal to participate will involve no penalty or loss of benefits 
to which the subject is otherwise entitled; the subject may discontinue participation at any 
time without penalty or loss of benefits to which the subject is otherwise entitled.  
 
Confidentiality   
Efforts will be made to keep personal information confidential.  Absolute confidentiality 
cannot be guaranteed.  Personal information may be disclosed if required by law. 
Organizations that may inspect and/or copy your research records for quality assurance 
and data analysis include groups such as the Ethics Committee for Medical Research and 
the Medicines Control Council. 
 
Restrictions on patients 
Medicines: 
All concomitant medication will be documented in CRF. If any additional medication is 
required during the study period, the clinical investigator has to be notified.  Concomitant 
medication must state generic and trade names, strength, frequency and duration of 
treatment. 
Diet: 
The patients must carry on with their normal diet. 
 
Safety of the patients 
The project is very safe.  The patients will be monitored daily during the intake of their 
supplement.  The supplement is a liquid multi vitamin.  During each visit, physical and 
medical examinations will be carried out on the patients by a clinical physician.  Blood 
samples will be drawn from the patients to determine their immune- and health status and 
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every 3 months their viral load and liver function.  Registered medical personnel will draw 
blood specimen from patients before, during and after supplementation for a period of one 
year. 
 
Financial implication for the patients 
There is no financial implication for the patients.  The patients do not have to pay for their 
medical consultations or any of their clinical results.  They will receive treatment for free.  
They will also receive the supplement freely.  During each visit they will also receive a meal 
and free transport to the clinic. 
The patients will not be paid for been part of the trail. 
 
STUDY SUPPLEMENT 
Supplement Ingredients 
Below is a summary of the ingredients of the multi-vitamin/anti-oxidant supplement 
what will be used during trail. 
 
Supplementation  
The patients will receive 1 pill once daily (between 07:00 - 09:00). Staff members of the 
South African Red Cross Community Home Based Care Program, in the community, will 
handle the dosing and monitoring of the supplement intake and compliance on daily basis.  
Patients must carry on with their normal diet. 
 
Contact details of researcher(s) –     Prof E van den Heever-Kriek (Project leader) 
               Cell nr: 082 770 5356 
     Mr. E Vermaak (Researcher) 
     Cell nr: 082 775 6261 
     Dr. P Basson (Researcher) 
     083 414 8445  
 
Contact details of REC Secretariat and Chair – for reporting of complaints/problems. 
Phone nr:  051-405 2812  
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Moralo wa phepo wa HIV/AIDS  
 
        Letsatsi: ------------------ 
 
TUMELLO YA HO NKA KAROLO DIPATLISISONG 
 
 
O kopilwe ho nka karolo thutong ya dipatlisiso. 
 
O ile wa tsebiswa ka thuto ena ke ………………………………………. . 
 
O ka nna wa ikopanya le Prof E van den Heever-Kriek nomorong ya 082 770 5356 nako e 
nngwe le e nngwe ebang o nale dipotso mabapi le dipatlisiso kapa ebang o ka tswa kotsi ka 
baka la dipatlisiso. 
 
O ka nna wa ikopanya le Mongodi wa Ethics Committee ya Faculty of Health Sciences, 
UFS nomorong ya mohala ya (051) 4052812 ebang o nale dipotso ka ditokelo tsa hao 
jwaloka eo ho etswang dipatlisiso ka yena. 
 
Ho nka karolo ha hao dipatlisisong tsena ke boithaopong ba hao, mme o keke wa 
fumantshwa kotlo kapa wa lahlehelwa ke menyetla ya hao ebang o ka hana kapa wa nka 
qeto ya ho kgaotsa ka ho nka karolo.   
 
Ha o dumela ho nka karolo, o tla nehwa khopi e saennweng ya tokomane ena hammoho le 
leqhephe la ba nkang karolo e leng le ngotsweng kgutsufatso ya dipatlisiso. 
 
Thuto ya dipatlisiso ho kenyellwa lesedi le ngotsweng ka hodimo, di ile tsa hlaloswa ho nna 
ka molomo.   
 
Ke utlwisisa hore ho nka karolo ha ka thutong ena ho bolelang.  Ke boetse ke utlwisisa hore 
tlhahiso leseding e mabapi le dintlha tse amang botho ba ka, e tla nkwa e le sephiri le hore 
ho nka karolo ha ka ke boithaopo le hore nka nna ka ikgula nako e nngwe le e nngwe.  
 
_ 
____________________   __________________ 
Tshaeno ya motho ya    Letsatsi 
nkang karolo    
 
 
 
_____________________   __________________ 
Tshaeno ya mofetoledi   Letsatsi 
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TOKOMANE YA TLHAHISO LESEDING 
 
SEHLOOHO SA THUTO: Thunthetso ya phepo ya mokedikedi wa tlatsetso mabapi le 
twantsho ya kokwanahloko le bophelo bo botle ho boemo ba bakudi ba HIV/AIDS 
lebatoweng la Bloemfontein.  
 
Monkakarolo ya ratehang, re o mema hore o be karolo ya teko ena ya bongaka mme re tla 
leboha haholo ebang o ka ipha sebaka sa ho ba karolo ya thuto ena.  Ka tlase, o tla fumana 
lesedi kaofela mabapi le thuto ena le maikarabelo a hao jwaloka monkakarolo. 
 
SELELEKELA 
 
Divithamini le dimenerale tse ngata ke ntho tsa bohlokwa twantshong ya tshwaetso ya HIV 
hobane di batlwa ke dithibela kokwanahloko le ditho tsa bohlokwa tsa mmele mabapi le ho 
hlasela kokwanahloko tse tshwaetsang.  Dipatlisiso di bontsha hore qalong ya tshwaetso ya 
HIV keketseho ya boima ba mmele kapa ntshetsopele ya boima boo, di ka fihlellwa ka 
phepo.    Tlhahisoleseding mabapi le ho ata ha phepo e mpe, dijo tse jewang le 
disebediswa tsa tlatsetso ho lwantshwa kokwanahloko ho batho ba nang le tshwaetso ya 
HIV dinaheng tse atlehileng moruong ke ntho e fumanehang ka bongata.  Leha ho le jwalo, 
tlhahisoleseding ena ke ntho e haellang ka hara Afrika moo phepo e mpe hammoho le 
kgaello ya tsamaiso e ntle ya phepo di atileng teng.  Ka tsela eo, thuto mabapi le ho 
hlahloba karolo ya tlatsetso phepong ya bakudi ba nang le tshwaetso ya HIV e ba ntho e 
hlokahalang haholo naheng e ntseng e tutuha jwaloka Afrika Borwa.  Tlhatlhobo ena ya 
teko ya bongaka e etseditswe ho fuputsa molemo wa phepo ka mokedikedi masoleng a 
mmele a bakudi ba nang le HIV/AIDS bao e leng hore masole a mmele ya bona ha a 
sebetse. 
 
SEBOPEHO SA THUTO 
Thuto ena e tla arolwa ka mekgahlelo e mene: 
5 Mokgahlelo wa ho qala 
6 Tlhatlhobo/leeto la motheo 
7 Maeto a kgwedi le kgwedi  
8 Leeto la ho qetela 
 
Nakong ya mokgahlelo wa pele wa porojeke ho tla fumanwa kananelo e ngotsweng fatshe 
ho tswa Ethics Committee of the Faculty of Heatlh Sciences ya Yunivesithi ya Foreistata, 
Bloemfontein, e mabapi le metjha e salwang morao pele ho sebediswa teko ya pele 
thutong.  Ke mokgahlelong ona moo basebetsi ba tla fumantshwang thupello ya bona. 
 
Boholo ba thuto bo kenyelletsa maeto a tlhatlhobo le maeto a kgwedi le kgwedi  nakong e 
ka etsang selemo se le seng.  Leeto la pele la kgwedi le kgwedi le tla hlophiswa matsatsing 
a supileng kamora tlhatlhobo.  Leeto la bobedi le tla hlophiswa matsatsi a mashome a 
mararo kamora ketelo ya pele, jj.  Ho tla dumellwa mokgelo wa matsatsi a -2 le +2 
tlhopisong ya maeto.  Setshwantsho sa 1 se ka tlase ke kakaretso ya maeto a thuto le 
pokelletso ya tlhahisoleseding ya porojeke. 
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Setshwantsho sa 1.  Kakaretso ya maeto a thuto le pokelletso ya tlhahisoleseding ya 
porojeke. 
 
Tsamaiso ya maeto  
Baarabi ba dipotso ba tla iswa Medi Clinic ka dipalangwang kgwedi le kgwedi.  Baarabi ba 
dipotso ba tla saena foromo ya tumello ketelong ya bona ya pele.  Babatlisisi ba tla buisana 
le baarabi ho netefatsa dintlha mabapi le morabe le tlwaelo e mabapi le dijo tseo ba di jang.  
Qetellong ya thuto, ho tla methwa taba ya hore na ba phethahatsa ka moo ho batlwang ka 
teng ka ho sebedisa lenane la dipotso.   
 
Babatlisisi ba tla sebedisa mokgwa wa ho lekanyetsa wa Anthropometric le baseline 
biochemical.  Mokgwa wa ho lekanyetsa wa Anthropometric o tla kenyelletsa:  Boima ba 
mmele, bophahamo, bophara ba letheka, diphesente tsa mafura, botenya ba ho menahana 
ha letlalo, le BMI.  
 
Basebetsi ba bongaka ba ngodisitsweng ba tla hula madi ho tswa bakuding pele ho fanwa 
kalafo ya tlatsetso kapa, nakong eo fanwang ka yona le kamora hoba ho fanwe ka yona, 
nakong ya selemo se le seng.  Disampole tsa madi di tla nkwa ke basebetsi ba bongaka ba 
ngodisitsweng nakong ya maeto a ditlhatlhobo le maeto a kgwedi le kgwedi, kamorao ho 
moo ba tla di romela Pathcare (pathology laboratory) mme ke moo di tla hlahlojwang teng 
ho netefatsa maemo a matla a masole a mmele, maemo a bophelo bo botle, bongata ba 
kokwanahloko, (kgwedi tse ding le tse ding tse tharo) thuto ya sebopeho sa madi le 
tshebetso ya sebete (kgwedi tse ding le tse ding tse tharo). 
 
PALO YA BATHO BAO HO ITHUTWANG KA BONA  
Baithaopi ba mashome a mahlano ba phelang ka HIV ba tla kgethwa kamora ketelo ya 
tlhatlhobo, baithaopi ba ileng ba phethahatsa ditlhoko tsa ho kenyelletswa, ba sa 
phethahatsang ditlhoko tsa ho behellwa ka thoko le ba fanneng ka tumello e ngotsweng 
fatshe, ba tla kenyelletswa thutong. 
Maemo a phepo le a masole a mmele a mokudi ya nang le tshwaetso ya 
HIV /AIDS 
 Consent form 
 Socio demographic 
profile questionnaire 
 Dietary Intake 
questionnaire 
 Anthropometry 
 Medical examination 
 Haematological 
parameters  
 Immune status 
 Viral load  
 Haematological 
parameters  
 Medical examination 
 Immune status 
 Anthropometry 
 Viral load  (every 3 
months) 
 Liver function (every 
3 months) 
 Anthropometry 
  Medical examination 
  Haematological 
parameters 
  Immune status 
  Viral load 
 Dietary intake 
questionnaire 
 Leeto la 
tlhatlhobo 
  Leeto la kgwedi le 
kgwedi 
         (Kgwedi tse 1-11) 
  Leeto la ho qetela 
         (Kgwedi ya bo 12) 
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Motjha wa ho kenyelletswa 
 
 Banna le basadi ho tloha dilemong tse 18 ho isa ho tse 65 ba nang le 
HIV/AIDS. 
 Palo ya disele tsa CD4+T- 200 – 350 cells/mm3 
 Sephetho e be se leng lethathameng le amohelehang mabapi le tsa 
bongaka, le nalaneng ya ho kula, le tlhatlhobong ya mokudi ka seqo 
hammoho le ho dumellana le sephetho sa laboratori se ananelwang ke 
mofuputsi wa bongaka. 
 Tjantjello ya ho itlhahisa mabapi le tlhatlhobo ya mmele pele dithuto di 
qalella le diphuputso tsa laboratori ya pele, le ya ka morao ho dithuto. 
 Bokgoni ba ho kutlwisiso le morolo wa ho saena setatemente sa tumello eo 
o e tsebang ka botlalo. 
 
Motjha wa ho itokolla 
Batho ba nale tokelo ya ho itokolla dithutong nakong e nngwe le e nngwe ho sa natswe 
lebaka, ntle le ho bea  tlhokomelo ya bona ya bongaka kotsing.  Bakudi bana ba nkwa 
jwaloka batho ba nyahladitseng morero.  Bakudi ba nyahladitseng morero bao e leng hore 
moriana o lwantshang kokwanahloko oo ho ithuwang ka ona one o sebediswa ho bona, ba 
tla kopjwa ho kenela tlhatlhobo tsa ha ho se ho qetilwe ka dithuto. 
 
Dintlha tse latelang di ka nna tsa lebisa boitokollong: 
 
 6.3.2.1  Ketsahalalo tse seng monate ka baka la ho sebedisa moriana o lwantshang 
kokwanahloko oo ho ithuwang ka ona, ke ho latela qeto ya mofuputsi wa bongaka.   
6.3.2.2   Bakudi ba tlolang metjha e latelwang, ke ho latela qeto ya mofuputsi wa bongaka. 
 
Boitsebiso ba mokudi 
 Mokudi e mong le e mong ya ngodisitsweng o tla fumana nomoro (01 – 50) mme o tla 
dula ka yona ho fihlella dithuto di fihla pheletsong.  
 Mokudi e mong le e mong ya ngodisitsweng o tla dula ka ditlhaku tsa pele tsa mabitso a 
hae tse fumanweng ka hara khopi ya bukana ya hae ya boitsebiso (eleng tlhaku tse 
tharo).   
 Mokudi e mong le e mong ya ngodisitsweng o tsejwa ka letsatsi la hae la tlhaho 
(nomoro tse tshelela). 
 
Ho nka karolo ke boithaopo, mme ya hanang ho nka karolo a keke a fumantshwa kotlo 
kapa tahlehelo ya menyetla eo a nang le tokelo hodima yona; mokudi a ka nna a kgaotsa 
ho tswelapele nako e nngwe le e nngwe ntle le ho fumantshwa kotlo kapa tahlehelo ya 
menyetla eo a nang le tokelo hodima yona.   
 
Sephiri   
 
Ho tla etswa matsapa a ho boloka tlhahiso leseding e amang motho e le sephiri. Sephiri se 
kekeng sa tsebahala ho hang se keke sa netefatswa.  Tlhahiso leseding e amang motho e 
ka nna ya phatlalatswa ebang e batlwa ka molao.   
 
Bahlophisi ba ka nna ba hlahloba kapa ba khopa direkoto tsa hao tsa dipatlisiso mabapi le 
tiiso ya boleng le qaqiso ya lesedi, mme ba ka nna ba kenyelletsa dihlopha tse jwaloka 
Ethics Committee for Medical Research and the Medicines Control Council 
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Dithibelo bakuding 
 
Meriana: 
Kaofela meriana e tsamaisanang e tla ngodiswa ka hara CRF.  Ebang ho ka hlokwa 
meriana e meng ya tlatsetso nakong ya dithuto mofuputsi wa bongaka o tla tlameha ho 
tsebiswa.  Meriana e tsamaisanang e tlameha ho bontsha ebang e sena mabitso a itseng a 
kgwebo kapa e nale ona, e bontshe matla a ona, le ka moo kalafo e ka phetwang ka teng le 
hore e nka nako e kae. 
 
Dijo: 
Bakudi ba tshwanetse ho tswelapele ka dijo tsa bona tse tlwaelehileng. 
 
Polokeho ya bakudi 
Porojeke e bolokehile haholo.  Baithuti ba tla dula ba disitswe tsatsi le leng le leng nakong 
eo ba nwang meriana ya bona ya tlatsetso e sebetsanang le kokwanahloko.  Moriana wa 
tlatsetso o sebetsanang le kokwanahloko ke liquid multi vitamin.  Ketelong e nngwe le e 
nngwe, bakudi ba tla hlahlojwa mmeleng le ho hlahloba meriana ya bona ke ngaka.  
Disampole tsa madi di tla hulwa ho bakudi ho tiisa maemo a bona a ho itwanela kgahlano 
le kokwanahloko le maemo a bona a bophelo, mme kgwedi tse ding le ding tse tharo ho tla 
hlahlojwa palo ya masole a mmele le tshebetso ya sebete.    Basebetsi ba bongaka ba 
ngodisitsweng ba tla hula madi ho bakudi pele ho phano ya meriana ya tlatsetso e 
lwantshang kokwanahloko, le nakong eo ho fanwang ka yona, le kamora hoba ho fanwe ka 
yona nakong e etsang selemo se le seng. 
 
Maemo a ditjhelete mabapi le bakudi 
Haho moo bakudi ba amehang teng mabapi le tefo ya ditjhelete.  Bakudi ha ba tlameha ho 
lefella tlhatlhobo ya bona ya bongaka kapa sephetho se seng le se seng sa bongaka.  Ba 
tla fumantshwa phekolo ntle le tefo.  Ba tla boela ba fumantshwa meriana ya bona ya 
tlatletso e lwantshang kokwanahloko mahala.  Nakong ya ketelo e nngwe le e nngwe ba tla 
fumantshwa dijo tsa mahala le dipalangwang tsa mahala ho ya tliliniking.  Baithuti ba ke ke 
ba lefjwa mabapi le karolo eo ba e nkileng tekong tsena. 
  
MERIANA YA TLATSETSO E LWANTSHANG KOKWANAHLOKO E SEBEDISETSWANG 
HO ITHUTA KA YONA E BITSWANG DI SUPPLEMENTS 
Dikateng tsa di supplements 
Ka tlase ho ngotswe dikateng tsa multi-vitamin/anti-oxidant supplement tse tla 
sebediswa nakong ya diteko. 
 
Bakudi ba tla fumantshwa Pelise engwe hangwe ka letsetsi wa supplement (pakeng tsa 
07:00 – 09:00). Basebetsi ba South African Red Cross Community Home Based Care 
Program ka hara setjhaba, ba tla sebetsana le ho fana ka moriana le ho disa taba ya ho 
nwa supplement, le hore batho ba phethahatsa ditshwanelo tsatsi le leng le le leng.  Bakudi 
ba tshwanetse ho tswelapele ka dijo tsa bona tse tlwaelehileng. 
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Dintlha mabapi le bafuputsi bao ho ikopangwang  
le bona:     
 
Prof E van den Heever-Kriek (Project leader) 
     Cell nr: 082 770 5356 
     Mr. E  Vermaak (Researcher) 
     Cell nr: 082 775 6261 
     Dr. P Basson (Researcher) 
     083 414 8445  
 
Dintlha mabapi le moo ho ikopangwang le mongodi le modulasetulo wa REC – mabapi le 
ho tlaleha ditletlebo/mathata 
Mohala nr:  051-405 2812  
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APPENDIX C 
 
SOCIO-DEMOGRAPHIC  QUESTIONNAIRE 
(All information in this questionnaire is confidential) 
 
 
Name:  
 
Respondent No.:     1-3 
Interviewer:     4-5 
 
 
 D D M M Y Y Y Y  
1. Date of Birth:         6-13 
2. Date of interview:         14-21 
3. Age  (if date of birth is unknown):         22-23 
 
Address:  
  
 
Telephone 
No. 
 (H)  (W) 
 
4. How many years have you been living in an urban area    
 (like Mangaung)?  _______________________   24-25 
 
5. Language:  26 
1. Sotho  
2. Tswana   
3. English   
4. Afrikaans   
5. 
Other, 
specify 
 
 
Number of children (born):   _______________   27-28 
Number of children (alive):   _______________   29-30 
 
6. Do you smoke at all?  31 
1. Yes  
2. No  
If YES, how many cigarettes per day?   32-33 
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7. Household composition: 
How many persons live in the house permanently     
(5-7 days per week)? ____________   34-35 
Number of children (< 18 yrs):  ______________   36-37 
Number of adults (> 18 yrs):     ______________   38-39 
 
 
8. Marital status of respondent:  40 
1. Unmarried  
2. Married  
3. Divorced  
4, Separated  
5. Widowed  
6. Living together  
7. Traditional marriage  
8. Other, specify  
 
9. What is your highest level of education?      41 
1. None 
2. Primary School 
3. Std 6-8 
4. Std 9-10 
5. Tertiary Education 
6. Don‟t know 
 
10. Employment status of respondent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     42 
1. Unemployed 
2. Self Employed 
3. Full-time wage earner (receive a salary) 
4. Other, specify (part-time, peace job etc.)  
__________________________ 
5. Don‟t know 
11. Husband/ partner’s employment status  43 
1. Retired by choice 
2. Unemployed 
3. Self Employed 
4. Full time wage earner (receive a salary) 
5. Other, specify (part-time, peace job etc.)  __________________ 
6. Not applicable, e.g. dead 
 
12. Who is the head of this household?  44 
1. Self 
2. Husband 
3. Child(ren) 
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4. Parent 
5. Grandparent 
6. Friend 
7. Other, specify  ______________________________ 
 
13. Type of dwelling:   45 
1. Brick, Concrete 
2. Traditional mud 
3. Tin 
4. Plank, wood 
5. Other, specify_____________________ 
 
 
14. Number of rooms in house (excluding bathroom,    
 toilet and kitchen, if separate)   46-47 
 
15. Where do you get drinking water most of the time?  48 
1. Own tap 
2. Communal tap 
3. River, dam 
4. Borehole, well 
5. Other, specify __________________________ 
 
16. What type of toilet does this household have?  49 
1. Flush 
2. Pit 
3. Bucket, pot 
4. VIP 
5. Other, specify ______________________ 
 
17. What fuel is used for cooking most of the time?  50 
1. Electric 
2. Gas 
3. Paraffin 
4. Wood, Coal 
5. Sun 
6. Open fire 
 
18. Do you use a cast iron pot for cooking?  51 
1. Never 
2. < Once a week 
3. > Once a week 
4. Every day 
 
19. Does the home have a WORKING: 
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Refrigerator and/or freezer  52 
1. Yes 
2. No 
Stove (gas, coal or electric) or Hot plate  53 
Yes 
No 
Primus or Paraffin Stove  54 
1. Yes 
2. No 
Microwave  55 
1. Yes 
2. No 
Radio and/or Television  56 
1. Yes 
2. No 
 
20. How many people contribute to the total income?  _________   57-58 
 
 
21. Household income per month  (including wages, rent, sales of vegs, 
etc., 
  
 State grants)  ___________________  59 
1. None 
2. R100 - R500 
3. R501 - R1000 
4. R1001 - R3000 
5. R3001 - R5000 
6. Over R5000 
7. Don‟t know 
 
22. Is this more or less the income that you had over the past six 
months? 
 60 
1. Yes 
2. No 
 
23. If NO, is it More or Less? 61 
1. More 
2. Less 
 
 
 
 
 
24. How much money is spent on food weekly?   62-63 
1. R0 – R50 
2. R51 – R100 
211 
 
3. R101 – R150 
4. R151 – R200 
5. R201 – R250 
6. R251 – R300 
7. R301 – R350 
8. R351 – R400 
9. Over R400 
 
 
   
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APPENDIX D 
 
 
QUANTITATIVE  FOOD  FREQUENCY  QUESTIONNAIRE 
 
 
Name:  
 
Respondent number:     1-3 
 
Interviewer:      4-5 
 
 
 
 
Greeting 
Please think carefully about the food and drinks you have consumed during the past 6 
months.  I will now go through a list of foods and drinks with you and I would like you to tell 
me: 
 if you eat these particular foods, 
 how the food is prepared, 
 how much of the food you eat at a time, and 
 how many times a day you eat it and if you do not eat it every day, how many times a 
week or a month it is eaten. 
 
To help you to describe the amount of a food, I will show you pictures or models of different 
amounts of the food.  Please say which picture or model is the closest to the amount eaten, 
or if it is smaller, between sizes or bigger than the pictures or models.  Amounts can also be 
reported as cups (c), tablespoons (T) or teaspoons (t). 
 
 There are no right or wrong answers. 
 Everything you tell me is confidential. 
 Is there anything you want to ask now? 
 Are you willing to go on with the questions? 
 
Encircle the appropriate answer. 
 
Do you follow any special diet? Yes (1) No (2)   6 
 
If Yes, please specify (encircle appropriate answer)     7 
1. Diabetic diet      
2. Slimming diet      
3. Allergies      
4. Other  (specify)______________________      
 
 
Do you use salt in your food? Yes (1) No (2) Don't know (3)  8 
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Are other, flavoured salts e.g. Aromat used in Yes (1) No (2) Don't know (3)  9 
your food? 
Please specify __________________________ 
 
 
Do you use beef/ chicken stock in your food? Yes (1) No (2) Don't know (3)  10 
 
 
Do you use any dietary supplements? Yes (1) No (2) Don't know (3)  11 
 
If Yes, please specify the type (name), how often, and how much: 
Vitamins: _________________________________________    12-14 
Minerals: _________________________________________    15-17 
Protein: __________________________________________    18-20 
Energy: __________________________________________    21-23 
Other: ___________________________________________    24-26 
 
 
Eating patterns  (frequency of eating): 
Please indicate which of the following best describes the eating pattern you usually follow (mark only 
one) 
1. More than three meals, with eating between meals  27 
2. Three meals, with eating between meals   
3. Three meals, with no eating between meals   
4. Two meals, with eating between meals   
5. Two meals, with no eating between meals   
6. One meal, with eating between meals   
7. One meal, with no eating between meals   
8. Nibble the whole day, no specific meals   
9. Others (please specify): 
___________________________________________________________________________ 
  
 
 
Do you eat breakfast?  28 
1. Regularly (>4 times a week)   
2. Sometimes (1 – 3 times a week)   
3. Never   
 
 
How often do you eat at the following places away from home?   
Family 1) 2) >Once 3) 4) 5) >Once   29 
 Never /week Weekly Monthly a month    
Friends 1) 2) >Once 3) 4) 5) >Once   30 
 Never /week Weekly Monthly a month    
Café 1) 2) >Once 3) 4) 5) >Once   31 
 Never /week Weekly Monthly a month    
Restaurant, Fast food 1) 2) >Once 3) 4) 5) >Once   32 
 Never /week Weekly Monthly a month    
Other, specify ___________ 1) 2) >Once 3) 4) 5) >Once   33 
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_______________________ Never /week Weekly Monthly a month    
 
 
Do you drink coffee with your meals?  34 
1. Yes 
2. No 
If Yes, at which meals? 
Breakfast 1) Yes 2) No  35 
Lunch 1) Yes 2) No  36 
Supper 1) Yes 2) No  37 
Snacks 1) Yes 2) No  38 
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Do you drink tea (except Rooibos) with your meals?  39 
1. Yes 
2. No 
 
If Yes, at which meals? 
Breakfast 1. Yes 2. No  40 
Lunch 1. Yes 2. No  41 
Supper 1. Yes 2. No  42 
Snacks 1. Yes 2. No  43 
 
 
With how many meals per day do you eat meat, fish or poultry?  44 
1. One meal 
2. Two meals 
3. All meals 
4. None 
 
 
Do you eat fresh fruit and/or vegetables with the following meals? 
Breakfast 1. Yes 2. No   45 
Lunch 1. Yes 2. No   46 
Supper 1. Yes 2. No   47 
Snacks 1. Yes 2. No   48 
 
 
 
   
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Summary  of  food  frequency  questionnaire 
 
 
FOOD CALCULATIONS CODE  –  AMOUNT PER DAY (G) 
 
          (1-8) 
          (9-16) 
          (17-24) 
          (25-32) 
          (33-40) 
          (41-48) 
          (49-56) 
          (57-64) 
          (65-72) 
          (73-80) 
          (1-8) 
          (9-16) 
          (17-24) 
          (25-32) 
          (33-40) 
          (41-48) 
          (49-56) 
          (57-64) 
          (65-72) 
          (73-80) 
          (1-8) 
          (9-16) 
          (17-24) 
          (25-32) 
          (33-40) 
          (41-48) 
          (49-56) 
          (57-64) 
          (65-72) 
          (73-80) 
          (1-8) 
          (9-16) 
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          (17-24) 
          (25-32) 
          (33-40) 
          (41-48) 
          (49-56) 
          (57-64) 
          (65-72) 
          (73-80) 
          (1-8) 
          (9-16) 
          (17-24) 
          (25-32) 
          (33-40) 
          (41-48) 
          (49-56) 
          (57-64) 
          (65-72) 
          (73-80) 
 
 
FOOD DESCRIPTION 
AMOUNT 
USUALLY 
EATEN 
TIMES EATEN CODE AMOUNT/DAY 
   Per  
day 
Per 
week 
Per  
month 
Seldom/ 
Never 
  
Maize-meal 
porridge 
Stiff (pap)      3400  
Maize-meal 
porridge 
Soft (slap pap)      3399  
Maize-meal 
porridge 
Crumbly (phutu)      3401  
Sour porridge Specify ratio Mabella/ 
Maize 
     3399  
Mabella 
porridge 
Stiff, coarse, fine      3437  
Mabella 
porridge 
Soft, coarse, fine      3437  
Oats porridge Brand name:      3239  
Breakfast 
cereals 
Puffed Wheat, plain      3325  
 Corn Flakes, plain      3243  
 Weet Bix      3244  
 Puffed Rice, sweet      3372  
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 Specify types usually 
eaten 
_____________________ 
_____________________ 
Brand names of cereals 
available at home now: 
_____________________ 
       
Milk on 
porridge or 
cereal: 
Circle type 
usually used 
None        
Whole/fresh      2718  
Sour      2787  
2% fat      2772  
Fat free/skimmed      2775  
Milk blend      2771  
Soy milk      2737  
Condensed (whole,sweet)      2714  
Condensed (skim, sweet)      2744  
Evaporated whole      2715  
Evaporated low fat      2827  
Non-dairy creamer      2751  
Is sugar 
added to 
porridge or 
cereal?  
(Tick  box) 
None                              
White                             
Brown                           
Syrup                             
Honey                            
Sweetener (type): 
___________________ 
      
3989 
4005 
3988 
3984 
 
Is fat added 
to porridge or 
cereal? 
(Tick box) 
None  
Animal fat (butter)  
Hard margarine  
Soft margarine  
Oil  
Peanut Butter  
      
3479 
3484 
3496 
3507 
3485 
 
Samp/Maize 
rice 
Bought 
Self ground 
     
3250 
3725 
 
Samp and 
beans 
Specify ratio (1:1)      3402  
Samp and 
peanuts 
Specify ratio        
Rice:  specify 
brand names: 
White 
Brown 
Sorghum rice 
     
3247 
3315 
3437 
 
Stamped 
wheat 
      3249  
Pastas Macaroni 
Spaghetti 
Spaghetti in tomato sauce 
Other: _______________ 
     
3262 
3262 
3258 
 
 
How many times a week do you eat porridge or breakfast cereal at any time of the day (NOT ONLY 
BREAKFAST)?____________ 
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FOOD 
 
DESCRIPTION 
 
AMOUNT 
USUALLY 
EATEN 
 
TIMES EATEN 
 
CODE 
 
AMOUNT/ 
DAY 
   Per  
day 
Per 
week 
Per  
month 
Seldom/ 
Never 
  
Bread/Bread 
rolls 
White      3210  
Bread 
slices: thin 
Brown      3211  
Medium, 
thick 
Whole wheat      3212  
Other 
breads 
Specify types e.g. 
Raisin 
Maize meal 
Sweetcorn 
Rye 
Other 
     
 
3214 
3278 
3379 
3213 
 
 
Pizza (speci-
fy toppings) 
Hot Dogs( 
specify 
sausage) 
Hamburgers 
(specify 
meat) 
Cheese, tomato & onion 
____________________ 
____________________ 
____________________ 
____________________ 
____________________ 
     
 
3353 
 
Are any of 
the 
following 
spreads 
used on 
bread? 
Fat spreads 
(Tick box) 
Butter  
Butro  
Animal fat (beef tallow)  
Lard  
Hard margarine (brick)  
Soft margarine (light)  
Cooking Fat  
     3479 
3523 
3494 
3495 
3484 
3496 
3516 
 
Peanut 
butter 
      3485  
Sweet 
spreads 
Jam 
Syrup 
Honey 
     
3985 
3988 
3984 
 
Marmite/ 
OXO/ 
Bovril 
      
4030 
4029 
4029 
 
Fish paste 
Meat paste 
      
3109 
2917 
 
Cheese Specify types: 
Cottage low-fat cheese 
Cream cheese 
Gouda  
Cheddar 
Other: ______________ 
____________________ 
      
2760 
2725 
2723 
2722 
 
 
Cheese 
spreads 
Low fat 
Full fat 
Specify types 
     
4310 
2730  
Atchar       3117  
Other 
spreads: 
(Specify 
tipes) 
____________________ 
____________________ 
____________________ 
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Dumpling       3210  
Vetkoek       3257  
Provita 
Crackers 
(refined) 
Crackers 
(whole 
wheat) 
      
3235 
3331 
3391 
 
Rusks 
 
 
 
Home-made: 
Bran 
Buttermilk 
White 
Boerebeskuit, white 
All-bran 
Raisins 
Buttermilk, white 
Buttermilk, whole wheat 
Other: ______________ 
     3330 
3329 
3364 
3364 
3380 
3380 
3215 
3255 
 
Scones       3237  
Muffins 
Plain 
Bran 
     
3408 
3407 
 
 
How many times a day do you eat bread? ___________ 
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DESCRIPTION 
AMOUNT 
USUALLY 
EATEN 
TIMES EATEN 
CODE 
AMOUNT 
/ DAY Per  
day 
Per 
week 
Per  
month 
Seldom
/ Never 
Chicken Boiled: with skin 
without skin 
     2926 
2963 
 
Do you eat the 
chicken with 
the skin? 
Fried: in batter/ 
crumbs 
Fried, but not 
coated 
     3018 
2925 
 
Yes       No    Roasted/grilled  
with skin 
without skin 
     2925 
 
2950 
 
Chicken bones 
stew 
      
A003 
 
Chicken 
heads, raw 
      
2999 
 
Chicken stew, 
with veg & skin 
      
3005 
 
Chicken feet, 
raw 
      
2997 
 
Chicken offal Giblets      2998  
Chicken pie 
Commercial  
Home-made 
     
2954 
2954 
 
Red meat: Beef 
Fried/grilled: 
with fat 
/ without fat 
     
2908 
2959 
 
 
Stewed/boiled: 
with fat 
/ without fat 
     
3006 
2909 
 
 
Mince with tomato 
and onion 
     2987  
Red meat: 
Mutton 
Fried/grilled: 
with fat 
/ without fat 
     
2927 
2934 
 
 
Stewed/boiled: 
with fat 
/ without fat 
     
3040 
2916 
 
Red meat: 
Pork 
Fried/grilled: 
with fat 
/ without fat 
     
2930 
2977 
 
 
Stewed/boiled: 
with fat 
/ without fat 
     
3046 
3045 
 
Red meat: 
Goat 
Fried/grilled: 
with fat 
/ without fat 
     4281  
 
Stewed/boiled: 
plain 
/ with veg 
     
4281 
4282 
 
Offal 
(Specify type) 
Intestines: boiled, 
nothing added 
     3003  
 "Vetderm" fried      3003  
 Stewed with 
vegetables 
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 Liver      2955  
 Kidney      2956  
 
Tripe "pens" 
trotters, head 
     3003  
 
Pluck (lungs, 
heart, gullet) 
     3019  
Specify vege-
tables used in 
meat stews 
(only if not 
mentioned 
elsewhere) 
        
Wors / 
sausage 
Fried      2931  
Bacon       2906  
Cold meats Polony      2919  
 Ham      2967  
 Vienna's canned      2936  
 Russian      2948  
 Frankfutter      2937  
 Other (specify)        
 ______________        
Canned meat Bully beef      2940  
 Other (specify)        
         
Meat pie Bought      2939  
 
Legumes: 
specify dried 
beans / peas / 
lentils 
Stews & curries 
(specify) 
Soups 
Salad 
     
 
3157 
3174 
 
Baked beans       3176  
Soya products 
e.g. Toppers / 
Imana 
Brands at home 
now: 
Don‟t know 
______________ 
(Show examples) 
     
 
3196 
 
Fried fish 
(fresh or 
frozen / fried in 
sun oil) 
With batter/ 
crumbs 
Without batter/ 
crumbs 
     
3072 
3060 
 
Fresh water 
fish 
(Specify type) 
Specify cooking 
method: 
Medium fat, 
batter, fried 
     3094  
Canned fish:         
Pilchards  In brine      3055  
 In tomato sauce      3102  
 
Mashed with fried 
onion 
     A005  
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Sardines In oil 
In tomato sauce 
     
3087 
3087 
 
Tuna In oil 
In brine 
     
3093 
3054 
 
Mackerel       3113  
Salmon       3101  
Pickled fish/ 
curried 
      3076  
Do you remove 
fish bones be-
fore eating 
canned fish 
YES   NO          
Fish cakes 
Specify canned 
or other 
Fried:  oil / butter / 
margarine, com-
mercial 
     3080  
Salted dried 
fish 
      3077  
Eggs Boiled/poached 
Scrambled in: 
oil 
butter 
margarine 
Fried in: 
oil 
butter 
margarine 
bacon fat 
Curried 
     2867 
 
2889 
2886 
2887 
 
2869 
2868 
2877 
2870 
2902 
 
 
How many times a week do you eat: 
Meat  
Beans  
Chicken  
Fish  
Eggs  
 
 
FOOD DESCRIPTION 
AMOUNT 
USUALLY 
EATEN 
TIMES EATEN 
CODE 
AMOUNT 
/DAY Per  
day 
Per 
week 
Per  
month 
Seldom
/ Never 
Cabbage Boiled, nothing 
added 
     3756  
 Boiled with potato, 
onion and fat 
     3813  
 Fried, in marga-
rine (nothing 
added) 
     3810  
 Fried, in oil 
(nothing added) 
     3912  
 Boiled, then fried 
with potato, onion 
     A006  
 Other: 
______________ 
       
Spinach / 
morogo / 
Boiled, nothing 
added 
     
3913 
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imfino / other 
green leafy 
vegetables: 
List names 
Boiled, fat added 
(margarine) 
     
3898 
 
Boiled with onion / 
tomato and fat 
     
A011 
 
- onion & potato 
(margarine) 
     
3901 
 
- onion, tomato & 
potato 
       
- with peanuts      
 
 
Other: 
______________ 
       
Tomato and 
onion 'gravy' / 
relish / chow 
Home made: 
- with fat 
- without fat 
      
3910 
3925 
 
Canned      4129  
         
         
Pumpkin 
(Specify type) 
Cooked in fat and 
sugar 
     
A010 
 
 Boiled, little sugar 
and fat 
     
A010 
 
 
Boiled      4164  
 Other: 
______________ 
     
 
 
Carrots 
Boiled, sugar & fat      3819  
 Boiled, nothing 
added 
     
3757 
 
 Boiled, potato, 
onion, no fat 
     
3934 
 
 Boiled, potato, 
onion, margarine 
     
3822 
 
 
Boiled, with sugar      3818  
 
With potato/onion      3934  
 Raw, salad 
(orange juice) 
     
3711 
 
 
Chakalaka        
 Other: 
______________ 
     
 
 
Mealies / 
Sweet corn 
On cob      3725  
Off cob - creamed 
sweet corn 
Off cob - whole 
kernel 
     3726 
 
3942 
 
Beetroot  Cooked, Salad 
(bought or home-
made) 
     3698 
3699 
 
 
Potatoes Boiled - with skin      4155  
 - without skin      3737  
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 Baked in skin 
(flesh and skin) 
- in skin (flesh 
only) 
     
3736 
3970 
 
 Mashed - skim 
milk, margarine 
     
3875 
 
 Mashed - whole 
milk, margarine 
     
3876 
 
 Roasted in beef 
fat 
     
3878 
 
 French fries / 
potato chips (oil) 
     
3740 
 
 Salad (mayon-
naise and egg) 
     
3928 
 
 Other: 
______________ 
     
 
 
Sweet Boiled with skin      3748  
potatoes - without skin      3903  
 Baked with skin      3748  
 - without skin      3903  
 Mashed      3903  
 
Other: 
______________ 
       
         
         
         
Peas Green, frozen      4146  
 
Green, frozen with 
sugar 
     3720  
 
With sugar and 
butter 
     3859  
 Tinned peas      4149  
Green peppers Raw 
Cooked 
(stew with oil) 
     3733 
3865 
 
Brinjal / egg 
plant 
Cooked 
Fried in oil 
Stew (oil, onions, 
tomato) 
     3700 
3802 
3798 
 
Mushrooms Raw 
Sautéed in brick 
margarine 
Sautéed in oil 
     3842 
3839 
3841 
 
Onions  Sautéed in sun oil 
Sautéed in marga-
rine 
     3730 
3844 
 
Salad 
vegetables 
Raw tomato      3750  
Lettuce      3723  
Cucumber      3718  
 Avocado's      3656  
Green Beans Boiled, nothing 
added 
     3696  
Cooked, potato, 
onion, margarine 
     3792  
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Cooked, potato, 
onion, no fat 
     3933  
Cauliflower Boiled      3716  
Other 
vegetables 
(Specify) 
______________ 
______________ 
       
If you fry veg 
or add fat, 
specify type of 
fat usually 
used 
Butter  
Butro  
Animal fat (beef 
tallow)  
Lard  
Hard margarine 
(brick)  
Soft margarine 
(tub)  
Soft margarine 
(light)  
Sunflower oil  
     3479 
3523 
 
3494 
3495 
 
3484 
 
3496 
 
3524 
3507 
 
 
How many times a week do you eat vegetables?  ________________ 
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FOOD DESCRIPTION 
AMOUNT 
USUALLY 
EATEN 
TIMES EATEN 
CODE 
AMOUNT
/DAY Per  
day 
Per 
week 
Per  
month 
Seldom 
/Never 
Mayonnaise / 
salad dressing 
Mayonnaise: 
- bought 
- home-made 
Cooked salad 
dressing 
Salad dressing 
low-oil 
Salad dressing 
French 
Oil: 
- Olive 
- Sunflower 
- Canola 
      
3488 
3506 
3503 
 
3505 
 
3487 
 
 
3509 
3507 
4280 
 
Apples Fresh 
Canned, unsweet-
ened 
     3532 
4216 
 
Pears Fresh 
Canned, in syrup 
     3582 
3583 
 
Bananas       3540  
Oranges 
Naartjie 
      3560 
3558 
 
Grapes       3550  
Peaches Fresh 
Canned in syrup 
     3565 
3567 
 
Apricots Fresh 
Canned in syrup 
     3534 
3535 
 
Mangoes Fresh      3556  
Pawpaw Raw      3563  
Pineapple Raw 
Canned (syrup) 
     3581 
3648 
 
Guavas Fresh 
Canned (syrup) 
     3551 
3553 
 
Watermelon       3576  
Spanspek Orange flesh 
Green flesh 
     3541 
3575 
 
Wild fruit / 
berries 
(Specify types) 
______________ 
______________ 
______________ 
______________ 
______________ 
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Dried fruit (also 
as snacks) 
Raisins 
Prunes (raw) 
Prunes (cooked 
with sugar) 
Peaches (raw) 
Peaches (cooked 
with sugar) 
Apples (raw) 
Dried fruit sweets 
Other: 
______________ 
______________ 
______________ 
______________ 
     3552 
3596 
3564 
 
3568 
 
3569 
 
3600 
3995 
 
Other fruit ______________ 
______________ 
______________ 
______________ 
_________ 
_________ 
_________ 
_________ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
______ 
 ________ 
________ 
________ 
________ 
 
How many times a week do you eat fruits?  _____________ 
 
 
WE NOW WILL ASK YOU QUESTIONS ABOUT WHAT YOU USUALLY DRINK 
BEVERAGES DESCRIPTION 
AMOUNT 
USUALLY 
TAKEN 
TIMES EATEN 
CODE 
AMOUNT 
/ DAY Per 
day 
Per 
week 
Per 
month 
Seldom 
/ Never 
Water       4042  
Tea 
Ceylon 
Rooibos 
     
4038 
4054 
 
Coffee       4037  
Sugar per cup 
of tea or coffee 
White 
Brown 
     3989 
4005 
 
Milk per cup of 
tea or coffee 
What type of 
milk do you put 
in tea and/or 
coffee? 
Fresh / Long life / 
Whole 
     2718  
Fresh / long life 
2% 
     2772  
Goat      2738  
Fresh / Long life / 
fat free (skimmed) 
     2775  
Whole milk pow-
der, reconstituted 
Specify brand: 
______________ 
     2831  
 Skimmed milk 
powder, reconsti-
tuted 
Specify brand: 
______________ 
     2719  
 Milk blend, recon-
stituted 
Specify brand: 
______________ 
     2771  
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 Whitener / non-
dairy creamer 
Specify brand: 
______________ 
     2751  
 Condensed milk 
(whole) 
     2714  
 Condensed milk 
(skimmed) 
     2744  
 Evaporated milk 
(whole) 
     2715  
 Evaporated milk 
(low-fat) 
     2827  
 None        
Milk as such: 
What type of 
milk do you 
drink? 
Fresh / long life / 
whole 
     2718  
Fresh/longlife/fat 
free (skimmed) 
     2772  
Fresh/long life/2%      2775  
Goat      2738  
 Sour / Maas      2787  
Buttermilk      2713  
 
 
BEVERAGES DESCRIPTION 
AMOUNT 
USUALLY 
TAKEN 
TIMES TAKEN 
CODE 
AMOUNT
/ DAY Per  
day 
Per 
week 
Per  
month 
Seldom
/ Never 
Milk drinks 
Specify brands, 
Including milk 
supplements 
and type of milk 
used 
Nestle Nesquik 
______________ 
Milo 
______________ 
Flavoured milk 
______________ 
Other 
______________ 
      
4287 
 
2735 
 
2774 
 
Yoghurt Drinking yoghurt 
Thick yoghurt, 
plain, fruit 
     2756 
2732 
 
Squash SixO 
Oros 
Lecol with sugar 
-artificial 
sweetener 
Kool Aid 
Other 
______________ 
______________ 
______________ 
     3990 
3982 
3982 
3990 
 
3982 
 
 
Fruit juice Fresh / Liquifruit / 
Ceres 
     2866  
 "Tropica"/ 
mixtures with milk 
     2791  
Fruit syrups Average 
Guava syrup 
     2865 
2864 
 
Fizzy drinks 
(Coke, Fanta) 
Sweetened 
Diet 
     
3981 
3990 
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Mageu/Motogo       4056  
Alcoholic bev-
erages such as 
Sorghum beer 
Sorghum beer 
Specify: 
______________ 
     4039  
Other 
(specify) 
Beer average 
Wine 
Cider 
______________ 
______________ 
______________ 
______________ 
______________ 
______________ 
     4031 
4033 
4057 
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PLEASE INDICATE WHAT TYPES AND AMOUNTS OF SNACKS, PUDDINGS AND SWEETS 
YOU EAT: 
 
FOODS DESCRIPTION 
AMOUNT 
USUALLY 
EATEN 
TIMES EATEN 
CODE 
AMOUNT 
/ DAY Per  
day 
Per 
week 
Per  
month 
Seldom
/ Never 
Potato crisps / 
chips 
      3417  
Peanuts 
Roasted, unsalted 
Roasted, salted 
     3452 
3458 
 
Cheese curls: 
Niknaks etc. 
Average 
Savoury 
     
3267 
3418 
 
Popcorn 
Plain (no salt and 
butter) 
Plain (salt and 
butter added) 
Sugar coated 
     
3332 
 
3359  
Raisins 
(seeds) 
      4231  
Chocolates Milk 
Kit Kat 
Peppermint crisp 
Specify types and 
names 
______________ 
______________ 
     3987 
4024 
3997 
 
Candies Sugus, gums, 
hard sweets 
(specify) 
______________ 
Peppermint 
     3986 
 
 
 
4004 
 
Sweets Toffees 
Hard boiled 
Fudge, caramels 
(specify) 
______________ 
     3991 
3986 
3991 
 
Biscuits / 
cookies 
Specify type 
Home made plain 
Shortbread, butter 
Commercial, plain 
Commercial with 
filling 
      
3233 
3296 
3216 
3217 
 
Cakes and 
tarts 
Chocolate, plain      3419  
Pancakes/ 
crumpets 
      3344  
Koeksisters       3231  
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Savouries Sausage rolls 
Samoosa –  
vegetable 
Samoosa –  
mutton 
Biscuits e.g. 
Bacon kips 
Other: 
______________ 
______________ 
     2939 
3414 
 
3355 
 
3331 
 
Pudding: jelly       3983  
Baked pudding Plain batter      3429  
Instant 
pudding 
Skim milk 
Whole milk 
     3314 
3266 
 
Ice cream Commercial 
regular 
Commercial rich 
Soft serve 
Sorbet 
Ice lollies 
Chocolate coated 
individual ice 
creams (e.g. 
Magnum) 
     3483 
 
3519 
3518 
3491 
3982 
 
Custard Home made, 
whole milk 
Ultramel 
     2716 
 
2716 
 
Cream Fresh      3520 / 
3480 
 
Other pud-
dings 
(Specify): 
______________ 
______________ 
______________ 
       
 
 
HOW MANY TIMES A WEEK DO YOU EAT SNACK FOODS?  _____________ 
 
 
 
SAUCES / GRAVIES / CONDIMENTS 
 
FOODS DESCRIPTION 
AMOUNT 
USUALLY 
EATEN 
TIMES EATEN 
CODE 
AMOUNT 
/ DAY Per  
day 
Per 
week 
Per  
month 
Seldom 
/ Never 
Tomato Sauce 
/ Worcester 
sauce 
      
3139 
4309 
 
Chutney Fruit      3168  
Tomato      3114  
Pickles       3866  
Packet soups       3158  
Beef / chicken 
stock 
      4029  
Others:  ______________ 
______________ 
______________ 
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Wild birds, animals, insects or fruits and berries (hunted or collected in rural areas or on 
farms (specify): 
         
         
         
 
 Please mention any other foods you eat more than once every two weeks which we have 
not talked about and/or foods eaten in other homes or places during the past week: 
 
 
 
 
FOOD DESCRIPTION 
AMOUNT 
USUALLY 
EATEN 
TIMES EATEN 
CODE 
AMOUNT 
/ DAY Per  
day 
Per 
week 
Per  
month 
Seldom 
/ Never 
         
         
         
         
 
 
Are there any foods that you eat which we haven't talked about?  Please list them: 
 
FOODS DESCRIPTION 
AMOUNT 
USUALLY 
EATEN 
TIMES EATEN 
CODE 
AMOUNT 
/ DAY 
   
Per  
day 
Per 
week 
Per  
month 
Seldom 
/ Never 
         
         
         
         
         
         
 
 
 
 
 
Thank you for your co-operation and patience. 
Good bye! 
 
 
 
 
ADAPTED FROM THE QUESTIONNAIRES OF THE THUSA STUDY (WITH 
ACKNOWLEDGEMENT TO THE RESEARCH GROUP OF PUCHO) AND THE NATIONAL FOOD 
CONSUMPTION SURVEY 
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APPENDIX E 
 
 
ANTHROPOMETRY INFORMATION 
 
 
Name: __________________ 
 
Respondent number:       1-3 
 
Measurer (interviewer):___________________       4-5 
 
Weight (kg):___________________      .  6-10 
 
Height (m): ____________________     .   11-14 
 
Circumferences (cm):         
Upper-arm:________________      .  15-18 
Waist: ___________________      .  19-23 
Hip: _____________________      .  24-28 
         
 
 
        
Age (yrs):____________________ 
       29-30 
Elbow width (cm): _____________      .  31-33 
Bodystat count: ________________        34-36 
         
         
Frame size 
       37 
1. Small         
2. Medium         
3. Large         
         
% Fat: ______________      .  38-41 
% Lean mass:________________      .  42-45 
 
 
 
 
 
 
235 
 
APPENDIX F 
 
ANTHRPOLOGY RESULTS 
 
 
Graphs for descriptive statistics over time 
 
 
Figure 1: Frame size of infected individuals. 
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Figure 2: Mean weight over time. 
 
 
Figure 3: Mean circumference measurements of infected individuals over time. 
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Figure 4: Mean elbow width of infected individuals over time. 
 
Figure 5: Mean BMI infected individuals over time. 
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Food Frequencies – Descriptive statistics 
 
The FREQ Procedure 
Frame_Size 
Frame_Size Frequency Percent Cumulative 
Frequency 
Cumulative 
Percent 
Large 5 12.50 5 12.50 
Medium 19 47.50 24 60.00 
Not known 8 20.00 32 80.00 
Small 7 17.50 39 97.50 
Small-Medium 1 2.50 40 100.00 
 
 
 
Antropometrie - Descriptive statistics 
 
The MEANS Procedure 
Variable N Mea
n 
Std 
Dev 
Medi
an 
Lower 
Quartil
e 
Upper 
Quartil
e 
Minimu
m 
Maximu
m 
Age 
Height 
Weight_Baseline 
Weight_Date3 
Weight_Date6 
Weight_Date9 
Weight_Date12 
Circ_Upper_Arm_Basel
ine 
Circ_Upper_Arm_Date
3 
Circ_Upper_Arm_Date
6 
Circ_Upper_Arm_Date
9 
40 
40 
40 
40 
40 
40 
40 
39 
40 
40 
40 
40 
40 
40 
39.9 
1.6 
64.8 
64.9 
65.0 
65.4 
65.1 
27.8 
27.5 
28.4 
28.0 
28.6 
82.8 
83.8 
9.1 
0.1 
10.8 
11.3 
11.0 
11.5 
11.4 
2.8 
2.7 
2.6 
3.2 
4.8 
9.1 
9.5 
38.5 
1.6 
64.6 
65.4 
65.8 
66.4 
66.2 
28.0 
28.0 
28.7 
28.0 
28.0 
81.0 
82.5 
33.5 
1.6 
56.6 
56.8 
56.8 
56.8 
56.7 
26.0 
26.0 
26.8 
26.3 
25.8 
76.0 
77.8 
46.0 
1.7 
71.9 
72.4 
72.4 
71.4 
71.4 
29.0 
29.0 
29.6 
29.4 
30.0 
90.0 
90.0 
26.0 
1.5 
42.0 
40.6 
41.0 
41.8 
42.3 
22.0 
21.0 
22.0 
22.0 
22.0 
70.0 
67.0 
64.0 
1.8 
91.1 
90.6 
91.1 
92.0 
92.3 
37.0 
35.0 
35.4 
34.5 
51.0 
112.0 
111.0 
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Variable N Mea
n 
Std 
Dev 
Medi
an 
Lower 
Quartil
e 
Upper 
Quartil
e 
Minimu
m 
Maximu
m 
Circ_Upper_Arm_Date
12 
Circ_Waist_Baseline 
Circ_Waist_Date3 
Circ_Waist_Date6 
Circ_Waist_Date9 
Circ_Waist_Date12 
Circ_Hip_Baseline 
Circ_Hip_Date3 
Circ_Hip_Date6 
Circ_Hip_Date9 
Circ_Hip_Date12 
 
 
40 
40 
40 
40 
40 
40 
40 
40 
40 
38 
39 
 
 
 
83.4 
83.9 
82.5 
101.2 
101.1 
101.2 
99.1 
100.9 
5.5 
4.6 
4.7 
 
 
 
10.0 
10.5 
9.8 
9.5 
10.1 
10.0 
17.4 
9.6 
1.7 
1.5 
1.4 
 
 
 
82.5 
84.6 
81.9 
100.5 
102.5 
102.0 
100.3 
100.1 
5.3 
4.0 
4.0 
 
 
 
76.0 
75.5 
75.5 
93.3 
91.5 
92.4 
92.0 
94.5 
4.0 
3.5 
4.0 
 
 
 
90.6 
91.3 
87.1 
107.5 
109.0 
109.4 
108.3 
107.2 
7.0 
5.0 
5.0 
 
 
 
63.0 
63.0 
63.0 
86.0 
81.0 
84.0 
10.3 
83.0 
3.5 
3.0 
3.0 
 
 
 
111.5 
105.2 
109.2 
124.0 
121.0 
124.5 
126.0 
124.3 
9.0 
8.2 
8.0 
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Antropometrie - Differences (Baselins vs. Date6 vs. Date12) 
 
The MEANS Procedure 
Variable N Median Lower 
Quartile 
Upper 
Quartile 
Mean Std 
Dev 
Minimum Maximum p-value 
(Signed 
Rank Test 
– 
Significant 
median 
difference) 
Diff_B_6_Weight 
Diff_B_12_Weight 
Diff_6_12_Weight 
Diff_B_6_Circ_Upper_Arm 
Diff_B_12_Circ_Upper_Arm 
Diff_6_12_Circ_Upper_Arm 
Diff_B_6_Circ_Waist 
Diff_B_12_Circ_Waist 
Diff_6_12_Circ_Waist 
Diff_B_6_Circ_Hip 
Diff_B_12_Circ_Hip 
Diff_6_12_Circ_Hip 
Diff_B_6_BMI 
Diff_B_12_BMI 
Diff_6_12_BMI 
 
34 
34 
34 
33 
33 
34 
34 
34 
34 
34 
34 
34 
34 
34 
34 
 
-0.55 
-0.15 
0.10 
-1.00 
-0.80 
0.00 
-0.60 
0.00 
0.25 
0.00 
0.15 
0.40 
-0.20 
0.00 
0.00 
 
-2.00 
-2.40 
-1.30 
-1.50 
-1.80 
-0.60 
-3.50 
-3.70 
-2.00 
-1.50 
-2.20 
-1.50 
-0.70 
-0.90 
-0.40 
 
1.00 
1.50 
1.50 
0.00 
1.00 
1.00 
3.00 
2.80 
2.30 
3.00 
4.00 
2.00 
0.40 
0.50 
0.60 
 
-0.20 
-0.34 
-0.15 
-0.60 
-0.28 
0.33 
-0.20 
0.12 
0.32 
-0.05 
0.12 
0.18 
-0.07 
-0.14 
-0.07 
 
2.38 
3.50 
2.84 
1.59 
2.18 
1.83 
5.21 
4.64 
3.41 
4.97 
5.06 
3.90 
0.92 
1.38 
1.13 
 
-4.30 
-9.00 
-7.60 
-3.20 
-3.80 
-3.00 
-13.00 
-8.00 
-6.20 
-11.50 
-13.00 
-11.00 
-1.60 
-4.00 
-3.40 
 
5.00 
8.20 
6.00 
3.00 
6.00 
5.00 
10.50 
11.70 
7.30 
13.50 
11.50 
9.50 
2.10 
3.00 
2.50 
 
0.4943 
0.6084 
0.9096 
0.0450 * 
0.3015 
0.6121 
0.7250 
0.9646 
0.6055 
0.8409 
0.5634 
0.5828 
0.4831 
0.6805 
0.8417 
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APPENDIX G 
LIVER FUNCTION TESTING 
UNICEL DXC 880i 
SYNCHRON ACCESS CLINICAL SYSTEM 
 
METHODOLOGY: 
ALB 
ALB reagent is used to measure albumin concentration by a timed endpoint method.1,2 In 
the reaction, albumin combines 
with bromcresol purple (BCP) to form a colored product. 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into the cuvette. 
The ratio used is one part sample to 100 parts reagent. The System monitors the change in 
absorbance at 600 
nanometers. This change in absorbance is directly proportional to the concentration of ALB 
in the sample and is used 
by the System to calculate and express ALB concentration. 
ALP 
ALP reagent is used to measure alkaline phosphatase activity by a kinetic rate method using 
a 
2-amino-2-methyl-1-propanol (AMP) buffer.1,2,3,4,5,6 In the reaction, alkaline phosphatase 
catalyzes the hydrolysis of 
the colorless organic phosphate ester substrate, p-nitrophenylphosphate, to the yellow 
colored product, p-nitrophenol, 
and phosphate. This reaction occurs at an alkaline pH of 10.3. 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into the cuvette. 
The ratio used is one part sample to 50 parts reagent. The system monitors the change in 
absorbance at 410 nanometers. 
This change in absorbance is directly proportional to the activity of ALP in the sample and 
is used by the System to 
calculate and express ALP activity. 
ALT 
ALT reagent is used to measure analyte activity by a kinetic rate method.1,2 In the reaction, 
alanine aminotransferase 
catalyzes the reversible transamination of L-alanine and alpha-ketoglutarate to pyruvate and 
L-glutamate. The pyruvate 
is then reduced to lactate in the presence of lactate dehydrogenase (LDH) with the 
concurrent oxidation of reduced 
â-nicotinamide adenine dinucleotide (NADH) to â-nicotinamide adenine dinucleotide 
(NAD). 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into the cuvette. 
The ratio used is one part sample to 11 parts reagent. The system monitors the change in 
absorbance at 340 nanometers. 
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This change in absorbance is directly proportional to the activity of ALT in the sample and 
is used by the System to 
calculate and express the ALT activity 
AST 
The AST reagent is used to measure aspartate aminotransferase activity by an enzymatic rate 
method.1,2 In the 
assay reaction, the AST catalyzes the reversible transamination of L-aspartate and á-
ketoglutarate to oxaloacetate 
and L-glutamate. The oxaloacetate is then reduced to malate in the presence of malate 
dehydrogenase (MDH) with 
the concurrent oxidation of â-Nicotinamide Adenine Dinucleotide (reduced form) (NADH) 
to â-Nicotinamide Adenine 
Dinucleotide (NAD). 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into a cuvette. 
The ratio used is one part sample to 11 parts reagent. The system monitors the rate of change 
in absorbance at 340 
nanometers over a fixed-time interval. This rate of change in absorbance is directly 
proportional to the activity of AST in 
the sample and is used by the SYNCHRON® System(s) to calculate and express the AST 
activity. 
GGT 
GGT reagent is used to measure the ã-glutamyl transferase activity by an enzymatic rate 
method.1 In the 
reaction, the ã-glutamyl transferase catalyzes the transfer of a gamma-glutamyl group from 
the colorless substrate, 
ã-glutamyl-p-nitroaniline, to the acceptor, glycylglycine with production of the colored 
product, p-nitroaniline. 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into the cuvette. 
The ratio used is one part sample to 20 parts reagent. The system monitors the change in 
absorbance at 410 nanometers. 
This change in absorbance is directly proportional to the activity of GGT in the sample and 
is used by the System to 
calculate and express GGT activity 
TBIL 
TBIL reagent is used to measure the total bilirubin concentration by a timed endpoint Diazo 
method.1,2,3 In the reaction, 
the bilirubin reacts with diazo reagent in the presence of caffeine, benzoate, and acetate as 
accelerators to form 
azobilirubin. 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into a cuvette. The 
ratio used is one part sample to 35 parts reagent. The system monitors the change in 
absorbance at 520 nanometers. 
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This change in absorbance is directly proportional to the concentration of TBIL in the 
sample and is used by the System 
to calculate and express TBIL concentration. 
 
DBIL 
DBIL reagent is used to measure DBIL concentration by a timed endpoint diazo method.1,2 
In the reaction, DBIL combines 
with diazo to form azobilirubin. 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into the cuvette. 
The ratio used is one part sample to 32 parts reagent. The system monitors the change in 
absorbance at 560 nanometers. 
This change in absorbance is directly proportional to the concentration of DBIL in the 
sample and is used by the System 
to calculate and express the DBIL concentration. 
TP 
TP reagent is used to measure the total protein concentration by a timed-endpoint biuret 
method.1 In the reaction, the 
peptide bonds in the protein sample bind to cupric ions in an alkaline medium to form 
colored peptide/copper complexes. 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into a cuvette. The 
ratio used is one part sample to 50 parts reagent. The System monitors the change in 
absorbance at 560 nanometers. 
This change in absorbance is directly proportional to the concentration of TP in the sample 
and is used by the System 
to calculate and express the TP concentration. 
LD 
catalyzes the reversible oxidation of L-lactate to pyruvate with the concurrent reduction of â-
nicotinamide adenine 
dinucleotide (NAD) to reduced â-nicotinamide adenine dinucleotide (NADH). 
The SYNCHRON® System(s) automatically proportions the appropriate sample and reagent 
volumes into a cuvette. The 
ratio used is one part sample to 20 parts reagent. The system monitors the change in 
absorbance at 340 nanometers. 
This change in absorbance is directly proportional to the activity of lactate dehydrogenase in 
the sample and is used by 
the System to calculate and express the lactate dehydrogenase activity. 
 
oOo 
